<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Linezolid for drug‐resistant pulmonary tuberculosis - Singh, B - 2019 | Cochrane Library</title> <meta content="Linezolid for drug‐resistant pulmonary tuberculosis - Singh, B - 2019 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012836.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Linezolid for drug‐resistant pulmonary tuberculosis - Singh, B - 2019 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012836.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD012836.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Linezolid for drug‐resistant pulmonary tuberculosis" name="citation_title"/> <meta content="Bhagteshwar Singh" name="citation_author"/> <meta content="b5ingh@hotmail.com" name="citation_author_email"/> <meta content="Derek Cocker" name="citation_author"/> <meta content="Hannah Ryan" name="citation_author"/> <meta content="Derek J Sloan" name="citation_author"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="3" name="citation_issue"/> <meta content="10.1002/14651858.CD012836.pub2" name="citation_doi"/> <meta content="2019" name="citation_date"/> <meta content="2019/03/20" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012836.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012836.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012836.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Antibiotics, Antitubercular [adverse effects, *therapeutic use]; Linezolid [adverse effects, *therapeutic use]; Non‐Randomized Controlled Trials as Topic; Randomized Controlled Trials as Topic; Treatment Outcome; Tuberculosis, Multidrug‐Resistant [*drug therapy, mortality]; Tuberculosis, Pulmonary [*drug therapy, mortality]; Withholding Treatment [statistics &amp; numerical data]" name="citation_keywords"/> <meta content="" name="citation_fulltext_world_readable"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012836.pub2&amp;doi=10.1002/14651858.CD012836.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012836.pub2&amp;doi=10.1002/14651858.CD012836.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012836.pub2&amp;doi=10.1002/14651858.CD012836.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012836.pub2&amp;doi=10.1002/14651858.CD012836.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012836.pub2&amp;doi=10.1002/14651858.CD012836.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012836.pub2&amp;doi=10.1002/14651858.CD012836.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012836.pub2&amp;doi=10.1002/14651858.CD012836.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012836.pub2&amp;doi=10.1002/14651858.CD012836.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012836.pub2&amp;doi=10.1002/14651858.CD012836.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012836.pub2&amp;doi=10.1002/14651858.CD012836.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012836.pub2&amp;doi=10.1002/14651858.CD012836.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012836.pub2&amp;doi=10.1002/14651858.CD012836.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012836.pub2&amp;doi=10.1002/14651858.CD012836.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012836.pub2&amp;doi=10.1002/14651858.CD012836.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012836.pub2&amp;doi=10.1002/14651858.CD012836.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012836.pub2&amp;doi=10.1002/14651858.CD012836.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012836.pub2&amp;doi=10.1002/14651858.CD012836.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012836.pub2&amp;doi=10.1002/14651858.CD012836.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012836.pub2&amp;doi=10.1002/14651858.CD012836.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012836.pub2&amp;doi=10.1002/14651858.CD012836.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012836.pub2&amp;doi=10.1002/14651858.CD012836.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012836.pub2&amp;doi=10.1002/14651858.CD012836.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012836.pub2&amp;doi=10.1002/14651858.CD012836.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773519000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773548000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000"}};Liferay.authToken="WcPhDegp";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD012836\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD012836\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012836\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012836\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513680837000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","zh_HANS","ru","ms","fr","fa"],languageCode:"en",accessStatus:"open-access",doi:"10.1002/14651858.CD012836.pub2",title:"Linezolid for drug\\u2010resistant pulmonary tuberculosis",firstPublishedDate:"Mar 20, 2019 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Infectious Diseases Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734739000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=WcPhDegp&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012836.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD012836.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD012836.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD012836.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012836.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD012836.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD012836.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD012836.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD012836.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD012836.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;Abstract&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;Plain language summary&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Conclusiones de los autores&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Antecedentes&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Objetivos&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Métodos&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Discusión&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD012836.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD012836.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD012836.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD012836.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>11440 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD012836.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012836.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012836.pub2/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012836.pub2/full#CD012836-abs-0005"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012836.pub2/full#CD012836-sec-0101"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012836.pub2/full#CD012836-sec-0030"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012836.pub2/full#CD012836-sec-0031"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012836.pub2/full#CD012836-sec-0036"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012836.pub2/full#CD012836-sec-0037"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012836.pub2/full#CD012836-sec-0074"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012836.pub2/full#CD012836-sec-0095"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD012836.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012836.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012836.pub2/appendices#CD012836-sec-0105"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012836.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012836.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012836.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012836.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD012836.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD012836.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD012836.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2019 The Authors. Cochrane Database of Systematic Reviews published by John Wiley &amp; Sons, Ltd. on behalf of The Cochrane Collaboration." data-creative-commons="true" href="/cdsr/doi/10.1002/14651858.CD012836.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> <div class="inline-status-wrapper"> </div> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Linezolid for drug‐resistant pulmonary tuberculosis</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012836.pub2/information#CD012836-cr-0002"><i class="icon corresponding-author fa fa-envelope"></i>Bhagteshwar Singh</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012836.pub2/information#CD012836-cr-0003">Derek Cocker</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012836.pub2/information#CD012836-cr-0004">Hannah Ryan</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012836.pub2/information#CD012836-cr-0005">Derek J Sloan</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD012836.pub2/information/en#CD012836-sec-0108">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 20 March 2019 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD012836.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD012836.pub2">https://doi.org/10.1002/14651858.CD012836.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD012836-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD012836-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD012836-abs-0004">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD012836-abs-0011">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD012836-abs-0003">Français</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD012836-abs-0002">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD012836-abs-0001" lang="en"> <section id="CD012836-sec-0001"> <h3 class="title" id="CD012836-sec-0001">Background</h3> <p>Linezolid was recently re‐classified as a Group A drug by the World Health Organization (WHO) for treatment of multi‐drug resistant tuberculosis (MDR‐TB) and extensively drug‐resistant tuberculosis (XDR‐TB), suggesting that it should be included in the regimen for all patients unless contraindicated. Linezolid use carries a considerable risk of toxicity, with the optimal dose and duration remaining unclear. Current guidelines are mainly based on evidence from observational non‐comparative studies. </p> </section> <section id="CD012836-sec-0002"> <h3 class="title" id="CD012836-sec-0002">Objectives</h3> <p>To assess the efficacy of linezolid when used as part of a second‐line regimen for treating people with MDR and XDR pulmonary tuberculosis, and to assess the prevalence and severity of adverse events associated with linezolid use in this patient group. </p> </section> <section id="CD012836-sec-0003"> <h3 class="title" id="CD012836-sec-0003">Search methods</h3> <p>We searched the following databases: the Cochrane Infectious Diseases Specialized Register; CENTRAL; MEDLINE; Embase; and LILACS up to 13 July 2018. We also checked article reference lists and contacted researchers in the field. </p> </section> <section id="CD012836-sec-0004"> <h3 class="title" id="CD012836-sec-0004">Selection criteria</h3> <p>We included studies in which some participants received linezolid, and others did not. We included randomized controlled trials (RCTs) of linezolid for MDR and XDR pulmonary tuberculosis to evaluate efficacy outcomes. We added non‐randomized cohort studies to evaluate adverse events. </p> <p>Primary outcomes were all‐cause and tuberculosis‐associated death, treatment failure, and cure. Secondary outcomes were treatment interrupted, treatment completed, and time to sputum culture conversion. We recorded frequency of all and serious adverse events, adverse events leading to drug discontinuation or dose reduction, and adverse events attributed to linezolid, particularly neuropathy, anaemia, and thrombocytopenia. </p> </section> <section id="CD012836-sec-0005"> <h3 class="title" id="CD012836-sec-0005">Data collection and analysis</h3> <p>Two review authors (BS and DC) independently assessed the search results for eligibility and extracted data from included studies. All review authors assessed risk of bias using the Cochrane ‘Risk of bias' tool for RCTs and the ROBINS‐I tool for non‐randomized studies. We contacted study authors for clarification and additional data when necessary. </p> <p>We were unable to perform a meta‐analysis as one of the RCTs adopted a study design where participants in the study group received linezolid immediately and participants in the control group received linezolid after two months, and therefore there were no comparable data from this trial. We deemed meta‐analysis of non‐randomized study data inappropriate. </p> </section> <section id="CD012836-sec-0006"> <h3 class="title" id="CD012836-sec-0006">Main results</h3> <p>We identified three RCTs for inclusion. One of these studies had serious problems with allocation of the study drug and placebo, so we could not analyse data for intervention effect from it. The remaining two RCTs recruited 104 participants. One randomized 65 participants to receive linezolid or not, in addition to a background regimen; the other randomized 39 participants to addition of linezolid to a background regimen immediately, or after a delay of two months. We included 14 non‐randomized cohort studies (two prospective, 12 retrospective), with a total of 1678 participants. </p> <p>Settings varied in terms of income and tuberculosis burden. One RCT and 7 out of 14 non‐randomized studies commenced recruitment in or after 2009. All RCT participants and 38.7% of non‐randomized participants were reported to have XDR‐TB. </p> <p>Dosing and duration of linezolid in studies were variable and reported inconsistently. Daily doses ranged from 300 mg to 1200 mg; some studies had planned dose reduction for all participants after a set time, others had incompletely reported dose reductions for some participants, and most did not report numbers of participants receiving each dose. Mean or median duration of linezolid therapy was longer than 90 days in eight of the 14 non‐randomized cohorts that reported this information. </p> <p>Duration of participant follow‐up varied between RCTs. Only five out of 14 non‐randomized studies reported follow‐up duration. </p> <p>Both RCTs were at low risk of reporting bias and unclear risk of selection bias. One RCT was at high risk of performance and detection bias, and low risk for attrition bias, for all outcomes. The other RCT was at low risk of detection and attrition bias for the primary outcome, with unclear risk of detection and attrition bias for non‐primary outcomes, and unclear risk of performance bias for all outcomes. Overall risk of bias for the non‐randomized studies was critical for three studies, and serious for the remaining 11. </p> <p>One RCT reported higher cure (risk ratio (RR) 2.36, 95% confidence interval (CI) 1.13 to 4.90, very low‐certainty evidence), lower failure (RR 0.26, 95% CI 0.10 to 0.70, very low‐certainty evidence), and higher sputum culture conversion at 24 months (RR 2.10, 95% CI 1.30 to 3.40, very low‐certainty evidence), amongst the linezolid‐treated group than controls, with no differences in other primary and secondary outcomes. This study also found more anaemia (17/33 versus 2/32), nausea and vomiting, and neuropathy (14/33 versus 1/32) events amongst linezolid‐receiving participants. Linezolid was discontinued early and permanently in two of 33 (6.1%) participants who received it. </p> <p>The other RCT reported higher sputum culture conversion four months after randomization (RR 2.26, 95% CI 1.19 to 4.28), amongst the group who received linezolid immediately compared to the group who had linezolid initiation delayed by two months. Linezolid was discontinued early and permanently in seven of 39 (17.9%) participants who received it. </p> <p>Linezolid discontinuation occurred in 22.6% (141/624; 11 studies), of participants in the non‐randomized studies. Total, serious, and linezolid‐attributed adverse events could not be summarized quantitatively or comparatively, due to incompleteness of data on duration of follow‐up and numbers of participants experiencing events. </p> </section> <section id="CD012836-sec-0007"> <h3 class="title" id="CD012836-sec-0007">Authors' conclusions</h3> <p>We found some evidence of efficacy of linezolid for drug‐resistant pulmonary tuberculosis from RCTs in participants with XDR‐TB but adverse events and discontinuation of linezolid were common. Overall, there is a lack of comparative data on efficacy and safety. Serious risk of bias and heterogeneity in conducting and reporting non‐randomized studies makes the existing, mostly retrospective, data difficult to interpret. Further prospective cohort studies or RCTs in high tuberculosis burden low‐income and lower‐middle‐income countries would be useful to inform policymakers and clinicians of the efficacy and safety of linezolid as a component of drug‐resistant TB treatment regimens. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD012836-abs-0005" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD012836-abs-0005">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD012836-abs-0010">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD012836-abs-0012">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD012836-abs-0009">Français</a> </li> <li class="section-language"> <a class="" href="full/ms#CD012836-abs-0008">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/ru#CD012836-abs-0007">Русский</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD012836-abs-0006">简体中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD012836-abs-0005" lang="en"> <h3>Linezolid for managing people with drug‐resistant tuberculosis</h3> <p><b>What is drug‐resistant tuberculosis, and how might linezolid work?</b> </p> <p>Tuberculosis is caused by infection with <i>Mycobacterium tuberculosis</i> bacteria. When there are symptoms or signs of illness, this is called active tuberculosis. An estimated one‐third of the world's population are infected with tuberculosis, and around 1.4 million people died from active tuberculosis in 2015. </p> <p>Bacteria that cause tuberculosis can develop resistance to the drugs most commonly used to treat tuberculosis, also called first‐line antibiotics. This is an increasing problem that makes treatment more difficult, because second‐line tuberculosis treatment drugs are less powerful against the bacteria, and more likely to cause harmful effects. Standard treatment for drug‐resistant tuberculosis requires patients to take multiple antibiotics for nearly two years. Linezolid is a second‐line drug that laboratory studies have found to be good at killing bacteria that cause tuberculosis, but that can also cause frequent, serious harmful effects. </p> <p><b>The review question</b> </p> <p>Recent international guidelines recommend trying to include linezolid in the treatment of all patients with multi‐drug resistant tuberculosis, but there is concern about whether enough good evidence exists to tell us how well it works, what dose is best, and how safe it is for people who take it. </p> <p><b>Study characteristics</b> </p> <p>We searched for evidence up to 13 July 2018. We analysed data from two trials, one of which randomly allocated 65 people with drug‐resistant tuberculosis to either a linezolid‐containing or linezolid‐free drug combination, and another that randomly allocated 39 participants to receive linezolid as part of their treatment from the start or have it added after a delay of two months. We also included 14 studies, including 1678 people, in which some participants received linezolid but others did not, but this was not determined at random. </p> <p><b>What are the main results of the review?</b> </p> <p>One trial showed a higher likelihood of cure and lower risk of treatment failure in participants receiving linezolid compared to those who did not. The second trial showed that participants who received linezolid immediately had a higher chance of tuberculosis being cleared from their sputum four months after the start of the study than those who added linezolid after a two‐month delay. </p> <p>When they examined safety, the first trial found a higher risk of developing low red blood cell counts, nausea and vomiting, and nerve damage in people receiving linezolid. From 11 of the non‐randomized studies that reported this, 22.6% of people had to stop linezolid due to adverse effects (side effects), though further comparisons of harmful effects were not possible due to incomplete reporting in the non‐randomized studies. </p> <p>Overall, although there is some evidence of benefit, we have very low certainty in its accuracy. More high‐quality studies are required before we can be certain how effective and safe linezolid is for drug‐resistant tuberculosis. </p> <p><b>How up‐to‐date is this review?</b> </p> <p>This review is current up to 13 July 2018.</p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD012836-sec-0101" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD012836-sec-0101">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD012836-sec-0167">Español</a> </li> </nav> </div> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD012836-sec-0101"></div> <h3 class="title" id="CD012836-sec-0102">Implications for practice</h3> <section id="CD012836-sec-0102"> <p>Two small randomized controlled trials (RCTs) in people with extensively drug‐resistant tuberculosis (XDR‐TB), reported better efficacy outcomes with linezolid use. The first reported higher cure (very low‐certainty evidence), lower failure (very low‐certainty evidence), and higher sputum culture conversion at 24 months (very low‐certainty evidence), in participants who received linezolid compared with those who did not receive linezolid. The second RCT reported higher sputum culture conversion rates at four months for participants receiving linezolid immediately versus those who delayed initiation by two months. A lack of high‐quality, comparative evidence resulted in our inability to calculate pooled effect estimates of efficacy and safety of linezolid, so we cannot conclude implications for its use in all patients with drug‐resistant tuberculosis. </p> </section> <h3 class="title" id="CD012836-sec-0103">Implications for research</h3> <section id="CD012836-sec-0103"> <p>Whilst our review presents very low‐certainty evidence for efficacy of linezolid for XDR‐TB, a lack of comparative design and reporting limits our certainty in the evidence for the use of linezolid in all patients with drug‐resistant pulmonary tuberculosis. </p> <p>The safety of linezolid, in comparison with alternative or background regimens for drug‐resistant pulmonary tuberculosis remains unclear, even when previous reviews are consulted. In addition, the questions of optimal dosing, duration and combination therapy all remain unanswered, with the majority of existing comparative datasets coming from retrospective studies carried out in high‐ and upper‐middle‐income countries. </p> <p>RCTs in low‐ and lower‐middle‐income countries comparing linezolid‐containing regimens with alternative regimens not containing linezolid would be desirable to inform guidance on its place in management of drug‐resistant pulmonary tuberculosis. Ongoing studies may help, though they have not been designed to examine linezolid's efficacy and safety specifically, and are unlikely to report before the next WHO guidelines are produced. In particular, we would welcome improved, comparable safety reporting in drug studies and observational studies, in order to answer difficult and important questions relating to toxicity and tolerability of drug‐resistant tuberculosis treatments. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD012836-sec-0030" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD012836-sec-0030"></div> <div class="table" id="CD012836-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Linezolid compared to no linezolid for drug‐resistant pulmonary tuberculosis</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Linezolid compared to no linezolid for drug‐resistant pulmonary tuberculosis</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> drug‐resistant pulmonary tuberculosis<br/> <b>Setting:</b> one study (<a href="./references#CD012836-bbs2-0013" title="TangS , YaoL , HaoX , ZhangX , LiuG , LiuX , et al. Efficacy, safety and tolerability of linezolid for the treatment of XDR‐TB: a study in China. European Respiratory Journal2015;45(1):161‐70. ">Tang 2015</a>): China; all adults; all extensively drug resistant; no participants with HIV (excluded)<br/> <b>Intervention:</b> linezolid<br/> <b>Comparison:</b> no linezolid </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="center" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (trials)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with no linezolid</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with linezolid</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Death</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>9 per 100</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>6 per 100<br/> (1 to 34) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.65<br/> (0.12 to 3.62) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>65<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>a,b,c,d</sup> </p> <p>due to risk of bias, imprecision, and indirectness</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We are uncertain whether or not linezolid reduces death</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Treatment failure</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>47 per 100</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>12 per 100<br/> (5 to 33) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.26<br/> (0.10 to 0.70) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>65<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>a,b,d,e</sup> </p> <p>due to risk of bias, imprecision, and indirectness</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We are uncertain whether or not linezolid reduces treatment failure</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Cure</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>22 per 100</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>52 per 100<br/> (25 to 100) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 2.36<br/> (1.13 to 4.90) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>65<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>a,b,d,f</sup> </p> <p>due to risk of bias, imprecision, and indirectness</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We are uncertain whether or not linezolid increases cure</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Treatment interrupted</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>9 per 100</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>12 per 100<br/> (3 to 50) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.29<br/> (0.31 to 5.33) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>65<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>a,b,c,d</sup> </p> <p>due to risk of bias, imprecision, and indirectness</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We are uncertain whether or not linezolid reduces treatment interruption</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Treatment completed</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>13 per 100</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>18 per 100<br/> (6 to 59) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.45<br/> (0.45 to 4.68) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>65<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>a,b,c,d</sup> </p> <p>due to risk of bias, imprecision, and indirectness</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We are uncertain whether linezolid increases treatment completion as the certainty of the evidence is very low </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Sputum culture conversion</b> <br/> <b>at 24 months</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>38 per 100</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>79 per 100<br/> (49 to 100) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 2.1<br/> (1.3 to 3.4) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>65<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>b,d,f</sup> </p> <p>due to risk of bias, imprecision, and indirectness</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We are uncertain whether or not linezolid increases sputum culture conversion</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Total adverse events</b><sup>g</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>28 (32 participants) in no‐linezolid group; 74 (33 participants) in linezolid group<sup>g</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>65<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>a,d,h,i</sup> </p> <p>due to risk of bias, imprecision, and indirectness</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We are uncertain whether or not linezolid reduces total adverse events</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Serious adverse events</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Antituberculous treatment</b> <br/> <b>discontinuation</b><sup>j</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>3 per 100</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>6 per 100<br/> (1 to 64) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.94<br/> (0.18 to 20.35) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>65<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>a,b,d,k</sup> </p> <p>due to risk of bias, imprecision, and indirectness</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We are uncertain whether or not linezolid reduces anti‐tuberculous treatment discontinuation</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Linezolid discontinuation</b><sup>l</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>2/33 participants receiving linezolid had permanent discontinuation of linezolid</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>65<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Comparison is not possible for this outcome</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>Abbreviations: CI:</b> confidence interval; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/> <b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>No serious inconsistency: only one study was included.<br/> <sup>b</sup>Downgraded by one level for serious indirectness: the population (drug‐resistant tuberculosis), though meeting criteria for inclusion in the review, only included adults, who had extensively drug‐resistant tuberculosis, and tested negative for HIV infection. Recruitment was from only one country (China). Participants were excluded if they could not afford linezolid.<br/> <sup>c</sup>Downgraded by two levels for very serious imprecision: the CI is wide, and the event rate is low.<br/> <sup>d</sup>Downgraded by two levels for risk of bias: random sequence generation and allocation concealment were not described, therefore leading to unclear risk of bias. There was no blinding, nor placebo control, so there was a high risk of performance and detection bias.<br/> <sup>e</sup>Serious imprecision, due to small sample size.<br/> <sup>f</sup>Downgraded by two levels for very serious imprecision: the CI is wide and sample size is small.<br/> <sup>g</sup>Due to lack of reporting of follow‐up duration, we were unable to calculate a risk ratio.<br/> <sup>h</sup>Downgraded by one level for serious indirectness: due to lack of follow‐up duration data, we were unable to perform comparative analysis for this outcome.<br/> <sup>i</sup>Downgraded by two levels for very serious imprecision, due to inability to calculate risk ratio.<br/> <sup>j</sup>Antituberculous treatment (ATT): a further two participants in each group discontinued ATT due to inability to afford the drugs. We included only discontinuations due to clinical reasons in the results, for the purpose of the review.<br/> <sup>k</sup>Downgraded by two levels for very serious imprecision: number of events was small, with a resulting wide CI, ranging from very large increase to an 82% decrease in discontinuation.<br/> <sup>l</sup>Some participants discontinued linezolid temporarily, but the number of those was not reported. Participants discontinuing linezolid due to being unable to afford it (n = 2) are not included in this number. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD012836-sec-0031" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD012836-sec-0031">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD012836-sec-0118">Español</a> </li> </nav> </div> </div> <section class="background" lang="en"> <div class="section-header" id="CD012836-sec-0031"></div> <section id="CD012836-sec-0032"> <h3 class="title" id="CD012836-sec-0032">Description of the condition</h3> <p>Tuberculosis is caused by infection with bacteria of the <i>Mycobacterium tuberculosis</i> complex. It remains one of the leading infectious causes of death worldwide; there were 1.4 million deaths from tuberculosis worldwide in 2015, with an additional 0.4 million deaths from tuberculosis amongst people living with HIV (<a href="./references#CD012836-bbs2-0178" title="World Health Organization. Global Tuberculosis Report. Geneva: World Health Organization, 2016. ">WHO 2016b</a>). Pulmonary tuberculosis is the most common form of tuberculosis, and the most important from a public health perspective because tuberculosis is transmitted by aerosolized droplets from people with active pulmonary tuberculosis when they cough (<a href="./references#CD012836-bbs2-0169" title="VashishthaR , MohanK , SinghB , DevarapuSK , SreenivasV , RanjanS , et al. Efficacy and safety of thrice weekly DOTS in tuberculosis patients with and without HIV co‐infection: an observational study. BMC Infectious Diseases2013;13:468. [DOI: 10.1186/1471‐2334‐13‐468] ">Vashishtha 2013</a>). It is estimated that around one third of the world's population are infected with tuberculosis, although of these only one in ten will develop active tuberculosis disease (<a href="./references#CD012836-bbs2-0170" title="World Health Organization. Global Tuberculosis Control Report. Geneva: World Health Organization, 2009. ">WHO 2009</a>). </p> <p>Most people with tuberculosis are infected with strains of <i>M tuberculosis</i> that are treatable with the standard first‐line drugs recommended by the World Health Organization (WHO) guidelines: rifampicin, isoniazid, pyrazinamide, and ethambutol (<a href="./references#CD012836-bbs2-0171" title="World Health Organization. Treatment of Tuberculosis Guidelines. 4th Edition. Geneva: World Health Organization, 2010. ">WHO 2010</a>). Early diagnosis and treatment with effective drugs is a mainstay of tuberculosis disease control, as well as being a life‐saving intervention for people with tuberculosis. </p> <p>Multidrug‐resistant tuberculosis (MDR‐TB) is tuberculosis disease that is caused by <i>M tuberculosis</i> strains that have acquired resistance to two important drugs in the first‐line regimen: rifampicin and isoniazid (<a href="./references#CD012836-bbs2-0165" title="SharmaSK , MohanA . Multidrug‐resistant tuberculosis: a menace that threatens to destabilize tuberculosis control. Chest2006;130(1):261‐72. ">Sharma 2006</a>). Rifampicin‐monoresistant tuberculosis is often managed as MDR‐TB (<a href="./references#CD012836-bbs2-0177" title="World Health Organization. WHO Treatment Guidelines for Drug‐Resistant Tuberculosis – 2016 update. Geneva: World Health Organization, 2016. ">WHO 2016a</a>). Extensively drug‐resistant tuberculosis (XDR‐TB), occurs when <i>M tuberculosis</i> strains are resistant to rifampicin, isoniazid, and any of the antibiotics in the fluoroquinolone class, as well as any of the three injectable drugs used in the second‐line treatment of tuberculosis: amikacin, kanamycin, and capreomycin (<a href="./references#CD012836-bbs2-0177" title="World Health Organization. WHO Treatment Guidelines for Drug‐Resistant Tuberculosis – 2016 update. Geneva: World Health Organization, 2016. ">WHO 2016a</a>). </p> <p>The WHO estimates that 480,000 cases of MDR‐TB occurred in 2015, with 190,000 deaths worldwide, and an estimated 9.5% of people with MDR‐TB actually having XDR‐TB (<a href="./references#CD012836-bbs2-0178" title="World Health Organization. Global Tuberculosis Report. Geneva: World Health Organization, 2016. ">WHO 2016b</a>). Detection of drug‐resistant tuberculosis is challenging and currently requires costly laboratory services. Access to effective treatment is far from universal. Despite rapid progress, only 12% of new tuberculosis cases were tested for drug resistance in 2014, with case detection at only 41% (<a href="./references#CD012836-bbs2-0175" title="World Health Organization. Global Tuberculosis Report 2015. Geneva: World Health Organization, 2015. [ISBN 978 92 4 156505 9] ">WHO 2015a</a>). Over the last decade treatment success rates have remained static at around 50% (<a href="./references#CD012836-bbs2-0175" title="World Health Organization. Global Tuberculosis Report 2015. Geneva: World Health Organization, 2015. [ISBN 978 92 4 156505 9] ">WHO 2015a</a>), and the international tuberculosis community has recognized that new drugs and regimens with improved efficacy are urgently needed to improve cure rates. The WHO End TB Strategy outlines measures for post‐2015 tuberculosis control; these include a goal to detect and treat everyone with drug‐resistant tuberculosis, which will require significant scaling up of resources and efforts (<a href="./references#CD012836-bbs2-0174" title="World Health Organization. The End TB Strategy. Geneva: World Health Organization, 2014. ">WHO 2014</a>). </p> <p>Constructing drug‐resistant tuberculosis chemotherapy regimens is difficult; several of the available agents are expensive and toxic, and efficacy is uncertain because data from clinical studies are limited (<a href="./references#CD012836-bbs2-0144" title="ChangKC , YewWW . Management of difficult multidrug‐resistant tuberculosis and extensively drug‐resistant tuberculosis: update 2012. Respirology2013;18(1):8‐21. [DOI: 10.1111/j.1440‐1843.2012.02257.x] ">Chang 2013a</a>). This is especially true for XDR‐TB. Treatment for drug‐resistant tuberculosis is long: conventional regimens are administered for a total of 20 months for most patients, with an initial intensive phase of around eight months, dependent upon response to therapy (<a href="./references#CD012836-bbs2-0177" title="World Health Organization. WHO Treatment Guidelines for Drug‐Resistant Tuberculosis – 2016 update. Geneva: World Health Organization, 2016. ">WHO 2016a</a>). This has led to efforts being channeled towards investigation of new and existing drugs and regimens, with a drive to shorten treatment duration, standardize study design and reporting (<a href="./references#CD012836-bbs2-0161" title="MitnickCD , RusenI , BainLJ , HorsburghCRJr . Issues in design and interpretation of MDR‐TB clinical trials: report of the first Global MDR‐TB Clinical Trials Landscape Meeting. BMC Proceedings2015;9(Suppl 8):S1. [DOI: 10.1186/1753‐6561‐9‐S8‐S1] ">Mitnick 2015</a>), and focus on low‐resource settings that are disproportionately affected by tuberculosis and MDR‐TB globally (<a href="./references#CD012836-bbs2-0166" title="SloanDJ , LewisJM . Management of multidrug‐resistant TB: novel treatments and their expansion to low resource settings. Transactions of the Royal Society of Tropical Medicine and Hygiene2016;110(3):163‐72. [DOI: 10.1093/trstmh/trv107] ">Sloan 2016</a>). </p> </section> <section id="CD012836-sec-0033"> <h3 class="title" id="CD012836-sec-0033">Description of the intervention</h3> <p>Linezolid was categorized as a ‘Group 5' drug in the 2011 WHO drug‐resistant tuberculosis guidelines (<a href="./references#CD012836-bbs2-0172" title="World Health Organization. Guidelines for the programmatic management of drug‐resistant tuberculosis: 2011 update. Geneva: World Health Organization, 2011. [ISBN 978 92 4 150158 3] ">WHO 2011</a>). Medications assigned to this group were not recommended for use as core drugs, due to insufficient evidence detailing their safety or efficacy. However, the 2016 WHO update re‐allocated it as a ‘Group C: other core second‐line agent', prioritizing its use over some more traditional agents (<a href="./references#CD012836-bbs2-0177" title="World Health Organization. WHO Treatment Guidelines for Drug‐Resistant Tuberculosis – 2016 update. Geneva: World Health Organization, 2016. ">WHO 2016a</a>). The number of linezolid‐treated patients included in reviews of evidence informing both the 2011 and 2016 WHO guidance was insufficient to provide efficacy and safety estimates (<a href="./references#CD012836-bbs2-0172" title="World Health Organization. Guidelines for the programmatic management of drug‐resistant tuberculosis: 2011 update. Geneva: World Health Organization, 2011. [ISBN 978 92 4 150158 3] ">WHO 2011</a>, <a href="./references#CD012836-bbs2-0152" title="FoxGJ , BenedettiA , CoxH , KohWJ , ViikleppP , AhujaS , et al. on behalf of the Collaborative Group for Meta‐Analysis of Individual Patient Data in MDR‐TB. Group 5 drugs for multidrug‐resistant tuberculosis: individual patient data meta‐analysis. European Respiratory Journal2017;49:1600993. ">Fox 2017</a>). In 2018, in a rapid communication from the WHO on treatment of MDR‐TB and rifampicin‐monoresistant‐TB, linezolid’s position was further upgraded to a ‘group A: Medicines to be prioritised' (<a href="./references#CD012836-bbs2-0179" title="World Health Organization. Rapid communication: key changes to treatment of multidrug‐ and rifampicin‐resistant tuberculosis (MDR/RR‐TB). Available at: www.who.int/tb/publications/2018/rapid_communications_MDR/en/2018. ">WHO 2018</a>). A summary of evidence for the 2018 recommendation has been published (<a href="./references#CD012836-bbs2-0142" title="AhmadN , AhujaSD , AkkermanOW , AlffenaarJC , AndersonLF , BaghaeiP , et al. Treatment correlates of successful outcomes in pulmonary multi‐drug resistant tuberculosis: an individual patient data meta‐analysis. Lancet2018;362:821‐34. ">Ahmad 2018</a>). </p> <p>Despite the promoted status of linezolid, concerns about serious adverse effects prompted the 2016 WHO update to caution that where close monitoring for adverse events is unavailable, “linezolid would best be reserved for MDR‐TB patients who have additional drug resistance...or who are intolerant to other components of the core regimen” (<a href="./references#CD012836-bbs2-0177" title="World Health Organization. WHO Treatment Guidelines for Drug‐Resistant Tuberculosis – 2016 update. Geneva: World Health Organization, 2016. ">WHO 2016a</a>). The 2018 WHO rapid communication, which recommends linezolid for all people with MDR‐TB unless it cannot be used, still states that, "Optimal duration of use of Lzd [linezolid] is not established. Use for at least 6 months was shown to be highly effective, although toxicity may limit its use” (<a href="./references#CD012836-bbs2-0179" title="World Health Organization. Rapid communication: key changes to treatment of multidrug‐ and rifampicin‐resistant tuberculosis (MDR/RR‐TB). Available at: www.who.int/tb/publications/2018/rapid_communications_MDR/en/2018. ">WHO 2018</a>). </p> <p>Five meta‐analyses have examined the evidence for linezolid in drug‐resistant tuberculosis (<a href="./references#CD012836-bbs2-0147" title="CoxH , FordN . Linezolid for the treatment of complicated drug‐resistant tuberculosis: a systematic review and meta‐analysis. International Journal of Tuberculosis and Lung Disease2012;16(4):447‐54. [DOI: 10.5588/ijtld.11.0451] ">Cox 2012</a>; <a href="./references#CD012836-bbs2-0167" title="SotgiuG , CentisR , D'AmbrosioL , AlffenaarJW , AngerHA , CamineroJA , et al. Efficacy, safety and tolerability of linezolid‐containing regimens in treating MDR‐TB and XDR‐TB: systematic review and meta‐analysis. European Respiratory Journal2012;40(6):1430‐42. [DOI: 10.1183/09031936.00022912] ">Sotgiu 2012</a>; <a href="./references#CD012836-bbs2-0146" title="ChangKC , YewWW , TamCM , LeungCC . WHO group 5 drugs and difficult multidrug‐resistant tuberculosis: a systematic review with cohort analysis and meta‐analysis. Antimicrobial Agents and Chemotherapy2013;57(9):4097–104. ">Chang 2013c</a>; <a href="./references#CD012836-bbs2-0180" title="ZhangX , FalagasME , VardakasKZ , WangR , QinR , WangJ , et al. Systematic review and meta‐analysis of the efficacy and safety of therapy with linezolid containing regimens in the treatment of multidrug‐resistant and extensively drug‐resistant tuberculosis. Journal of Thoracic Disease2015;7(4):603‐15. [DOI: 10.3978/j.issn.2072‐1439.2015.03.10] ">Zhang 2015</a>; <a href="./references#CD012836-bbs2-0142" title="AhmadN , AhujaSD , AkkermanOW , AlffenaarJC , AndersonLF , BaghaeiP , et al. Treatment correlates of successful outcomes in pulmonary multi‐drug resistant tuberculosis: an individual patient data meta‐analysis. Lancet2018;362:821‐34. ">Ahmad 2018</a>). They include mostly observational data, much of it retrospective. Few randomized studies have been undertaken. There remains much debate surrounding linezolid, due to the lack of high‐quality evidence. Many suggest it should be more widely used, hence its upgrade in the recent WHO guidance (<a href="./references#CD012836-bbs2-0143" title="CamineroJA , ScardigliA . Classification of antituberculosis drugs: a new proposal based on the most recent evidence. European Respiratory Journal2015;46(4):887‐93. ">Caminero 2015</a>; <a href="./references#CD012836-bbs2-0142" title="AhmadN , AhujaSD , AkkermanOW , AlffenaarJC , AndersonLF , BaghaeiP , et al. Treatment correlates of successful outcomes in pulmonary multi‐drug resistant tuberculosis: an individual patient data meta‐analysis. Lancet2018;362:821‐34. ">Ahmad 2018</a>; <a href="./references#CD012836-bbs2-0179" title="World Health Organization. Rapid communication: key changes to treatment of multidrug‐ and rifampicin‐resistant tuberculosis (MDR/RR‐TB). Available at: www.who.int/tb/publications/2018/rapid_communications_MDR/en/2018. ">WHO 2018</a>). </p> <p>Considerable reliance on retrospective data may have exacerbated the effect of confounders in the meta‐analyses of treatment efficacy (<a href="./references#CD012836-bbs2-0147" title="CoxH , FordN . Linezolid for the treatment of complicated drug‐resistant tuberculosis: a systematic review and meta‐analysis. International Journal of Tuberculosis and Lung Disease2012;16(4):447‐54. [DOI: 10.5588/ijtld.11.0451] ">Cox 2012</a>; <a href="./references#CD012836-bbs2-0167" title="SotgiuG , CentisR , D'AmbrosioL , AlffenaarJW , AngerHA , CamineroJA , et al. Efficacy, safety and tolerability of linezolid‐containing regimens in treating MDR‐TB and XDR‐TB: systematic review and meta‐analysis. European Respiratory Journal2012;40(6):1430‐42. [DOI: 10.1183/09031936.00022912] ">Sotgiu 2012</a>; <a href="./references#CD012836-bbs2-0146" title="ChangKC , YewWW , TamCM , LeungCC . WHO group 5 drugs and difficult multidrug‐resistant tuberculosis: a systematic review with cohort analysis and meta‐analysis. Antimicrobial Agents and Chemotherapy2013;57(9):4097–104. ">Chang 2013c</a>; <a href="./references#CD012836-bbs2-0180" title="ZhangX , FalagasME , VardakasKZ , WangR , QinR , WangJ , et al. Systematic review and meta‐analysis of the efficacy and safety of therapy with linezolid containing regimens in the treatment of multidrug‐resistant and extensively drug‐resistant tuberculosis. Journal of Thoracic Disease2015;7(4):603‐15. [DOI: 10.3978/j.issn.2072‐1439.2015.03.10] ">Zhang 2015</a>; <a href="./references#CD012836-bbs2-0142" title="AhmadN , AhujaSD , AkkermanOW , AlffenaarJC , AndersonLF , BaghaeiP , et al. Treatment correlates of successful outcomes in pulmonary multi‐drug resistant tuberculosis: an individual patient data meta‐analysis. Lancet2018;362:821‐34. ">Ahmad 2018</a>). These reviews also selected, and focus on, efficacy rather than safety. As highlighted by the WHO documents, safety is a major area of concern with linezolid (<a href="./references#CD012836-bbs2-0163" title="RamachandranGS , SwaminathanS . Safety and tolerability profile of second‐line anti‐tuberculosis medications. Drug Safety2015;38(3):253‐69. ">Ramachandran 2015</a>). </p> </section> <section id="CD012836-sec-0034"> <h3 class="title" id="CD012836-sec-0034">How the intervention might work</h3> <p>Linezolid is an oxazolidinone antibiotic that disrupts protein synthesis by binding to the 70S initiation complex of bacterial ribosomes (<a href="./references#CD012836-bbs2-0166" title="SloanDJ , LewisJM . Management of multidrug‐resistant TB: novel treatments and their expansion to low resource settings. Transactions of the Royal Society of Tropical Medicine and Hygiene2016;110(3):163‐72. [DOI: 10.1093/trstmh/trv107] ">Sloan 2016</a>). It also binds to human mitochondria and inhibits protein synthesis, which is the mechanism of toxicity in clinical use (<a href="./references#CD012836-bbs2-0148" title="DeVrieseAS , CosterRV , SmetJ , SenecaS , LoveringA , VanHauteLL , et al. Linezolid‐induced inhibition of mitochondrial protein synthesis. Clinical Infectious Diseases2006;42(8):1111‐7. ">De Vriese 2006</a>). It is active against most Gram‐positive bacteria, with extensive evidence of in vitro activity against isolates of <i>M tuberculosis</i>, including those resistant to first‐line drugs (<a href="./references#CD012836-bbs2-0151" title="ErturanZ , UzunM . In vitro activity of linezolid against multidrug‐resistant Mycobacterium tuberculosis isolates. International Journal of Antimicrobial Agents2005;26(1):78‐80. [DOI: 10.1016/j.ijantimicag.2005.03.006] ">Erturan 2005</a>; <a href="./references#CD012836-bbs2-0158" title="HuangTS , LiuYC , SyCL , ChenYS , TuHZ , ChenBC . In vitro activities of linezolid against clinical isolates of Mycobacterium tuberculosis complex isolated in Taiwan over 10 years. Antimicrobial Agents and Chemotherapy2008;52(6):2226‐7. [DOI: 10.1128/AAC.00414‐07] ">Huang 2008</a>). </p> <p>Linezolid can be taken orally or intravenously. Its excellent oral bioavailability is an advantage, avoiding the need for long‐term daily injections (<a href="./references#CD012836-bbs2-0150" title="DrydenMS . Linezolid pharmacokinetics and pharmacodynamics in clinical treatment. Journal of Antimicrobial Chemotherapy2011;66(Suppl 4):iv7‐15. [DOI: 10.1093/jac/dkr072] ">Dryden 2011</a>). Though an adult dose of 600 mg twice daily is commonly used for up to 28 days to treat infections due to Gram‐positive bacteria, a variety of dosing strategies have been used in the context of drug‐resistant tuberculosis, where treatment duration is much longer. These have ranged from 300 mg to 1200 mg daily, with once‐ or twice‐daily administration. Lower doses have been tried in an attempt to increase tolerability and reduce toxicity (<a href="./references#CD012836-bbs2-0076" title="ParkIN , HongSB , OhYM , KimMN , LimCM , LeeSD , et al. Efficacy and tolerability of daily‐half dose linezolid in patients with intractable multidrug‐resistant tuberculosis. Journal of Antimicrobial Chemotherapy2006;58(3):701‐4. ">Park 2006</a>; <a href="./references#CD012836-bbs2-0009" title="MiglioriGB , EkerB , RichardsonMD , SotgiuG , ZellwegerJP , SkrahinaA , et al. A retrospective TBNET assessment of linezolid safety, tolerability and efficacy in multidrug‐resistant tuberculosis. European Respiratory Journal2009;34(2):387‐93. ">Migliori 2009</a>; <a href="./references#CD012836-bbs2-0111" title="YewWW , ChangKC , ChauCH . What is the optimal dosage of linezolid in treatment of complicated multidrug‐resistant tuberculosis?. European Respiratory Journal2009;34(6):1492‐4. ">Yew 2009</a>; <a href="./references#CD012836-bbs2-0059" title="KohWJ , KangYR , JeonK , KwonOJ , LyuJ , KimWS , et al. Daily 300 mg dose of linezolid for multidrug‐resistant and extensively drug‐resistant tuberculosis: updated analysis of 51 patients. Journal of Antimicrobial Chemotherapy2012;67(6):1503‐7. ">Koh 2012</a>). A thrice‐weekly intermittent dosing regimen has also been attempted in limited cohorts to extend the duration of linezolid therapy (<a href="./references#CD012836-bbs2-0145" title="ChangKC , YewWW , CheungSW , LeungCC , TamCM , ChauCH , et al. Can intermittent dosing optimize prolonged linezolid treatment of difficult multidrug‐resistant tuberculosis?. Antimicrobial Agents and Chemotherapy2013;57(7):3445‐9. [DOI: 10.1128/AAC.00388‐13] ">Chang 2013b</a>). The optimal dosing and duration of linezolid remains unclear from the perspective of preventing emergence of resistance, as well as efficacy, tolerability, and toxicity. </p> <p>Adverse effects of linezolid include suppression of the bone marrow causing anaemia and thrombocytopenia, peripheral neuropathy, and optic neuropathy leading to disability and blindness, which is usually irreversible. More commonly, gastrointestinal upset may lead to difficulties with adherence (<a href="./references#CD012836-bbs2-0163" title="RamachandranGS , SwaminathanS . Safety and tolerability profile of second‐line anti‐tuberculosis medications. Drug Safety2015;38(3):253‐69. ">Ramachandran 2015</a>). Adverse events with courses of linezolid longer than one month appear to be common within antituberculous drug regimens, affecting over 80% of participants in some studies (<a href="./references#CD012836-bbs2-0008" title="LeeM , ChoSN , BarryCE . Linezolid for XDR‐TB ‐ final study outcomes. New England Journal of Medicine2015;373(3):290‐1. LeeM , LeeJ , CarrollMW , ChoiH , MinS , SongT , et al. Linezolid for treatment of chronic extensively drug‐resistant tuberculosis. New England Journal of Medicine2012;367(16):1508‐18. ">Lee 2012</a>). </p> </section> <section id="CD012836-sec-0035"> <h3 class="title" id="CD012836-sec-0035">Why it is important to do this review</h3> <p>We set out to perform a systematic review reporting on the efficacy of linezolid for drug‐resistant tuberculosis, balanced against an estimate of the risk of linezolid‐associated adverse events. Such estimates will assist policy makers who are deciding on the place of linezolid in their national and regional drug‐resistant tuberculosis programmes, as well as individual clinicians trying to interpret the wide variety of published data on how effective, safe, and tolerable linezolid is in people being treated for MDR‐TB and XDR‐TB. </p> <p>Existing evidence, while of low quality, has concluded that linezolid is efficacious in MDR‐TB, leading to its inclusion as a drug to be prioritized in the latest WHO guidance (<a href="./references#CD012836-bbs2-0179" title="World Health Organization. Rapid communication: key changes to treatment of multidrug‐ and rifampicin‐resistant tuberculosis (MDR/RR‐TB). Available at: www.who.int/tb/publications/2018/rapid_communications_MDR/en/2018. ">WHO 2018</a>). However, evidence regarding appropriate dosing and duration is lacking. Importantly, as linezolid is rolled out for wider use, closer interrogation of the adverse events data is desirable. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD012836-sec-0036" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD012836-sec-0036">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD012836-sec-0123">Español</a> </li> </nav> </div> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD012836-sec-0036"></div> <p>To assess the efficacy of linezolid when used as part of a second‐line regimen for treating people with MDR and XDR pulmonary tuberculosis, and to assess the prevalence and severity of adverse events associated with linezolid use in this patient group. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD012836-sec-0037" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD012836-sec-0037">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD012836-sec-0124">Español</a> </li> </nav> </div> </div> <section class="methods" lang="en"> <div class="section-header" id="CD012836-sec-0037"></div> <section id="CD012836-sec-0038"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD012836-sec-0039"> <h4 class="title">Types of studies</h4> <p>To assess the efficacy of linezolid we included randomized controlled trials (RCTs) and quasi‐RCTs. </p> <p>To assess the prevalence and severity of adverse events associated with the use of linezolid, we included RCTs and quasi‐RCTs, and both prospective and retrospective, non‐randomized cohort studies, as defined by the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD012836-bbs2-0160" title="LokeYK , PriceD , HerxheimerA . Chapter 14: Adverse effects. In: Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.handbook.cochrane.org. ">Loke 2011</a>), in which some participants received linezolid and others did not. </p> </section> <section id="CD012836-sec-0040"> <h4 class="title">Types of participants</h4> <p>Adults and children with a diagnosis of MDR (including rifampicin‐monoresistant, managed as MDR) or XDR pulmonary tuberculosis. </p> </section> <section id="CD012836-sec-0041"> <h4 class="title">Types of interventions</h4> <section id="CD012836-sec-0042"> <h5 class="title">Intervention</h5> <p>Antituberculous treatment (ATT) regimens that contained linezolid at any dose and for any duration. </p> </section> <section id="CD012836-sec-0043"> <h5 class="title">Control</h5> <p>ATT regimens that did not contain linezolid.</p> </section> </section> <section id="CD012836-sec-0044"> <h4 class="title">Types of outcome measures</h4> <p>These outcome measures are based on those specified by the WHO for tuberculosis programme outcome reporting in MDR‐ and XDR‐TB (<a href="./references#CD012836-bbs2-0173" title="World Health Organization. Definitions and reporting framework for tuberculosis – 2013 revision (updated December 2014). Geneva: World Health Organization, 2013. ">WHO 2013</a>). </p> <section id="CD012836-sec-0045"> <h5 class="title">Primary outcomes</h5> <p> <ul id="CD012836-list-0001"> <li> <p>All‐cause death: all deaths that occurred during each included study and until the end of follow‐up </p> </li> <li> <p>Tuberculosis‐associated death: all deaths attributed to tuberculosis by the study investigators that occurred during each study and until the end of follow‐up </p> </li> <li> <p>Treatment failure: participants who did not show conversion from sputum culture positive to negative by the end of the intensive phase of ATT, or who had reverted from culture‐negative to culture‐positive, or who had failed to respond clinically to treatment as defined by the study investigators </p> </li> <li> <p>Cure: participants who completed ATT as planned without evidence of failure and had at least three consecutive negative sputum cultures in specimens taken at least 30 days apart after the intensive phase of treatment. </p> </li> </ul> </p> </section> <section id="CD012836-sec-0046"> <h5 class="title">Secondary outcomes</h5> <p> <ul id="CD012836-list-0002"> <li> <p>Treatment interrupted: participants who stopped taking ATT for one month or longer at any point in the course of treatment </p> </li> <li> <p>Treatment completed: participants who completed ATT as planned but did not have at least three consecutive negative sputum cultures in specimens taken at least 30 days apart after the intensive phase of treatment </p> </li> <li> <p>Time to sputum culture conversion: the length of time between starting treatment and conversion from sputum culture positive to sputum culture negative. </p> </li> </ul> </p> <section id="CD012836-sec-0047"> <h6 class="title">Adverse events</h6> <p> <ul id="CD012836-list-0003"> <li> <p>All adverse events</p> </li> <li> <p>All serious adverse events</p> </li> <li> <p>Adverse events that led to discontinuation of antituberculous drugs or dose reduction</p> </li> <li> <p>Adverse events attributed to linezolid, particularly peripheral and optic neuropathy, anaemia, thrombocytopenia, lactic acidosis, and serotonin syndrome </p> </li> </ul> </p> </section> </section> </section> </section> <section id="CD012836-sec-0048"> <h3 class="title">Search methods for identification of studies</h3> <p>We attempted to identify all relevant studies regardless of language or publication status (published, unpublished, in press, and in progress). </p> <section id="CD012836-sec-0049"> <h4 class="title">Electronic searches</h4> <p>We searched the following databases for relevant studies using the search terms detailed in <a href="http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD012242/full#CD012242-sec2-0008" target="_blank">Appendix 1</a>: </p> <p> <ul id="CD012836-list-0004"> <li> <p>the Cochrane Infectious Diseases Specialized Register</p> </li> <li> <p>the Cochrane Central Register of Controlled Trials (CENTRAL; 2018, Issue 7) published in the Cochrane Library </p> </li> <li> <p>MEDLINE (PubMed)</p> </li> <li> <p>Embase (OVID)</p> </li> <li> <p>LILACS</p> </li> </ul> </p> <p>We also checked the WHO International Clinical Trials Registry Platform (WHO ICTRP; <a href="http://www.who.int/ictrp/en/" target="_blank">www.who.int/ictrp/en/</a>), and ClinicalTrials.gov (<a href="https://clinicaltrials.gov/ct2/home" target="_blank">clinicaltrials.gov/ct2/home</a>), for ongoing studies using the terms: ‘linezolid' and ‘tuberculosis'. </p> <p>The latest searches were conducted on 13 July 2018.</p> </section> <section id="CD012836-sec-0050"> <h4 class="title">Searching other resources</h4> <p>We contacted researchers in the field to identify unpublished or ongoing studies.</p> </section> </section> <section id="CD012836-sec-0051"> <h3 class="title" id="CD012836-sec-0051">Data collection and analysis</h3> <section id="CD012836-sec-0052"> <h4 class="title">Selection of studies</h4> <p>Two review authors (BS and DC) screened the titles and abstracts of the search results independently and coded them as either ‘retrieve' (eligible or potentially eligible/unclear), or ‘do not retrieve'. We retrieved the full‐text study reports of all potentially eligible studies and two review authors (BS and DC) independently screened them for inclusion and recorded the reasons for exclusion of ineligible studies. We resolved any disagreement through discussion or, when required, we consulted a third review author. We identified and excluded duplicates and collated multiple reports of the same study so that each study, rather than each report, was the unit of interest in the review. We contacted study authors for clarification if a study's eligibility was unclear. We resolved any disagreements through discussion and listed the excluded studies and the reasons for their exclusion in the <a href="./references#CD012836-sec-0115" title="">Characteristics of excluded studies</a> table. We recorded the selection process in sufficient detail to complete a PRISMA flow diagram (<a href="./references#CD012836-bbs2-0162" title="MoherD , LiberatiA , TetzlaffJ , AltmanDG , The PRISMA Group (2009). Preferred reporting items for systematic reviews and meta‐analyses: The PRISMA Statement. PLoS Medicine 6;7:e1000097. [DOI: 10.1371/journal.pmed1000097] ">Moher 2009</a>; <a href="#CD012836-fig-0001">Figure 1</a>). </p> <div class="figure" id="CD012836-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram" data-id="CD012836-fig-0001" src="/cdsr/doi/10.1002/14651858.CD012836.pub2/media/CDSR/CD012836/image_n/nCD012836-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram</p> </div> </div> </div> </section> <section id="CD012836-sec-0053"> <h4 class="title">Data extraction and management</h4> <p>We designed and piloted a data extraction form, and modified the form based on the results of the pilot. Two review authors (BS and DC) independently extracted data from each included study using the finalized data extraction form. BS and DC compared the extracted data to identify any possible errors, and resolved any discrepancies through discussion and by referring to the original study articles. We extracted the following data from each included study, where available. </p> <p> <ul id="CD012836-list-0005"> <li> <p>Country and clinical setting, start and end dates of the study, study design, inclusion and exclusion criteria, number of participants eligible for inclusion and number of participants allocated to each group </p> </li> <li> <p>Participant characteristics: age, sex, history of previous tuberculosis treatment, known contact with MDR‐TB patient, duration of symptoms at presentation, comorbidity (HIV infection, other immunosuppression and other diseases), diagnostic methods used (e.g. culture‐based drug susceptibility testing, Xpert MTB/RIF, line probe assay for drug susceptibility), drug susceptibility profile of participants at entry to the study </p> </li> <li> <p>Intervention data: description of drugs, dose, route of administration in both the intensive and continuation phase, and duration of all drugs for both phases. Administration of other drugs or therapeutic procedures, including surgery </p> </li> </ul> </p> <section id="CD012836-sec-0054"> <h5 class="title">Primary outcomes</h5> <p>For the primary outcomes we extracted the following data.</p> <section id="CD012836-sec-0055"> <h6 class="title">All‐cause death</h6> <p> <ul id="CD012836-list-0006"> <li> <p>Number of deaths, stratified by drug susceptibility profile, age and HIV status</p> </li> <li> <p>Timing of death after start of treatment</p> </li> </ul> </p> </section> <section id="CD012836-sec-0056"> <h6 class="title">Tuberculosis‐associated death</h6> <p> <ul id="CD012836-list-0007"> <li> <p>Number of deaths attributed to tuberculosis by the investigators, stratified by drug susceptibility profile, age and HIV status </p> </li> </ul> </p> </section> <section id="CD012836-sec-0057"> <h6 class="title">Treatment failure</h6> <p> <ul id="CD012836-list-0008"> <li> <p>Number of participants who did not show sputum culture conversion by the end of the intensive phase of ATT, stratified by drug susceptibility profile, age and HIV status </p> </li> <li> <p>Number of participants who reverted from culture negative to culture positive, stratified by drug susceptibility profile, age and HIV status </p> </li> <li> <p>Number of participants who failed to respond clinically to treatment as defined by the investigators, stratified by drug susceptibility profile, age and HIV status </p> </li> <li> <p>Method of monitoring treatment and defining treatment failure</p> </li> <li> <p>Time between start of treatment and treatment failure</p> </li> <li> <p>Outcome following classification as treatment failure</p> </li> </ul> </p> </section> <section id="CD012836-sec-0058"> <h6 class="title">Cure</h6> <p> <ul id="CD012836-list-0009"> <li> <p>Number of participants who completed ATT as planned and had at least three negative sputum cultures in specimens taken at least 30 days apart during the last months of treatment, stratified by drug susceptibility profile, age, and HIV status </p> </li> </ul> </p> </section> </section> <section id="CD012836-sec-0059"> <h5 class="title">Secondary outcomes</h5> <p>For the secondary outcomes we extracted the following data.</p> <section id="CD012836-sec-0060"> <h6 class="title">Treatment interrupted</h6> <p> <ul id="CD012836-list-0010"> <li> <p>Number of participants who stopped taking ATT for one month or more at any point in the course of treatment, stratified by drug susceptibility profile, age and HIV status </p> </li> <li> <p>Method of monitoring treatment adherence</p> </li> <li> <p>Reasons for treatment interruption</p> </li> </ul> </p> </section> <section id="CD012836-sec-0061"> <h6 class="title">Treatment completed</h6> <p> <ul id="CD012836-list-0011"> <li> <p>Number of participants who completed ATT as planned but did not have at least three negative sputum cultures in specimens taken at least 30 days apart during the last months of treatment. </p> </li> <li> <p>Method of monitoring treatment.</p> </li> </ul> </p> </section> <section id="CD012836-sec-0062"> <h6 class="title">Time to sputum culture conversion</h6> <p> <ul id="CD012836-list-0012"> <li> <p>Time between starting treatment and conversion from sputum culture positive to sputum culture negative </p> </li> <li> <p>Method of monitoring treatment, including frequency of sputum sampling</p> </li> </ul> </p> </section> </section> <section id="CD012836-sec-0063"> <h5 class="title">Follow‐up</h5> <p>Length of follow‐up, follow‐up methods, number and characteristics of losses to follow‐up.</p> </section> <section id="CD012836-sec-0064"> <h5 class="title">Adverse events</h5> <p>We extracted information on the total number of the following.</p> <p> <ul id="CD012836-list-0013"> <li> <p>Adverse events</p> </li> <li> <p>Serious adverse events</p> </li> <li> <p>Participants experiencing adverse events</p> </li> <li> <p>Adverse events that led to discontinuation of antituberculous drugs or linezolid dose reduction </p> </li> <li> <p>Adverse events attributed to linezolid, particularly peripheral and optic neuropathy, anaemia, thrombocytopenia, lactic acidosis, and serotonin syndrome </p> </li> </ul> </p> <p>For each outcome, we extracted the number of participants assigned and the number of participants analysed in each treatment group. For dichotomous outcomes, we extracted the number of participants who experienced the event. For count data outcomes, we extracted the number of events in the intervention and control groups. </p> </section> </section> <section id="CD012836-sec-0065"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>For RCTs and quasi‐RCTs, two review authors independently assessed the methodological quality of each included study using the Cochrane ‘Risk of bias' tool and reported the results in a ‘Risk of bias' table (<a href="./references#CD012836-bbs2-0156" title="HigginsJP , AltmanDG , GøtzschePC , JüniP , MoherD , OxmanAD , et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ2011;343:d5928. [DOI: 10.1136/bmj.d5928] ">Higgins 2011a</a>). We resolved any disagreements through discussion. Regarding generation of allocation sequence and allocation concealment, we classified each as either adequate, inadequate, or unclear in each included study according to <a href="./references#CD012836-bbs2-0159" title="JüniP , AltmanDG , EggerM . Systematic reviews in health care: assessing the quality of controlled clinical trials. BMJ2001;323(7303):42‐6. ">Jüni 2001</a>. We reported who was blinded in each included study, and we assessed the risk of bias associated with blinding separately for each primary outcome. If at least 90% of participants were followed up to study completion we classified inclusion of all randomized participants as adequate; otherwise we classified inclusion as inadequate. We attempted to contact the study authors if information was unspecified or unclear. </p> <p>For non‐randomized studies, we used the ROBINS‐I risk of bias tool (<a href="./references#CD012836-bbs2-0168" title="SterneJA , HigginsJP , ReevesBC , SavovićJ , TurnerL , ROBINS‐I development group. ROBINS‐I: a tool for assessing Risk Of Bias In Non‐randomized Studies of Interventions. Available from www.riskofbias.info (accessed 14 June 2016). ">Sterne 2016</a>), and adapted and piloted it before we used it to assess all included non‐randomized studies. The following are areas of confounding that we expected to be relevant to all or most included studies. </p> <p> <ul id="CD012836-list-0014"> <li> <p>Extent of drug resistance: number of effective drugs available</p> </li> <li> <p>Severity of tuberculosis disease at start of treatment</p> </li> <li> <p>HIV co‐infection</p> </li> <li> <p>Timing of addition of linezolid to the regimen</p> </li> <li> <p>Duration of linezolid treatment</p> </li> <li> <p>Background antituberculous therapy regimen (the other drugs composing the overall regimen) </p> </li> <li> <p>Supportive care available in study setting</p> </li> </ul> </p> </section> <section id="CD012836-sec-0066"> <h4 class="title">Measures of treatment effect</h4> <p>We used risk ratio (RR) as the measure of treatment effect for analysis.</p> </section> <section id="CD012836-sec-0067"> <h4 class="title">Unit of analysis issues</h4> <p>We did not anticipate that any cluster‐RCTs would meet the inclusion criteria of the review. </p> <p>For multi‐armed studies, where we wished to include more than one intervention study arm, we planned to split the control group to avoid including the same participants more than once. </p> </section> <section id="CD012836-sec-0068"> <h4 class="title">Dealing with missing data</h4> <p>The primary analysis was an intention‐to‐treat analysis where all participants randomized to treatment were included in the denominator. This analysis assumed that all people lost to follow‐up did not have the outcome in question. We carried out a sensitivity analysis to explore the impact of missing data on the summary effect estimates for all‐cause death, cure and failure. </p> </section> <section id="CD012836-sec-0069"> <h4 class="title">Assessment of heterogeneity</h4> <p>We planned to assess heterogeneity by visually inspecting the forest plots to determine closeness of point estimates to each other and overlap of confidence intervals (CIs). We planned to use the Chi² test with a P value of 0.10 to indicate statistical significance (<a href="./references#CD012836-bbs2-0149" title="DeeksJJ , HigginsJP , Altman DG (editors) on behalf of the Cochrane Statistical Methods Group. Chapter 9: Analysing data and undertaking meta‐analyses. In: Higgins JPT, Churchill R, Chandler J, Cumpston MS (editors), Cochrane Handbook for Systematic Reviews of Interventions version 5.2.0 (updated June 2017), Cochrane, 2017. Available from www.training.cochrane.org/handbook. ">Deeks 2017</a>), and the I² statistic (<a href="./references#CD012836-bbs2-0155" title="HigginsJP , ThompsonSG , DeeksJJ , AltmanDG . Measuring inconsistency in meta‐analyses. BMJ2003;327:557‐60. ">Higgins 2003</a>), to assess heterogeneity with a value of 50% taken to indicate significant statistical heterogeneity. </p> </section> <section id="CD012836-sec-0070"> <h4 class="title">Assessment of reporting biases</h4> <p>We planned to conduct visual inspection of the funnel plot of the studies for any obvious asymmetry that could be evidence of publication bias if we included at least 10 studies. </p> </section> <section id="CD012836-sec-0071"> <h4 class="title">Data synthesis</h4> <p>Using Review Manager 5 (RevMan 5), we planned to perform a meta‐analysis on the data in included studies, but not to combine data from RCTs and non‐randomized studies (<a href="./references#CD012836-bbs2-0164" title="Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">Review Manager 2014</a>). As we anticipated significant variability in samples from participants across the different studies, we planned to use a random‐effects model for meta‐analysis, unless there was a very small number of included studies with low heterogeneity, in which case we planned to use a fixed‐effect model. </p> <p>For non‐randomized data, we did not plan to perform a meta‐analysis. We planned to report these data descriptively in a table that included how the data were collected, and the reported outcomes (unadjusted). If the study authors had adjusted data, we planned to provide this estimate with a short description of the adjustments the study authors made. </p> <p>We assessed the certainty of the evidence using the GRADE approach. We used GRADEpro GDT software to construct a ‘Summary of findings' table (<a href="./references#CD012836-bbs2-0153" title="GRADE Working Group, McMaster University. GRADEpro GDT. Version accessed 15 May 2017. Hamilton (ON): GRADE Working Group, McMaster University, 2015. ">GRADEpro GDT 2015</a>). </p> </section> <section id="CD012836-sec-0072"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We planned to investigate heterogeneity through the following subgroup analyses.</p> <p> <ul id="CD012836-list-0015"> <li> <p>Drug‐resistance profile, determined by:</p> <ul id="CD012836-list-0016"> <li> <p>% XDR</p> </li> <li> <p>% fluoroquinolone‐resistant (resistant to any fluoroquinolone, but susceptible to injectables) </p> </li> <li> <p>% injectable‐resistant (resistant to any injectable, but susceptible to fluoroquinolones)</p> </li> </ul> </li> <li> <p>HIV status (seropositive and seronegative)</p> </li> <li> <p>Age (adults and children)</p> </li> <li> <p>Daily dose of linezolid (600 mg or less and over 600 mg adult equivalent)</p> </li> <li> <p>Duration of linezolid (six months or less and longer than six months)</p> </li> <li> <p>Total cumulative dose of linezolid</p> </li> <li> <p>Other drugs within the background antituberculous drug regimen</p> </li> </ul> </p> </section> <section id="CD012836-sec-0073"> <h4 class="title">Sensitivity analysis</h4> <p>We performed a worst‐case scenario analysis by imputing the missing data as poor outcomes in the linezolid group and good outcomes in the control group, and by comparing this to an available‐case analysis to explore the effect of missing data on the primary outcomes all‐cause death, cure and failure. </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD012836-sec-0074" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD012836-sec-0074"></div> <section id="CD012836-sec-0075"> <h3 class="title">Description of studies</h3> <section id="CD012836-sec-0076"> <h4 class="title">Results of the search</h4> <p>Searches identified 781 records. Of these, we excluded 23 duplicate records. Of the remaining 758, we excluded 621 after assessing titles and abstracts. Following this, we retrieved 137 full‐text publications to assess for inclusion. <a href="#CD012836-fig-0001">Figure 1</a> shows the screening process in a flow diagram. </p> </section> <section id="CD012836-sec-0077"> <h4 class="title">Included studies</h4> <p>We included 17 studies: three randomized studies (138 participants), and 14 non‐randomized cohort studies (1678 participants), of which two were prospective and 12 were retrospective (<a href="#CD012836-fig-0001">Figure 1</a>). A summary description is provided in <a href="#CD012836-tbl-0002">Table 1</a>, with more detailed characteristics in the ‘<a href="./references#CD012836-sec-0114" title="">Characteristics of included studies</a>' section. </p> <div class="table" id="CD012836-tbl-0002"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Summary of characteristics of included studies</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Study design</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Country</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Recruitment dates</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Age</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Drug resistance</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>HIV status reported</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Linezolid daily dose</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Linezolid duration</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>Number of participants</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Linezolid</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>No linezolid</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Total</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012836-bbs2-0008" title="LeeM , ChoSN , BarryCE . Linezolid for XDR‐TB ‐ final study outcomes. New England Journal of Medicine2015;373(3):290‐1. LeeM , LeeJ , CarrollMW , ChoiH , MinS , SongT , et al. Linezolid for treatment of chronic extensively drug‐resistant tuberculosis. New England Journal of Medicine2012;367(16):1508‐18. ">Lee 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCT, no placebo, partial blinding</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Republic of Korea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2008 to 2011</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adults &gt; 20 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All XDR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes, excluded</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>600 mg, then randomized to 300 mg or 600 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Median 781 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19 immediate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20 delayed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>39</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012836-bbs2-0011" title="PadayatchiN , Mac KenzieWR , Hirsch‐MovermanY , FengPJ , VillarinoE , SaukkonenJ , et al. Lessons from a randomised clinical trial for multidrug‐resistant tuberculosis. International Journal of Tuberculosis and Lung Disease2012, issue 12:1582‐7. ">Padayatchi 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCT, placebo, blinding</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>South Africa</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2009 to 2010</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adults &gt; 18 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All MDR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes, included, mostly on antiretrovirals</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>600 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>112 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012836-bbs2-0013" title="TangS , YaoL , HaoX , ZhangX , LiuG , LiuX , et al. Efficacy, safety and tolerability of linezolid for the treatment of XDR‐TB: a study in China. European Respiratory Journal2015;45(1):161‐70. ">Tang 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCT, no placebo/blinding</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>China</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2009 to 2011</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adults 18 to 64 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All XDR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes, excluded</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1200 mg 4 to 6 weeks, then 300 to 600 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Until sputum culture negative</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>65</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012836-bbs2-0009" title="MiglioriGB , EkerB , RichardsonMD , SotgiuG , ZellwegerJP , SkrahinaA , et al. A retrospective TBNET assessment of linezolid safety, tolerability and efficacy in multidrug‐resistant tuberculosis. European Respiratory Journal2009;34(2):387‐93. ">Migliori 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Retrospective cohort</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Belarus, Germany, Italy, Switzerland</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2001 to 2007</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18/195 XDR, rest MDR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>600 to 1200 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Median 93 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>85</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>110</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>195</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012836-bbs2-0015" title="UdwadiaZF , SenT , MoharilG . Assessment of linezolid efficacy and safety in MDR‐ and XDR‐TB: an Indian perspective. European Respiratory Journal2010;35(4):936‐8; author reply 938‐40. ">Udwadia 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prospective cohort</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>India</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2000 to 2007</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adults &gt; 18 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7/18 XDR, rest MDR (linezolid group)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1200 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean 247 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>78</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012836-bbs2-0006" title="JoKW , LeeSD , KimWS , KimDS , ShimTS . Treatment outcomes and moxifloxacin susceptibility in ofloxacin‐resistant multidrug‐resistant tuberculosis. International Journal of Tuberculosis and Lung Disease2014;18(1):39‐43. ">Jo 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Retrospective cohort</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Republic of Korea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2006 to 2012</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adults &gt;18 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26/70 XDR, rest MDR; all ofloxacin‐resistant</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes, 9/70 tested – all negative</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>300 to 600 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Median 259 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>44</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>70</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012836-bbs2-0012" title="SeddonJA , HesselingAC , Godfrey‐FaussettP , SchaafHS . High treatment success in children treated for multidrug‐resistant tuberculosis: an observational cohort study. Thorax2014;69(5):471‐7. ">Seddon 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Retrospective cohort</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>South Africa</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2009 to 2012</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Children &lt; 15 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6/149 (2/3 receiving linezolid) XDR, 16/149 rifampicin‐monoresistant, rest MDR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes, included, mostly on antiretrovirals</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Median 480 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>146</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>149</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012836-bbs2-0017" title="ZhangL , PangY , YuX , WangY , GaoM , HuangH , et al. Linezolid in the treatment of extensively drug‐resistant tuberculosis. Infection2014;42(4):705‐11. ">Zhang 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Retrospective cohort</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>China</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2012 to 2013</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adults &gt; 18 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All XDR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes, all negative</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>600 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unknown ("at least one month")</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>43</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012836-bbs2-0005" title="JeongBH , JeonK , ParkHY , KwonOJ , LeeKS , KimHK , et al. Outcomes of pulmonary MDR‐TB: impacts of fluoroquinolone resistance and linezolid treatment. Journal of Antimicrobial Chemotherapy2015;70(11):3127‐33. ">Jeong 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Retrospective cohort</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Republic of Korea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2005 to 2011</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adults &gt; 18 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All fluoroquinolone‐resistant MDR, or XDR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes, no HIV‐positive participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>300 to 600 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Median 426 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>58</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>86</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>144</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012836-bbs2-0007" title="KwakN , KimHR , YooCG , KimYW , HanSK , YimJJ . Changes in treatment outcomes of multidrug‐resistant tuberculosis. International Journal of Tuberculosis and Lung Disease2015;19(5):525‐30. ">Kwak 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Retrospective cohort</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Republic of Korea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2006 to 2010</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26/123 XDR, rest MDR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>111</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>123</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012836-bbs2-0016" title="VanAltenaR , DeVriesG , HaarCH , DeLangeWC , Magis‐EscurraC , Van denHofS , et al. Highly successful treatment outcome of multidrug‐resistant tuberculosis in the Netherlands, 2000‐2009. International Journal of Tuberculosis and Lung Disease2015;19(4):406‐12. ">Van Altena 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Retrospective cohort</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Netherlands</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2000 to 2009</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4/112 XDR, rest MDR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes, included</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>600 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean 99 days, median 56 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>53</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>51</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>104</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012836-bbs2-0002" title="GalliL , LancellaL , TersigniC , VenturiniE , ChiappiniE , BergaminiB , et al. Pediatric tuberculosis in Italian children: epidemiological and clinical data from the Italian register of pediatric tuberculosis. International Journal of Molecular Sciences2016;17(6):960. ">Galli 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Retrospective cohort</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Italy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2010 to 2012</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Children &lt; 18 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/11 XDR, rest MDR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012836-bbs2-0004" title="JenseniusM , WinjeBA , BlombergB , MengshoelAT , LippeBV , HannulaR , et al. Multidrug‐resistant tuberculosis in Norway: a nationwide study, 1995‐2014. International Journal of Tuberculosis and Lung Disease2016;20(6):786‐92. ">Jensenius 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Retrospective cohort</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Norway</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1995 to 2014</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All, range 2 to 57 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6/89 XDR, rest MDR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes, included</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"Usually" 1200 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>68</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012836-bbs2-0014" title="TiberiS , PayenMC , SotgiuG , D'AmbrosioL , GuizadoVA , AlffenaarJW , et al. Effectiveness and safety of meropenem/ clavulanate‐containing regimens in the treatment of MDR‐ and XDR‐TB. European Respiratory Journal2016;47(4):1235‐43. TiberiS , SotgiuG , D'AmbrosioL , CentisR , ArbexMA , ArrascueEA , et al. Comparison of effectiveness and safety of imipenem/clavulanate‐versus meropenem/clavulanate‐containing regimens in the treatment of MDR‐ and XDR‐TB. European Respiratory Journal2016;47(6):1758‐66. ">Tiberi 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Retrospective cohort</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Belarus, Belgium, Brazil, Ecuador, Greece, Holland, Italy, Peru, Slovakia, UK</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2003 to 2015</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adults &gt; 15 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>XDR and MDR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes, included, mostly on antiretrovirals</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>300 to 1200 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>267</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>81</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>348</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012836-bbs2-0003" title="GuglielmettiL , JaspardM , LeDûD , LachâtreM , Marigot‐OuttandyD , BernardC , French MDR‐TB Management Group. Long‐term outcome and safety of prolonged bedaquiline treatment for multidrug‐resistant tuberculosis. European Respiratory Journal2017;49:1601799. [DOI: 10.1183/13993003.01799‐2016] ">Guglielmetti 2017</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Retrospective cohort</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>France</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2011 to 2013</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24/45 XDR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes, included</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>600 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>45</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012836-bbs2-0001" title="FerlazzoG , MohrE , LaxmeshwarC , HewisonC , HughesJ , JonckheereS , et al. Early safety and efficacy of the combination of bedaquiline and delamanid for the treatment of patients with drug‐resistant tuberculosis in Armenia, India, and South Africa: a retrospective cohort study. Lancet Infectious Diseases2018;18:536‐44. [DOI: 10.1016/S1473‐3099(18)30100‐2] ">Ferlazzo 2018</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Retrospective cohort</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Armenia, India, South Africa</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2016</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&gt; 18 years and one 14‐year old</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14/28 XDR, rest MDR (10 fluoroquinolone resistant)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes, included</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012836-bbs2-0010" title="OlayanjuO , LimberisJ , EsmailA , OelofseS , GinaP , PietersenE , et al. Long‐term bedaquiline‐related treatment outcomes in patients with extensively drug‐resistant tuberculosis from South Africa. European Respiratory Journal2018;51:1800544. [DOI: 10.1183/13993003.00544‐2018] ">Olayanju 2018</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prospective cohort</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>South Africa</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2008 to 2017</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adults &gt; 18 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All XDR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes, included</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>55</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>217</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>272</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>Abbreviations: MDR: multi‐drug resistant; RCT: randomized controlled trial; XDR: extensively drug resistant. </p> </div> </div> <section id="CD012836-sec-0078"> <h5 class="title">Geographical location and time period</h5> <p>The RCTs were conducted in the Republic of Korea, South Africa and China.</p> <p>Locations were diverse amongst the non‐randomized studies. Three were based in the Republic of Korea; a low tuberculosis burden and low MDR‐TB burden country (<a href="./references#CD012836-bbs2-0006" title="JoKW , LeeSD , KimWS , KimDS , ShimTS . Treatment outcomes and moxifloxacin susceptibility in ofloxacin‐resistant multidrug‐resistant tuberculosis. International Journal of Tuberculosis and Lung Disease2014;18(1):39‐43. ">Jo 2014</a>; <a href="./references#CD012836-bbs2-0005" title="JeongBH , JeonK , ParkHY , KwonOJ , LeeKS , KimHK , et al. Outcomes of pulmonary MDR‐TB: impacts of fluoroquinolone resistance and linezolid treatment. Journal of Antimicrobial Chemotherapy2015;70(11):3127‐33. ">Jeong 2015</a>; <a href="./references#CD012836-bbs2-0007" title="KwakN , KimHR , YooCG , KimYW , HanSK , YimJJ . Changes in treatment outcomes of multidrug‐resistant tuberculosis. International Journal of Tuberculosis and Lung Disease2015;19(5):525‐30. ">Kwak 2015</a>), according to WHO definitions of tuberculosis, tuberculosis/HIV and MDR‐TB burden (<a href="./references#CD012836-bbs2-0176" title="World Health Organization. Use of high burden country lists for TB by WHO in the post‐2015 era. Geneva: World Health Organization, 2015. ">WHO 2015b</a>). Four were conducted in low tuberculosis burden and low MDR‐TB burden European countries; Netherlands (<a href="./references#CD012836-bbs2-0016" title="VanAltenaR , DeVriesG , HaarCH , DeLangeWC , Magis‐EscurraC , Van denHofS , et al. Highly successful treatment outcome of multidrug‐resistant tuberculosis in the Netherlands, 2000‐2009. International Journal of Tuberculosis and Lung Disease2015;19(4):406‐12. ">Van Altena 2015</a>), Italy (<a href="./references#CD012836-bbs2-0002" title="GalliL , LancellaL , TersigniC , VenturiniE , ChiappiniE , BergaminiB , et al. Pediatric tuberculosis in Italian children: epidemiological and clinical data from the Italian register of pediatric tuberculosis. International Journal of Molecular Sciences2016;17(6):960. ">Galli 2016</a>), Norway (<a href="./references#CD012836-bbs2-0004" title="JenseniusM , WinjeBA , BlombergB , MengshoelAT , LippeBV , HannulaR , et al. Multidrug‐resistant tuberculosis in Norway: a nationwide study, 1995‐2014. International Journal of Tuberculosis and Lung Disease2016;20(6):786‐92. ">Jensenius 2016</a>) and France (<a href="./references#CD012836-bbs2-0003" title="GuglielmettiL , JaspardM , LeDûD , LachâtreM , Marigot‐OuttandyD , BernardC , French MDR‐TB Management Group. Long‐term outcome and safety of prolonged bedaquiline treatment for multidrug‐resistant tuberculosis. European Respiratory Journal2017;49:1601799. [DOI: 10.1183/13993003.01799‐2016] ">Guglielmetti 2017</a>). Two studies recruited from Europe, but also from high MDR‐TB burden former Soviet Union states (<a href="./references#CD012836-bbs2-0009" title="MiglioriGB , EkerB , RichardsonMD , SotgiuG , ZellwegerJP , SkrahinaA , et al. A retrospective TBNET assessment of linezolid safety, tolerability and efficacy in multidrug‐resistant tuberculosis. European Respiratory Journal2009;34(2):387‐93. ">Migliori 2009</a>; <a href="./references#CD012836-bbs2-0014" title="TiberiS , PayenMC , SotgiuG , D'AmbrosioL , GuizadoVA , AlffenaarJW , et al. Effectiveness and safety of meropenem/ clavulanate‐containing regimens in the treatment of MDR‐ and XDR‐TB. European Respiratory Journal2016;47(4):1235‐43. TiberiS , SotgiuG , D'AmbrosioL , CentisR , ArbexMA , ArrascueEA , et al. Comparison of effectiveness and safety of imipenem/clavulanate‐versus meropenem/clavulanate‐containing regimens in the treatment of MDR‐ and XDR‐TB. European Respiratory Journal2016;47(6):1758‐66. ">Tiberi 2016</a>). One of these also recruited from centres in South America, with low tuberculosis burden and mixed MDR‐TB burden (<a href="./references#CD012836-bbs2-0014" title="TiberiS , PayenMC , SotgiuG , D'AmbrosioL , GuizadoVA , AlffenaarJW , et al. Effectiveness and safety of meropenem/ clavulanate‐containing regimens in the treatment of MDR‐ and XDR‐TB. European Respiratory Journal2016;47(4):1235‐43. TiberiS , SotgiuG , D'AmbrosioL , CentisR , ArbexMA , ArrascueEA , et al. Comparison of effectiveness and safety of imipenem/clavulanate‐versus meropenem/clavulanate‐containing regimens in the treatment of MDR‐ and XDR‐TB. European Respiratory Journal2016;47(6):1758‐66. ">Tiberi 2016</a>). One study was conducted in China (<a href="./references#CD012836-bbs2-0017" title="ZhangL , PangY , YuX , WangY , GaoM , HuangH , et al. Linezolid in the treatment of extensively drug‐resistant tuberculosis. Infection2014;42(4):705‐11. ">Zhang 2014</a>), another in India (<a href="./references#CD012836-bbs2-0015" title="UdwadiaZF , SenT , MoharilG . Assessment of linezolid efficacy and safety in MDR‐ and XDR‐TB: an Indian perspective. European Respiratory Journal2010;35(4):936‐8; author reply 938‐40. ">Udwadia 2010</a>), and two in South Africa (<a href="./references#CD012836-bbs2-0012" title="SeddonJA , HesselingAC , Godfrey‐FaussettP , SchaafHS . High treatment success in children treated for multidrug‐resistant tuberculosis: an observational cohort study. Thorax2014;69(5):471‐7. ">Seddon 2014</a>; <a href="./references#CD012836-bbs2-0010" title="OlayanjuO , LimberisJ , EsmailA , OelofseS , GinaP , PietersenE , et al. Long‐term bedaquiline‐related treatment outcomes in patients with extensively drug‐resistant tuberculosis from South Africa. European Respiratory Journal2018;51:1800544. [DOI: 10.1183/13993003.00544‐2018] ">Olayanju 2018</a>); these three countries have high tuberculosis, tuberculosis/HIV and MDR‐TB burden. <a href="./references#CD012836-bbs2-0001" title="FerlazzoG , MohrE , LaxmeshwarC , HewisonC , HughesJ , JonckheereS , et al. Early safety and efficacy of the combination of bedaquiline and delamanid for the treatment of patients with drug‐resistant tuberculosis in Armenia, India, and South Africa: a retrospective cohort study. Lancet Infectious Diseases2018;18:536‐44. [DOI: 10.1016/S1473‐3099(18)30100‐2] ">Ferlazzo 2018</a> recruited from Armenia (former Soviet Union country, previously on the high MDR‐TB burden list), India and South Africa. </p> <p>All RCTs and non‐randomized studies were conducted in high‐income or upper‐middle‐income countries except for those that recruited in India, a lower‐middle‐income country. </p> <p>The RCTs recruited between 2008 and 2011. There was a wide time range amongst the cohort studies: seven of the 14 started recruitment in 2009 or later and three completed recruitment in 2009, with the earliest starting in 1995 and the latest completing in 2017. </p> </section> <section id="CD012836-sec-0079"> <h5 class="title">Participants</h5> <p>Two studies included children only (<a href="./references#CD012836-bbs2-0012" title="SeddonJA , HesselingAC , Godfrey‐FaussettP , SchaafHS . High treatment success in children treated for multidrug‐resistant tuberculosis: an observational cohort study. Thorax2014;69(5):471‐7. ">Seddon 2014</a>; <a href="./references#CD012836-bbs2-0002" title="GalliL , LancellaL , TersigniC , VenturiniE , ChiappiniE , BergaminiB , et al. Pediatric tuberculosis in Italian children: epidemiological and clinical data from the Italian register of pediatric tuberculosis. International Journal of Molecular Sciences2016;17(6):960. ">Galli 2016</a>). <a href="./references#CD012836-bbs2-0004" title="JenseniusM , WinjeBA , BlombergB , MengshoelAT , LippeBV , HannulaR , et al. Multidrug‐resistant tuberculosis in Norway: a nationwide study, 1995‐2014. International Journal of Tuberculosis and Lung Disease2016;20(6):786‐92. ">Jensenius 2016</a> recruited participants of all ages. The remainder, including both RCTs, were conducted in adults (four studies not reporting ages (<a href="./references#CD012836-bbs2-0009" title="MiglioriGB , EkerB , RichardsonMD , SotgiuG , ZellwegerJP , SkrahinaA , et al. A retrospective TBNET assessment of linezolid safety, tolerability and efficacy in multidrug‐resistant tuberculosis. European Respiratory Journal2009;34(2):387‐93. ">Migliori 2009</a>; <a href="./references#CD012836-bbs2-0007" title="KwakN , KimHR , YooCG , KimYW , HanSK , YimJJ . Changes in treatment outcomes of multidrug‐resistant tuberculosis. International Journal of Tuberculosis and Lung Disease2015;19(5):525‐30. ">Kwak 2015</a>; <a href="./references#CD012836-bbs2-0016" title="VanAltenaR , DeVriesG , HaarCH , DeLangeWC , Magis‐EscurraC , Van denHofS , et al. Highly successful treatment outcome of multidrug‐resistant tuberculosis in the Netherlands, 2000‐2009. International Journal of Tuberculosis and Lung Disease2015;19(4):406‐12. ">Van Altena 2015</a>; <a href="./references#CD012836-bbs2-0003" title="GuglielmettiL , JaspardM , LeDûD , LachâtreM , Marigot‐OuttandyD , BernardC , French MDR‐TB Management Group. Long‐term outcome and safety of prolonged bedaquiline treatment for multidrug‐resistant tuberculosis. European Respiratory Journal2017;49:1601799. [DOI: 10.1183/13993003.01799‐2016] ">Guglielmetti 2017</a>), we assumed to have mostly or exclusively included adults). </p> <p>Most studies included both MDR‐ and XDR‐TB cases. Two RCTs (<a href="./references#CD012836-bbs2-0008" title="LeeM , ChoSN , BarryCE . Linezolid for XDR‐TB ‐ final study outcomes. New England Journal of Medicine2015;373(3):290‐1. LeeM , LeeJ , CarrollMW , ChoiH , MinS , SongT , et al. Linezolid for treatment of chronic extensively drug‐resistant tuberculosis. New England Journal of Medicine2012;367(16):1508‐18. ">Lee 2012</a>; <a href="./references#CD012836-bbs2-0013" title="TangS , YaoL , HaoX , ZhangX , LiuG , LiuX , et al. Efficacy, safety and tolerability of linezolid for the treatment of XDR‐TB: a study in China. European Respiratory Journal2015;45(1):161‐70. ">Tang 2015</a>), one prospective cohort study (<a href="./references#CD012836-bbs2-0010" title="OlayanjuO , LimberisJ , EsmailA , OelofseS , GinaP , PietersenE , et al. Long‐term bedaquiline‐related treatment outcomes in patients with extensively drug‐resistant tuberculosis from South Africa. European Respiratory Journal2018;51:1800544. [DOI: 10.1183/13993003.00544‐2018] ">Olayanju 2018</a>), and one retrospective cohort (<a href="./references#CD012836-bbs2-0017" title="ZhangL , PangY , YuX , WangY , GaoM , HuangH , et al. Linezolid in the treatment of extensively drug‐resistant tuberculosis. Infection2014;42(4):705‐11. ">Zhang 2014</a>), included only XDR‐TB cases, and <a href="./references#CD012836-bbs2-0006" title="JoKW , LeeSD , KimWS , KimDS , ShimTS . Treatment outcomes and moxifloxacin susceptibility in ofloxacin‐resistant multidrug‐resistant tuberculosis. International Journal of Tuberculosis and Lung Disease2014;18(1):39‐43. ">Jo 2014</a> and <a href="./references#CD012836-bbs2-0005" title="JeongBH , JeonK , ParkHY , KwonOJ , LeeKS , KimHK , et al. Outcomes of pulmonary MDR‐TB: impacts of fluoroquinolone resistance and linezolid treatment. Journal of Antimicrobial Chemotherapy2015;70(11):3127‐33. ">Jeong 2015</a> included MDR cases with at least fluoroquinolone resistance (including XDR). Half (14/28) of the cases in <a href="./references#CD012836-bbs2-0001" title="FerlazzoG , MohrE , LaxmeshwarC , HewisonC , HughesJ , JonckheereS , et al. Early safety and efficacy of the combination of bedaquiline and delamanid for the treatment of patients with drug‐resistant tuberculosis in Armenia, India, and South Africa: a retrospective cohort study. Lancet Infectious Diseases2018;18:536‐44. [DOI: 10.1016/S1473‐3099(18)30100‐2] ">Ferlazzo 2018</a> were XDR. The remaining studies included a minority of cases with XDR. </p> <p><a href="./references#CD012836-bbs2-0012" title="SeddonJA , HesselingAC , Godfrey‐FaussettP , SchaafHS . High treatment success in children treated for multidrug‐resistant tuberculosis: an observational cohort study. Thorax2014;69(5):471‐7. ">Seddon 2014</a> included 16 (of 149 total) children with rifampicin‐monoresistant‐tuberculosis, managed as MDR‐TB. No other studies reported participants with rifampicin‐monoresistant‐tuberculosis. </p> <p>HIV infection status was reported in all but four studies. Eight included participants with HIV infection; two RCTs (<a href="./references#CD012836-bbs2-0008" title="LeeM , ChoSN , BarryCE . Linezolid for XDR‐TB ‐ final study outcomes. New England Journal of Medicine2015;373(3):290‐1. LeeM , LeeJ , CarrollMW , ChoiH , MinS , SongT , et al. Linezolid for treatment of chronic extensively drug‐resistant tuberculosis. New England Journal of Medicine2012;367(16):1508‐18. ">Lee 2012</a>; <a href="./references#CD012836-bbs2-0013" title="TangS , YaoL , HaoX , ZhangX , LiuG , LiuX , et al. Efficacy, safety and tolerability of linezolid for the treatment of XDR‐TB: a study in China. European Respiratory Journal2015;45(1):161‐70. ">Tang 2015</a>), excluded HIV‐positive individuals; and three reported no known HIV‐positive participants, but with variable reporting of whether participants had been tested. Studies reporting on antiretroviral therapy (<a href="./references#CD012836-bbs2-0011" title="PadayatchiN , Mac KenzieWR , Hirsch‐MovermanY , FengPJ , VillarinoE , SaukkonenJ , et al. Lessons from a randomised clinical trial for multidrug‐resistant tuberculosis. International Journal of Tuberculosis and Lung Disease2012, issue 12:1582‐7. ">Padayatchi 2012</a>; <a href="./references#CD012836-bbs2-0012" title="SeddonJA , HesselingAC , Godfrey‐FaussettP , SchaafHS . High treatment success in children treated for multidrug‐resistant tuberculosis: an observational cohort study. Thorax2014;69(5):471‐7. ">Seddon 2014</a>), described administration to most participants with HIV infection. </p> </section> <section id="CD012836-sec-0080"> <h5 class="title">Interventions</h5> <p>Linezolid dose varied widely. Of the RCTs, <a href="./references#CD012836-bbs2-0008" title="LeeM , ChoSN , BarryCE . Linezolid for XDR‐TB ‐ final study outcomes. New England Journal of Medicine2015;373(3):290‐1. LeeM , LeeJ , CarrollMW , ChoiH , MinS , SongT , et al. Linezolid for treatment of chronic extensively drug‐resistant tuberculosis. New England Journal of Medicine2012;367(16):1508‐18. ">Lee 2012</a> investigated the effect of immediate versus delayed (two months after randomization) linezolid 600 mg daily initiation, with a second randomization point after sputum culture conversion to either continue on 600 mg or take a reduced 300 mg daily. <a href="./references#CD012836-bbs2-0011" title="PadayatchiN , Mac KenzieWR , Hirsch‐MovermanY , FengPJ , VillarinoE , SaukkonenJ , et al. Lessons from a randomised clinical trial for multidrug‐resistant tuberculosis. International Journal of Tuberculosis and Lung Disease2012, issue 12:1582‐7. ">Padayatchi 2012</a> used a dose of 600 mg daily and <a href="./references#CD012836-bbs2-0013" title="TangS , YaoL , HaoX , ZhangX , LiuG , LiuX , et al. Efficacy, safety and tolerability of linezolid for the treatment of XDR‐TB: a study in China. European Respiratory Journal2015;45(1):161‐70. ">Tang 2015</a> used a high initial dose (1200 mg), followed at four to six weeks by a planned reduction to 300 mg or 600 mg daily. Amongst the non‐randomized studies, dosing ranged from 300 mg to 1200 mg daily, with inconsistent reporting. Five non‐randomized studies did not report a dosing strategy. In several of the remaining studies, the numbers of participants receiving each dose were not clear. </p> <p>Duration of receipt of linezolid, where known (eight studies), was for a mean or median of over 90 days. Five studies reported average duration of over 180 days, with four of these being over one year. We did not know the duration of four studies; one RCT (<a href="./references#CD012836-bbs2-0013" title="TangS , YaoL , HaoX , ZhangX , LiuG , LiuX , et al. Efficacy, safety and tolerability of linezolid for the treatment of XDR‐TB: a study in China. European Respiratory Journal2015;45(1):161‐70. ">Tang 2015</a>), administered linezolid until sputum culture conversion from positive to negative; and <a href="./references#CD012836-bbs2-0017" title="ZhangL , PangY , YuX , WangY , GaoM , HuangH , et al. Linezolid in the treatment of extensively drug‐resistant tuberculosis. Infection2014;42(4):705‐11. ">Zhang 2014</a> reported administration for, "at least one month", without further detail. </p> <p>It was not clear for most non‐randomized studies whether linezolid had been used from the commencement of MDR or XDR ATT, or added later. <a href="./references#CD012836-bbs2-0007" title="KwakN , KimHR , YooCG , KimYW , HanSK , YimJJ . Changes in treatment outcomes of multidrug‐resistant tuberculosis. International Journal of Tuberculosis and Lung Disease2015;19(5):525‐30. ">Kwak 2015</a> reported that linezolid, in addition to all XDR‐TB cases, "was added for patients refractory to at least 3–6 months of medical treatment" in those with MDR‐TB. </p> <p>Background regimens were mostly reported to be individualized according to susceptibilities, clinical parameters and WHO guidance, and often not reported in detail. Where reported, most participants received fluoroquinolones, injectable drugs, ethionamide or prothionamide, and para‐aminosalicylic acid. </p> <p>Few studies reported place of treatment. Where reported, ATT was said to be administered on an inpatient basis, at least initially, with some describing continuation of therapy as an outpatient. An exception, <a href="./references#CD012836-bbs2-0001" title="FerlazzoG , MohrE , LaxmeshwarC , HewisonC , HughesJ , JonckheereS , et al. Early safety and efficacy of the combination of bedaquiline and delamanid for the treatment of patients with drug‐resistant tuberculosis in Armenia, India, and South Africa: a retrospective cohort study. Lancet Infectious Diseases2018;18:536‐44. [DOI: 10.1016/S1473‐3099(18)30100‐2] ">Ferlazzo 2018</a> described some participants receiving outpatient therapy from the outset. </p> <p>Four studies reported surgical resection being carried out in a minority of participants: <a href="./references#CD012836-bbs2-0007" title="KwakN , KimHR , YooCG , KimYW , HanSK , YimJJ . Changes in treatment outcomes of multidrug‐resistant tuberculosis. International Journal of Tuberculosis and Lung Disease2015;19(5):525‐30. ">Kwak 2015</a>; <a href="./references#CD012836-bbs2-0016" title="VanAltenaR , DeVriesG , HaarCH , DeLangeWC , Magis‐EscurraC , Van denHofS , et al. Highly successful treatment outcome of multidrug‐resistant tuberculosis in the Netherlands, 2000‐2009. International Journal of Tuberculosis and Lung Disease2015;19(4):406‐12. ">Van Altena 2015</a>; <a href="./references#CD012836-bbs2-0004" title="JenseniusM , WinjeBA , BlombergB , MengshoelAT , LippeBV , HannulaR , et al. Multidrug‐resistant tuberculosis in Norway: a nationwide study, 1995‐2014. International Journal of Tuberculosis and Lung Disease2016;20(6):786‐92. ">Jensenius 2016</a>; and <a href="./references#CD012836-bbs2-0014" title="TiberiS , PayenMC , SotgiuG , D'AmbrosioL , GuizadoVA , AlffenaarJW , et al. Effectiveness and safety of meropenem/ clavulanate‐containing regimens in the treatment of MDR‐ and XDR‐TB. European Respiratory Journal2016;47(4):1235‐43. TiberiS , SotgiuG , D'AmbrosioL , CentisR , ArbexMA , ArrascueEA , et al. Comparison of effectiveness and safety of imipenem/clavulanate‐versus meropenem/clavulanate‐containing regimens in the treatment of MDR‐ and XDR‐TB. European Respiratory Journal2016;47(6):1758‐66. ">Tiberi 2016</a>. </p> </section> <section id="CD012836-sec-0081"> <h5 class="title">Follow‐up</h5> <p>Of the three RCTs, <a href="./references#CD012836-bbs2-0008" title="LeeM , ChoSN , BarryCE . Linezolid for XDR‐TB ‐ final study outcomes. New England Journal of Medicine2015;373(3):290‐1. LeeM , LeeJ , CarrollMW , ChoiH , MinS , SongT , et al. Linezolid for treatment of chronic extensively drug‐resistant tuberculosis. New England Journal of Medicine2012;367(16):1508‐18. ">Lee 2012</a> conducted follow‐up until 12 months after completion of ATT, <a href="./references#CD012836-bbs2-0011" title="PadayatchiN , Mac KenzieWR , Hirsch‐MovermanY , FengPJ , VillarinoE , SaukkonenJ , et al. Lessons from a randomised clinical trial for multidrug‐resistant tuberculosis. International Journal of Tuberculosis and Lung Disease2012, issue 12:1582‐7. ">Padayatchi 2012</a> followed participants until 12 months from commencement of ATT, and <a href="./references#CD012836-bbs2-0013" title="TangS , YaoL , HaoX , ZhangX , LiuG , LiuX , et al. Efficacy, safety and tolerability of linezolid for the treatment of XDR‐TB: a study in China. European Respiratory Journal2015;45(1):161‐70. ">Tang 2015</a> reported follow‐up until the end of treatment. </p> <p>The cohort studies reported follow‐up procedures incompletely. <a href="./references#CD012836-bbs2-0017" title="ZhangL , PangY , YuX , WangY , GaoM , HuangH , et al. Linezolid in the treatment of extensively drug‐resistant tuberculosis. Infection2014;42(4):705‐11. ">Zhang 2014</a> followed participants until three months after discontinuing linezolid (i.e. not to the end of ATT). <a href="./references#CD012836-bbs2-0005" title="JeongBH , JeonK , ParkHY , KwonOJ , LeeKS , KimHK , et al. Outcomes of pulmonary MDR‐TB: impacts of fluoroquinolone resistance and linezolid treatment. Journal of Antimicrobial Chemotherapy2015;70(11):3127‐33. ">Jeong 2015</a> followed participants until the end of treatment. <a href="./references#CD012836-bbs2-0003" title="GuglielmettiL , JaspardM , LeDûD , LachâtreM , Marigot‐OuttandyD , BernardC , French MDR‐TB Management Group. Long‐term outcome and safety of prolonged bedaquiline treatment for multidrug‐resistant tuberculosis. European Respiratory Journal2017;49:1601799. [DOI: 10.1183/13993003.01799‐2016] ">Guglielmetti 2017</a> aimed to follow‐up until 24 months after ATT completion, <a href="./references#CD012836-bbs2-0001" title="FerlazzoG , MohrE , LaxmeshwarC , HewisonC , HughesJ , JonckheereS , et al. Early safety and efficacy of the combination of bedaquiline and delamanid for the treatment of patients with drug‐resistant tuberculosis in Armenia, India, and South Africa: a retrospective cohort study. Lancet Infectious Diseases2018;18:536‐44. [DOI: 10.1016/S1473‐3099(18)30100‐2] ">Ferlazzo 2018</a> until six months from commencement, and <a href="./references#CD012836-bbs2-0010" title="OlayanjuO , LimberisJ , EsmailA , OelofseS , GinaP , PietersenE , et al. Long‐term bedaquiline‐related treatment outcomes in patients with extensively drug‐resistant tuberculosis from South Africa. European Respiratory Journal2018;51:1800544. [DOI: 10.1183/13993003.00544‐2018] ">Olayanju 2018</a> reported monthly follow‐up for the duration of hospital stay. Follow‐up duration and frequency were unclear for the remaining studies (<a href="./references#CD012836-bbs2-0009" title="MiglioriGB , EkerB , RichardsonMD , SotgiuG , ZellwegerJP , SkrahinaA , et al. A retrospective TBNET assessment of linezolid safety, tolerability and efficacy in multidrug‐resistant tuberculosis. European Respiratory Journal2009;34(2):387‐93. ">Migliori 2009</a>; <a href="./references#CD012836-bbs2-0015" title="UdwadiaZF , SenT , MoharilG . Assessment of linezolid efficacy and safety in MDR‐ and XDR‐TB: an Indian perspective. European Respiratory Journal2010;35(4):936‐8; author reply 938‐40. ">Udwadia 2010</a>; <a href="./references#CD012836-bbs2-0006" title="JoKW , LeeSD , KimWS , KimDS , ShimTS . Treatment outcomes and moxifloxacin susceptibility in ofloxacin‐resistant multidrug‐resistant tuberculosis. International Journal of Tuberculosis and Lung Disease2014;18(1):39‐43. ">Jo 2014</a>; <a href="./references#CD012836-bbs2-0012" title="SeddonJA , HesselingAC , Godfrey‐FaussettP , SchaafHS . High treatment success in children treated for multidrug‐resistant tuberculosis: an observational cohort study. Thorax2014;69(5):471‐7. ">Seddon 2014</a>; <a href="./references#CD012836-bbs2-0007" title="KwakN , KimHR , YooCG , KimYW , HanSK , YimJJ . Changes in treatment outcomes of multidrug‐resistant tuberculosis. International Journal of Tuberculosis and Lung Disease2015;19(5):525‐30. ">Kwak 2015</a>; <a href="./references#CD012836-bbs2-0016" title="VanAltenaR , DeVriesG , HaarCH , DeLangeWC , Magis‐EscurraC , Van denHofS , et al. Highly successful treatment outcome of multidrug‐resistant tuberculosis in the Netherlands, 2000‐2009. International Journal of Tuberculosis and Lung Disease2015;19(4):406‐12. ">Van Altena 2015</a>; <a href="./references#CD012836-bbs2-0002" title="GalliL , LancellaL , TersigniC , VenturiniE , ChiappiniE , BergaminiB , et al. Pediatric tuberculosis in Italian children: epidemiological and clinical data from the Italian register of pediatric tuberculosis. International Journal of Molecular Sciences2016;17(6):960. ">Galli 2016</a>; <a href="./references#CD012836-bbs2-0004" title="JenseniusM , WinjeBA , BlombergB , MengshoelAT , LippeBV , HannulaR , et al. Multidrug‐resistant tuberculosis in Norway: a nationwide study, 1995‐2014. International Journal of Tuberculosis and Lung Disease2016;20(6):786‐92. ">Jensenius 2016</a>; <a href="./references#CD012836-bbs2-0014" title="TiberiS , PayenMC , SotgiuG , D'AmbrosioL , GuizadoVA , AlffenaarJW , et al. Effectiveness and safety of meropenem/ clavulanate‐containing regimens in the treatment of MDR‐ and XDR‐TB. European Respiratory Journal2016;47(4):1235‐43. TiberiS , SotgiuG , D'AmbrosioL , CentisR , ArbexMA , ArrascueEA , et al. Comparison of effectiveness and safety of imipenem/clavulanate‐versus meropenem/clavulanate‐containing regimens in the treatment of MDR‐ and XDR‐TB. European Respiratory Journal2016;47(6):1758‐66. ">Tiberi 2016</a>). </p> </section> <section id="CD012836-sec-0082"> <h5 class="title">Outcome measures</h5> <p>Two RCTs (<a href="./references#CD012836-bbs2-0011" title="PadayatchiN , Mac KenzieWR , Hirsch‐MovermanY , FengPJ , VillarinoE , SaukkonenJ , et al. Lessons from a randomised clinical trial for multidrug‐resistant tuberculosis. International Journal of Tuberculosis and Lung Disease2012, issue 12:1582‐7. ">Padayatchi 2012</a>; <a href="./references#CD012836-bbs2-0013" title="TangS , YaoL , HaoX , ZhangX , LiuG , LiuX , et al. Efficacy, safety and tolerability of linezolid for the treatment of XDR‐TB: a study in China. European Respiratory Journal2015;45(1):161‐70. ">Tang 2015</a>), reported the review's primary outcomes of all‐cause and tuberculosis‐associated death and treatment failure. <a href="./references#CD012836-bbs2-0011" title="PadayatchiN , Mac KenzieWR , Hirsch‐MovermanY , FengPJ , VillarinoE , SaukkonenJ , et al. Lessons from a randomised clinical trial for multidrug‐resistant tuberculosis. International Journal of Tuberculosis and Lung Disease2012, issue 12:1582‐7. ">Padayatchi 2012</a> did not report cure, due to follow‐up not extending beyond 12 months, while <a href="./references#CD012836-bbs2-0013" title="TangS , YaoL , HaoX , ZhangX , LiuG , LiuX , et al. Efficacy, safety and tolerability of linezolid for the treatment of XDR‐TB: a study in China. European Respiratory Journal2015;45(1):161‐70. ">Tang 2015</a> did. These RCTs also reported the review's secondary outcomes of treatment interrupted and treatment completed (the <a href="./references#CD012836-bbs2-0011" title="PadayatchiN , Mac KenzieWR , Hirsch‐MovermanY , FengPJ , VillarinoE , SaukkonenJ , et al. Lessons from a randomised clinical trial for multidrug‐resistant tuberculosis. International Journal of Tuberculosis and Lung Disease2012, issue 12:1582‐7. ">Padayatchi 2012</a> study did so for treatment of up to 12 months). <a href="./references#CD012836-bbs2-0008" title="LeeM , ChoSN , BarryCE . Linezolid for XDR‐TB ‐ final study outcomes. New England Journal of Medicine2015;373(3):290‐1. LeeM , LeeJ , CarrollMW , ChoiH , MinS , SongT , et al. Linezolid for treatment of chronic extensively drug‐resistant tuberculosis. New England Journal of Medicine2012;367(16):1508‐18. ">Lee 2012</a> did not report these outcomes separately for participants receiving immediate versus delayed linezolid, though apart from death (no‐one died in either arm), they would have been less informative because there was only two months' delay in commencement of linezolid. </p> <p>All three RCTs (<a href="./references#CD012836-bbs2-0008" title="LeeM , ChoSN , BarryCE . Linezolid for XDR‐TB ‐ final study outcomes. New England Journal of Medicine2015;373(3):290‐1. LeeM , LeeJ , CarrollMW , ChoiH , MinS , SongT , et al. Linezolid for treatment of chronic extensively drug‐resistant tuberculosis. New England Journal of Medicine2012;367(16):1508‐18. ">Lee 2012</a>; <a href="./references#CD012836-bbs2-0011" title="PadayatchiN , Mac KenzieWR , Hirsch‐MovermanY , FengPJ , VillarinoE , SaukkonenJ , et al. Lessons from a randomised clinical trial for multidrug‐resistant tuberculosis. International Journal of Tuberculosis and Lung Disease2012, issue 12:1582‐7. ">Padayatchi 2012</a>; <a href="./references#CD012836-bbs2-0013" title="TangS , YaoL , HaoX , ZhangX , LiuG , LiuX , et al. Efficacy, safety and tolerability of linezolid for the treatment of XDR‐TB: a study in China. European Respiratory Journal2015;45(1):161‐70. ">Tang 2015</a>) reported sputum culture conversion from positive to negative, but not as stipulated in the review protocol (i.e. time to conversion). </p> <p>Adverse events were reported by all RCTs, although <a href="./references#CD012836-bbs2-0013" title="TangS , YaoL , HaoX , ZhangX , LiuG , LiuX , et al. Efficacy, safety and tolerability of linezolid for the treatment of XDR‐TB: a study in China. European Respiratory Journal2015;45(1):161‐70. ">Tang 2015</a> did not distinguish serious adverse events from the others. <a href="./references#CD012836-bbs2-0008" title="LeeM , ChoSN , BarryCE . Linezolid for XDR‐TB ‐ final study outcomes. New England Journal of Medicine2015;373(3):290‐1. LeeM , LeeJ , CarrollMW , ChoiH , MinS , SongT , et al. Linezolid for treatment of chronic extensively drug‐resistant tuberculosis. New England Journal of Medicine2012;367(16):1508‐18. ">Lee 2012</a> did not separate adverse events between immediate and delayed linezolid groups. </p> <p>Adverse events reporting in the non‐randomized studies was variable. Only six out of 14 studies reported, or provided following our request to the authors, comparative total numbers of adverse events experienced by those who received linezolid versus those who did not (<a href="./references#CD012836-bbs2-0012" title="SeddonJA , HesselingAC , Godfrey‐FaussettP , SchaafHS . High treatment success in children treated for multidrug‐resistant tuberculosis: an observational cohort study. Thorax2014;69(5):471‐7. ">Seddon 2014</a>; <a href="./references#CD012836-bbs2-0007" title="KwakN , KimHR , YooCG , KimYW , HanSK , YimJJ . Changes in treatment outcomes of multidrug‐resistant tuberculosis. International Journal of Tuberculosis and Lung Disease2015;19(5):525‐30. ">Kwak 2015</a>; <a href="./references#CD012836-bbs2-0002" title="GalliL , LancellaL , TersigniC , VenturiniE , ChiappiniE , BergaminiB , et al. Pediatric tuberculosis in Italian children: epidemiological and clinical data from the Italian register of pediatric tuberculosis. International Journal of Molecular Sciences2016;17(6):960. ">Galli 2016</a>; <a href="./references#CD012836-bbs2-0003" title="GuglielmettiL , JaspardM , LeDûD , LachâtreM , Marigot‐OuttandyD , BernardC , French MDR‐TB Management Group. Long‐term outcome and safety of prolonged bedaquiline treatment for multidrug‐resistant tuberculosis. European Respiratory Journal2017;49:1601799. [DOI: 10.1183/13993003.01799‐2016] ">Guglielmetti 2017</a>; <a href="./references#CD012836-bbs2-0001" title="FerlazzoG , MohrE , LaxmeshwarC , HewisonC , HughesJ , JonckheereS , et al. Early safety and efficacy of the combination of bedaquiline and delamanid for the treatment of patients with drug‐resistant tuberculosis in Armenia, India, and South Africa: a retrospective cohort study. Lancet Infectious Diseases2018;18:536‐44. [DOI: 10.1016/S1473‐3099(18)30100‐2] ">Ferlazzo 2018</a>; <a href="./references#CD012836-bbs2-0010" title="OlayanjuO , LimberisJ , EsmailA , OelofseS , GinaP , PietersenE , et al. Long‐term bedaquiline‐related treatment outcomes in patients with extensively drug‐resistant tuberculosis from South Africa. European Respiratory Journal2018;51:1800544. [DOI: 10.1183/13993003.00544‐2018] ">Olayanju 2018</a>). A further three reported or provided a total frequency of adverse events for the linezolid‐receiving groups, but not for those who did not receive linezolid (<a href="./references#CD012836-bbs2-0006" title="JoKW , LeeSD , KimWS , KimDS , ShimTS . Treatment outcomes and moxifloxacin susceptibility in ofloxacin‐resistant multidrug‐resistant tuberculosis. International Journal of Tuberculosis and Lung Disease2014;18(1):39‐43. ">Jo 2014</a>; <a href="./references#CD012836-bbs2-0017" title="ZhangL , PangY , YuX , WangY , GaoM , HuangH , et al. Linezolid in the treatment of extensively drug‐resistant tuberculosis. Infection2014;42(4):705‐11. ">Zhang 2014</a>; <a href="./references#CD012836-bbs2-0014" title="TiberiS , PayenMC , SotgiuG , D'AmbrosioL , GuizadoVA , AlffenaarJW , et al. Effectiveness and safety of meropenem/ clavulanate‐containing regimens in the treatment of MDR‐ and XDR‐TB. European Respiratory Journal2016;47(4):1235‐43. TiberiS , SotgiuG , D'AmbrosioL , CentisR , ArbexMA , ArrascueEA , et al. Comparison of effectiveness and safety of imipenem/clavulanate‐versus meropenem/clavulanate‐containing regimens in the treatment of MDR‐ and XDR‐TB. European Respiratory Journal2016;47(6):1758‐66. ">Tiberi 2016</a>). The remaining five studies provided data on frequency of linezolid discontinuation or adverse events, or both, attributed to linezolid only. </p> </section> </section> <section id="CD012836-sec-0083"> <h4 class="title">Excluded studies</h4> <p>We excluded 96 studies after review of the full texts (<a href="#CD012836-fig-0001">Figure 1</a>). We excluded 67 studies because they were neither a randomized study nor cohort study; 26 did not describe any use of linezolid; and one did not fit the population eligibility criteria of the review. We excluded two studies due to absence of adverse events data. Full details are given in the <a href="./references#CD012836-sec-0115" title="">Characteristics of excluded studies</a> section. </p> <p>A further 23 remained unclassified, due to no response from study authors following our requests for data. See the <a href="./references#CD012836-bbs1-0003" title="">Studies awaiting classification</a> section for further details. </p> </section> </section> <section id="CD012836-sec-0084"> <h3 class="title">Risk of bias in included studies</h3> <p>We assessed risk of bias for the included RCTs using the Cochrane ‘Risk of bias' assessment tool (<a href="./references#CD012836-bbs2-0156" title="HigginsJP , AltmanDG , GøtzschePC , JüniP , MoherD , OxmanAD , et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ2011;343:d5928. [DOI: 10.1136/bmj.d5928] ">Higgins 2011a</a>). We assessed the risk of bias in the cohort studies using ROBINS‐I tool (<a href="./references#CD012836-bbs2-0168" title="SterneJA , HigginsJP , ReevesBC , SavovićJ , TurnerL , ROBINS‐I development group. ROBINS‐I: a tool for assessing Risk Of Bias In Non‐randomized Studies of Interventions. Available from www.riskofbias.info (accessed 14 June 2016). ">Sterne 2016</a>). See the ‘<a href="./references#CD012836-sec-0114" title="">Characteristics of included studies</a>' section, which includes a ‘Risk of bias' table for each included study. We summarized the results of the ‘Risk of bias' assessments across all included RCTs in <a href="#CD012836-fig-0002">Figure 2</a> and non‐randomized studies in <a href="#CD012836-fig-0003">Figure 3</a>. </p> <div class="figure" id="CD012836-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias in included RCTs" data-id="CD012836-fig-0002" src="/cdsr/doi/10.1002/14651858.CD012836.pub2/media/CDSR/CD012836/image_n/nCD012836-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias in included RCTs</p> </div> </div> </div> <div class="figure" id="CD012836-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Risk of bias in included non‐randomized studies" data-id="CD012836-fig-0003" src="/cdsr/doi/10.1002/14651858.CD012836.pub2/media/CDSR/CD012836/image_n/nCD012836-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias in included non‐randomized studies</p> </div> </div> </div> <p>Most of the subheadings that follow address risk of bias in RCTs; for non‐randomized studies, see the subheading <a href="#CD012836-sec-0089">Other potential sources of bias</a>. </p> <section id="CD012836-sec-0085"> <h4 class="title">Allocation</h4> <p><a href="./references#CD012836-bbs2-0008" title="LeeM , ChoSN , BarryCE . Linezolid for XDR‐TB ‐ final study outcomes. New England Journal of Medicine2015;373(3):290‐1. LeeM , LeeJ , CarrollMW , ChoiH , MinS , SongT , et al. Linezolid for treatment of chronic extensively drug‐resistant tuberculosis. New England Journal of Medicine2012;367(16):1508‐18. ">Lee 2012</a> had low risk of bias for random sequence generation, due to use of permuted block randomization. <a href="./references#CD012836-bbs2-0011" title="PadayatchiN , Mac KenzieWR , Hirsch‐MovermanY , FengPJ , VillarinoE , SaukkonenJ , et al. Lessons from a randomised clinical trial for multidrug‐resistant tuberculosis. International Journal of Tuberculosis and Lung Disease2012, issue 12:1582‐7. ">Padayatchi 2012</a> and <a href="./references#CD012836-bbs2-0013" title="TangS , YaoL , HaoX , ZhangX , LiuG , LiuX , et al. Efficacy, safety and tolerability of linezolid for the treatment of XDR‐TB: a study in China. European Respiratory Journal2015;45(1):161‐70. ">Tang 2015</a> had unclear risk of bias as procedures were not clearly described. </p> <p><a href="./references#CD012836-bbs2-0011" title="PadayatchiN , Mac KenzieWR , Hirsch‐MovermanY , FengPJ , VillarinoE , SaukkonenJ , et al. Lessons from a randomised clinical trial for multidrug‐resistant tuberculosis. International Journal of Tuberculosis and Lung Disease2012, issue 12:1582‐7. ">Padayatchi 2012</a> described adequate allocation concealment procedures, with resulting low risk of bias, whilst <a href="./references#CD012836-bbs2-0008" title="LeeM , ChoSN , BarryCE . Linezolid for XDR‐TB ‐ final study outcomes. New England Journal of Medicine2015;373(3):290‐1. LeeM , LeeJ , CarrollMW , ChoiH , MinS , SongT , et al. Linezolid for treatment of chronic extensively drug‐resistant tuberculosis. New England Journal of Medicine2012;367(16):1508‐18. ">Lee 2012</a> and <a href="./references#CD012836-bbs2-0013" title="TangS , YaoL , HaoX , ZhangX , LiuG , LiuX , et al. Efficacy, safety and tolerability of linezolid for the treatment of XDR‐TB: a study in China. European Respiratory Journal2015;45(1):161‐70. ">Tang 2015</a> did not report these, so risk of bias was unclear. </p> </section> <section id="CD012836-sec-0086"> <h4 class="title">Blinding</h4> <p><a href="./references#CD012836-bbs2-0008" title="LeeM , ChoSN , BarryCE . Linezolid for XDR‐TB ‐ final study outcomes. New England Journal of Medicine2015;373(3):290‐1. LeeM , LeeJ , CarrollMW , ChoiH , MinS , SongT , et al. Linezolid for treatment of chronic extensively drug‐resistant tuberculosis. New England Journal of Medicine2012;367(16):1508‐18. ">Lee 2012</a> described blinding of laboratory personnel only, which allowed outcomes other than the primary outcome of sputum culture conversion to be influenced by knowledge of the intervention. We deemed this to represent an unclear risk of performance bias. For detection bias, we judged the primary outcome to be at low risk, but bias was unclear for other outcomes. <a href="./references#CD012836-bbs2-0011" title="PadayatchiN , Mac KenzieWR , Hirsch‐MovermanY , FengPJ , VillarinoE , SaukkonenJ , et al. Lessons from a randomised clinical trial for multidrug‐resistant tuberculosis. International Journal of Tuberculosis and Lung Disease2012, issue 12:1582‐7. ">Padayatchi 2012</a> reported appropriate blinding of participants and personnel initially (low risk of performance bias), but at 20 weeks, unblinding occurred, which may have affected measurement of outcomes at 12 months, resulting in high risk of detection bias. <a href="./references#CD012836-bbs2-0013" title="TangS , YaoL , HaoX , ZhangX , LiuG , LiuX , et al. Efficacy, safety and tolerability of linezolid for the treatment of XDR‐TB: a study in China. European Respiratory Journal2015;45(1):161‐70. ">Tang 2015</a> reported no blinding, so there was a high risk of performance and detection bias. </p> </section> <section id="CD012836-sec-0087"> <h4 class="title">Incomplete outcome data</h4> <p><a href="./references#CD012836-bbs2-0008" title="LeeM , ChoSN , BarryCE . Linezolid for XDR‐TB ‐ final study outcomes. New England Journal of Medicine2015;373(3):290‐1. LeeM , LeeJ , CarrollMW , ChoiH , MinS , SongT , et al. Linezolid for treatment of chronic extensively drug‐resistant tuberculosis. New England Journal of Medicine2012;367(16):1508‐18. ">Lee 2012</a> had low loss to follow‐up at four months (i.e. for the primary outcome), but substantially higher at the end of planned follow‐up. We deemed it to be at low risk for the primary outcome of sputum culture conversion but unclear for other outcomes, because of the well‐conducted nature of the study. Due to a high proportion of loss to follow‐up, without reasons for withdrawal being clear or specified by intervention group, we deemed <a href="./references#CD012836-bbs2-0011" title="PadayatchiN , Mac KenzieWR , Hirsch‐MovermanY , FengPJ , VillarinoE , SaukkonenJ , et al. Lessons from a randomised clinical trial for multidrug‐resistant tuberculosis. International Journal of Tuberculosis and Lung Disease2012, issue 12:1582‐7. ">Padayatchi 2012</a> to be at high risk of attrition bias. Loss to follow‐up was lower in <a href="./references#CD012836-bbs2-0013" title="TangS , YaoL , HaoX , ZhangX , LiuG , LiuX , et al. Efficacy, safety and tolerability of linezolid for the treatment of XDR‐TB: a study in China. European Respiratory Journal2015;45(1):161‐70. ">Tang 2015</a>, with specified, balanced reasons for withdrawal, resulting in our judgement of low risk of bias. </p> </section> <section id="CD012836-sec-0088"> <h4 class="title">Selective reporting</h4> <p>There was no evidence of selective reporting by <a href="./references#CD012836-bbs2-0008" title="LeeM , ChoSN , BarryCE . Linezolid for XDR‐TB ‐ final study outcomes. New England Journal of Medicine2015;373(3):290‐1. LeeM , LeeJ , CarrollMW , ChoiH , MinS , SongT , et al. Linezolid for treatment of chronic extensively drug‐resistant tuberculosis. New England Journal of Medicine2012;367(16):1508‐18. ">Lee 2012</a>, with some elements of the original protocol and substantial additional data being provided in a supplement. <a href="./references#CD012836-bbs2-0011" title="PadayatchiN , Mac KenzieWR , Hirsch‐MovermanY , FengPJ , VillarinoE , SaukkonenJ , et al. Lessons from a randomised clinical trial for multidrug‐resistant tuberculosis. International Journal of Tuberculosis and Lung Disease2012, issue 12:1582‐7. ">Padayatchi 2012</a> reported, within the commentary study and the full study protocol and report, available online, much more than expected from an RCT, with no evidence of selective reporting. Though <a href="./references#CD012836-bbs2-0013" title="TangS , YaoL , HaoX , ZhangX , LiuG , LiuX , et al. Efficacy, safety and tolerability of linezolid for the treatment of XDR‐TB: a study in China. European Respiratory Journal2015;45(1):161‐70. ">Tang 2015</a> did not publish a separate protocol, all outcomes stated in the methods section of the study were reported in the results. </p> </section> <section id="CD012836-sec-0089"> <h4 class="title">Other potential sources of bias</h4> <section id="CD012836-sec-0090"> <h5 class="title">RCTs</h5> <p><a href="./references#CD012836-bbs2-0011" title="PadayatchiN , Mac KenzieWR , Hirsch‐MovermanY , FengPJ , VillarinoE , SaukkonenJ , et al. Lessons from a randomised clinical trial for multidrug‐resistant tuberculosis. International Journal of Tuberculosis and Lung Disease2012, issue 12:1582‐7. ">Padayatchi 2012</a> reported discordance of administration of the study drug (linezolid) and placebo in at least 25% of participants, found incidentally in the pharmacokinetics study nested within the main study. Though not identified with certainty, the study authors concluded, "it appears that the mixing of tablets due to sporadic, human error occurred at the clinical site on more than one occasion over a long time period, rather than in the pharmacy." </p> <p>There was no other source of bias apparent for <a href="./references#CD012836-bbs2-0008" title="LeeM , ChoSN , BarryCE . Linezolid for XDR‐TB ‐ final study outcomes. New England Journal of Medicine2015;373(3):290‐1. LeeM , LeeJ , CarrollMW , ChoiH , MinS , SongT , et al. Linezolid for treatment of chronic extensively drug‐resistant tuberculosis. New England Journal of Medicine2012;367(16):1508‐18. ">Lee 2012</a> or <a href="./references#CD012836-bbs2-0013" title="TangS , YaoL , HaoX , ZhangX , LiuG , LiuX , et al. Efficacy, safety and tolerability of linezolid for the treatment of XDR‐TB: a study in China. European Respiratory Journal2015;45(1):161‐70. ">Tang 2015</a>. </p> </section> <section id="CD012836-sec-0091"> <h5 class="title">Non‐randomized studies</h5> <p>The ROBINS‐I assessment process judges risk of bias in seven domains, resulting in an overall judgement of risk of bias corresponding to the highest level of risk displayed in any one domain. For example, if a study is judged to have a serious risk of bias in one study domain, but low risk of bias in all others, the overall risk of bias for the study will be serious. </p> <p>Risk of bias within the seven domains, and overall, is displayed for all 14 studies in <a href="#CD012836-fig-0003">Figure 3</a>. We deemed overall risk of bias to be critical for three studies (<a href="./references#CD012836-bbs2-0015" title="UdwadiaZF , SenT , MoharilG . Assessment of linezolid efficacy and safety in MDR‐ and XDR‐TB: an Indian perspective. European Respiratory Journal2010;35(4):936‐8; author reply 938‐40. ">Udwadia 2010</a>; <a href="./references#CD012836-bbs2-0006" title="JoKW , LeeSD , KimWS , KimDS , ShimTS . Treatment outcomes and moxifloxacin susceptibility in ofloxacin‐resistant multidrug‐resistant tuberculosis. International Journal of Tuberculosis and Lung Disease2014;18(1):39‐43. ">Jo 2014</a>; <a href="./references#CD012836-bbs2-0017" title="ZhangL , PangY , YuX , WangY , GaoM , HuangH , et al. Linezolid in the treatment of extensively drug‐resistant tuberculosis. Infection2014;42(4):705‐11. ">Zhang 2014</a>) and serious for the remaining 11 studies. We deemed all studies to have serious risk of bias in measurement of outcomes, consistent with mostly retrospective design, some with unpublished repurposed data on linezolid. We judged 13 of the 14 studies to have serious risk of bias for confounding, which is again reflective of the largely retrospective studies included. Twelve were at low risk of bias for selection of participants into the study, and 12 were at low risk of bias from deviations from intended interventions. </p> </section> </section> </section> <section id="CD012836-sec-0092"> <h3 class="title" id="CD012836-sec-0092">Effects of interventions</h3> <p>See: <a href="./full#CD012836-tbl-0001"><b>Summary of findings for the main comparison</b> Linezolid compared to no linezolid for drug‐resistant pulmonary tuberculosis</a> </p> <section id="CD012836-sec-0093"> <h4 class="title">RCTs</h4> <p>Due to the significant discordance of study drug and placebo administration in <a href="./references#CD012836-bbs2-0011" title="PadayatchiN , Mac KenzieWR , Hirsch‐MovermanY , FengPJ , VillarinoE , SaukkonenJ , et al. Lessons from a randomised clinical trial for multidrug‐resistant tuberculosis. International Journal of Tuberculosis and Lung Disease2012, issue 12:1582‐7. ">Padayatchi 2012</a>, we deemed this study unsuitable for any analysis of intervention effect. This left two RCTs, <a href="./references#CD012836-bbs2-0008" title="LeeM , ChoSN , BarryCE . Linezolid for XDR‐TB ‐ final study outcomes. New England Journal of Medicine2015;373(3):290‐1. LeeM , LeeJ , CarrollMW , ChoiH , MinS , SongT , et al. Linezolid for treatment of chronic extensively drug‐resistant tuberculosis. New England Journal of Medicine2012;367(16):1508‐18. ">Lee 2012</a> and <a href="./references#CD012836-bbs2-0013" title="TangS , YaoL , HaoX , ZhangX , LiuG , LiuX , et al. Efficacy, safety and tolerability of linezolid for the treatment of XDR‐TB: a study in China. European Respiratory Journal2015;45(1):161‐70. ">Tang 2015</a>. As these did not provide comparable outcome data, we were unable to meta‐analyse their results. </p> <p><a href="#CD012836-tbl-0003">Table 2</a> shows findings from <a href="./references#CD012836-bbs2-0008" title="LeeM , ChoSN , BarryCE . Linezolid for XDR‐TB ‐ final study outcomes. New England Journal of Medicine2015;373(3):290‐1. LeeM , LeeJ , CarrollMW , ChoiH , MinS , SongT , et al. Linezolid for treatment of chronic extensively drug‐resistant tuberculosis. New England Journal of Medicine2012;367(16):1508‐18. ">Lee 2012</a>, which reported no deaths prior to or while receiving linezolid. Sputum culture conversion at four months after randomization (the study's primary outcome), was reported to be higher for participants receiving linezolid immediately versus those receiving linezolid after a delay of two months: 15 out of 19 versus 7 out of 20 (RR 2.26, 95% CI 1.19 to 4.28). Cure (27/39 randomized), treatment failure (4/39), and treatment interruption (7/39), were not disaggregated by timing of linezolid introduction (<a href="./references#CD012836-bbs2-0008" title="LeeM , ChoSN , BarryCE . Linezolid for XDR‐TB ‐ final study outcomes. New England Journal of Medicine2015;373(3):290‐1. LeeM , LeeJ , CarrollMW , ChoiH , MinS , SongT , et al. Linezolid for treatment of chronic extensively drug‐resistant tuberculosis. New England Journal of Medicine2012;367(16):1508‐18. ">Lee 2012</a>). Permanent linezolid discontinuation was reported in seven out of 39 (17.9%) participants. </p> <div class="table" id="CD012836-tbl-0003"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Findings from the Lee 2012 randomized trial</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Factor</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Participants who received linezolid immediately</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Participants who received delayed linezolid</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Relative effect RR (95% CI)</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Study characteristics</p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Korea, all XDR, HIV co‐infection excluded, adults</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participants</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Death</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/19</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/20</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unable to calculate</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sputum culture conversion at 4 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15/19 (78.9%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7/20 (35.0%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.26 (1.19 to 4.28)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Total adverse events</p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>56<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serious adverse events</p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>37<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Linezolid discontinuation</p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>7/39 (17.9%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><sup>a</sup>Adverse events reported without disaggregation for linezolid receipt being immediate or delayed; total adverse events reported in <a href="./references#CD012836-bbs2-0008" title="LeeM , ChoSN , BarryCE . Linezolid for XDR‐TB ‐ final study outcomes. New England Journal of Medicine2015;373(3):290‐1. LeeM , LeeJ , CarrollMW , ChoiH , MinS , SongT , et al. Linezolid for treatment of chronic extensively drug‐resistant tuberculosis. New England Journal of Medicine2012;367(16):1508‐18. ">Lee 2012</a> but not updated in 2015 article; serious adverse events updated in 2015 article (in 2012 article, 33 were reported) </p> <p>Abbreviations: CI: confidence interval; N/A: not applicable; RR: risk ratio; XDR: extensively drug‐resistant </p> </div> </div> <p><a href="#CD012836-tbl-0004">Table 3</a> summarizes findings from <a href="./references#CD012836-bbs2-0013" title="TangS , YaoL , HaoX , ZhangX , LiuG , LiuX , et al. Efficacy, safety and tolerability of linezolid for the treatment of XDR‐TB: a study in China. European Respiratory Journal2015;45(1):161‐70. ">Tang 2015</a>. This study reported significantly higher cure (RR 2.36, 95% CI 1.13 to 4.90), and lower failure (RR 0.26, 95% CI 0.10 to 0.70), in participants receiving linezolid, compared to those who did not. No significant difference was reported in the proportions of participants with outcomes of treatment completed, death or treatment interrupted, between linezolid and control groups. Time to sputum culture conversion was not reported in the way that we had planned to analyze this outcome: 26 out of 33 (78.8%) of those receiving linezolid had sputum culture conversion at 24 months; the corresponding figure for those who did not receive linezolid was 12 out of 32 (37.6%; <a href="./references#CD012836-bbs2-0013" title="TangS , YaoL , HaoX , ZhangX , LiuG , LiuX , et al. Efficacy, safety and tolerability of linezolid for the treatment of XDR‐TB: a study in China. European Respiratory Journal2015;45(1):161‐70. ">Tang 2015</a>). Treatment interruption, defined in the paper as "default", was reported in four out of 33 of the linezolid‐receiving and three out of 32 of the control groups, respectively. Linezolid was discontinued permanently in two out of 33 participants, though an undefined larger number had temporary linezolid interruptions. </p> <div class="table" id="CD012836-tbl-0004"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Findings from the Tang 2015 randomized trial</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Factor</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Participants who received linezolid</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Participants who did not receive linezolid</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Relative effect RR (95% CI)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study characteristics</p> </td> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p>China, all XDR, HIV co‐infection excluded, adults</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Death</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2/33 (6.1%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3/32 (9.4%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.65 (0.12 to 3.62)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Failure</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4/33 (12.1%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15/32 (46.9%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.26 (0.10 to 0.70)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cure</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>17/33 (51.5%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7/32 (21.9%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.36 (1.13 to 4.90)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Treatment completed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6/33 (18.2%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4/32 (12.5%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.45 (0.45 to 4.68)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Treatment interruption ("default")</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4/33 (12.1%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3/32 (9.4%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.29 (0.31 to 5.33)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sputum culture conversion at 24 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26/33 (78.8%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12/32 (37.6%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.10 (1.30 to 3.40)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Total adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>74</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unable to calculate</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Serious adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unable to calculate</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Linezolid discontinuation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2/33 (6.1%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/A</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>Abbreviations: CI: confidence interval; N/A: not applicable; NR: not reported; RR: risk ratio; XDR: extensively drug‐resistant </p> </div> </div> <p>With regards to adverse events, <a href="./references#CD012836-bbs2-0008" title="LeeM , ChoSN , BarryCE . Linezolid for XDR‐TB ‐ final study outcomes. New England Journal of Medicine2015;373(3):290‐1. LeeM , LeeJ , CarrollMW , ChoiH , MinS , SongT , et al. Linezolid for treatment of chronic extensively drug‐resistant tuberculosis. New England Journal of Medicine2012;367(16):1508‐18. ">Lee 2012</a> reported 56 adverse events in total, 33 of which they deemed serious (the second report of this study reported another four serious adverse events, but without a corresponding figure for non‐serious adverse events). The adverse events included 21 out of 39 instances of peripheral neuropathy, 7 out of 39 optic neuropathy and 7 out of 39 with myelosuppression (bone marrow suppression). <a href="./references#CD012836-bbs2-0013" title="TangS , YaoL , HaoX , ZhangX , LiuG , LiuX , et al. Efficacy, safety and tolerability of linezolid for the treatment of XDR‐TB: a study in China. European Respiratory Journal2015;45(1):161‐70. ">Tang 2015</a> reported a significantly higher incidence of anaemia (17/33 versus 2/32), nausea and vomiting (16/33 versus 3/32), peripheral neuropathy (8/33 versus 1/32), and optic neuropathy (6/33 versus 0/32), amongst participants in receipt of linezolid, compared with controls. Confidence intervals were not provided for these results; significance was reported on the basis of P values. </p> <p>We undertook a sensitivity analysis of the death, cure and failure outcomes for <a href="./references#CD012836-bbs2-0013" title="TangS , YaoL , HaoX , ZhangX , LiuG , LiuX , et al. Efficacy, safety and tolerability of linezolid for the treatment of XDR‐TB: a study in China. European Respiratory Journal2015;45(1):161‐70. ">Tang 2015</a>. Imputing worst‐case and best‐case outcomes by linezolid administration for participants with incomplete data did not change the similar proportion of death in the two groups. Cure remained higher and failure remained lower for participants who received linezolid, albeit with a loss of statistical significance when worst‐case scenario outcomes were imputed (lower CI = 0.89 for cure, and upper CI 1.05 for failure). The worst‐case analysis assumes that all the missing participants in the linezolid group did not achieve cure and failed therapy, and all the missing participants not receiving linezolid achieved cure and did not fail therapy (<a href="#CD012836-tbl-0005">Table 4</a>). </p> <div class="table" id="CD012836-tbl-0005"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Sensitivity analysis for Tang 2015</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Sensitivity analysis</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Participants who received linezolid</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Participants who did not receive linezolid</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Relative effect RR (95% CI)</b> </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="4" rowspan="1" valign=""> <p><b>Death</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ITT analysis (as in review protocol)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2/33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3/32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.65 (0.12 to 3.62)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Worst‐case analysis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6/33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3/32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.94 (0.53 to 7.10)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Best‐case analysis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2/33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6/32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.32 (0.07 to 1.48)</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="4" rowspan="1" valign=""> <p><b>Cure</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ITT analysis (as in review protocol)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>17/33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7/32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.36 (1.13 to 4.90)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Worst‐case analysis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>17/33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10/32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.65 (0.89 to 3.04)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Best‐case analysis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>21/33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7/32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.91 (1.44 to 5.88)</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="4" rowspan="1" valign=""> <p><b>Failure</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ITT analysis (as in review protocol)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4/33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15/32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.26 (0.10 to 0.70)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Worst‐case analysis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8/33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15/32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.52 (0.26 to 1.05)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Best‐case analysis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4/33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18/32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.22 (0.08 to 0.57)</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>Abbreviations: CI: confidence interval; ITT: intention to treat; RR: risk ratio.</p> </div> </div> </section> <section id="CD012836-sec-0094"> <h4 class="title">Non‐randomized studies</h4> <p><a href="#CD012836-tbl-0006">Table 5</a> contains a summary of findings from the included non‐randomized studies, and <a href="#CD012836-tbl-0007">Table 6</a> shows more detailed adverse event data from these studies. We did not plan primary and secondary outcome data extraction and meta‐analysis for non‐randomized cohorts. </p> <div class="table" id="CD012836-tbl-0006"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">Summary of findings in non‐randomized studies</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Baseline characteristics</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Participants who received linezolid</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Participants who did not receive linezolid</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Number of studies reporting outcomes</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p>6</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Participants</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p>639 participants, including 8 children</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p>487 participants, including 160 children</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Proportion with XDR‐TB<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p>440/1137 (38.7%)</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p>343/628 (54.6%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Included participants with HIV</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p>8/12</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p>4/6</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Outcomes</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Number of events</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Number of participants (studies)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Number of events</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Number of participants (studies)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Total adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>602</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>426 (8)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>813</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>478 (5)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Serious adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>57</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>164 (7)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>47</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>270 (5)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Linezolid discontinuation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>141</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>624 (11)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/A</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><sup>a</sup>Where reported; not disaggregated for participants receiving linezolid </p> <p>Abbreviation: XDR: extensively drug‐resistant</p> </div> </div> <div class="table" id="CD012836-tbl-0007"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 6.</span> <span class="table-title">Adverse events outcomes data in non‐randomized studies</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Study</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Total adverse events</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Serious adverse events</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Linezolid discontinuation</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>Linezolid‐attributed adverse events</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Our observations</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Linezolid</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>No linezolid</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Linezolid</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>No linezolid</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Total</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Neuropathy</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Bone marrow</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012836-bbs2-0009" title="MiglioriGB , EkerB , RichardsonMD , SotgiuG , ZellwegerJP , SkrahinaA , et al. A retrospective TBNET assessment of linezolid safety, tolerability and efficacy in multidrug‐resistant tuberculosis. European Respiratory Journal2009;34(2):387‐93. ">Migliori 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19/85</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>52/85</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3/85</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30/85</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No comparative data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012836-bbs2-0015" title="UdwadiaZF , SenT , MoharilG . Assessment of linezolid efficacy and safety in MDR‐ and XDR‐TB: an Indian perspective. European Respiratory Journal2010;35(4):936‐8; author reply 938‐40. ">Udwadia 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9/18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8/18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No comparative data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012836-bbs2-0006" title="JoKW , LeeSD , KimWS , KimDS , ShimTS . Treatment outcomes and moxifloxacin susceptibility in ofloxacin‐resistant multidrug‐resistant tuberculosis. International Journal of Tuberculosis and Lung Disease2014;18(1):39‐43. ">Jo 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20/26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6/26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8/26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>22/26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16/26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2/26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No comparative data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012836-bbs2-0012" title="SeddonJA , HesselingAC , Godfrey‐FaussettP , SchaafHS . High treatment success in children treated for multidrug‐resistant tuberculosis: an observational cohort study. Thorax2014;69(5):471‐7. ">Seddon 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>245/142</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11/146</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No RR/P‐value reported; small group received linezolid</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012836-bbs2-0017" title="ZhangL , PangY , YuX , WangY , GaoM , HuangH , et al. Linezolid in the treatment of extensively drug‐resistant tuberculosis. Infection2014;42(4):705‐11. ">Zhang 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11/15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11/15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4/15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No comparative data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012836-bbs2-0007" title="KwakN , KimHR , YooCG , KimYW , HanSK , YimJJ . Changes in treatment outcomes of multidrug‐resistant tuberculosis. International Journal of Tuberculosis and Lung Disease2015;19(5):525‐30. ">Kwak 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8/12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>36/111</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8/12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>32/111</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2/12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3/12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2/12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No RR/P‐value reported; linezolid added if failing therapy, or XDR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012836-bbs2-0005" title="JeongBH , JeonK , ParkHY , KwonOJ , LeeKS , KimHK , et al. Outcomes of pulmonary MDR‐TB: impacts of fluoroquinolone resistance and linezolid treatment. Journal of Antimicrobial Chemotherapy2015;70(11):3127‐33. ">Jeong 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012836-bbs2-0005" title="JeongBH , JeonK , ParkHY , KwonOJ , LeeKS , KimHK , et al. Outcomes of pulmonary MDR‐TB: impacts of fluoroquinolone resistance and linezolid treatment. Journal of Antimicrobial Chemotherapy2015;70(11):3127‐33. ">Jeong 2015</a> reported no adverse event data other than linezolid dose reduction </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012836-bbs2-0016" title="VanAltenaR , DeVriesG , HaarCH , DeLangeWC , Magis‐EscurraC , Van denHofS , et al. Highly successful treatment outcome of multidrug‐resistant tuberculosis in the Netherlands, 2000‐2009. International Journal of Tuberculosis and Lung Disease2015;19(4):406‐12. ">Van Altena 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5/53</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No comparative data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012836-bbs2-0002" title="GalliL , LancellaL , TersigniC , VenturiniE , ChiappiniE , BergaminiB , et al. Pediatric tuberculosis in Italian children: epidemiological and clinical data from the Italian register of pediatric tuberculosis. International Journal of Molecular Sciences2016;17(6):960. ">Galli 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2/5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2/5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No RR/P‐value reported; small sample size</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012836-bbs2-0004" title="JenseniusM , WinjeBA , BlombergB , MengshoelAT , LippeBV , HannulaR , et al. Multidrug‐resistant tuberculosis in Norway: a nationwide study, 1995‐2014. International Journal of Tuberculosis and Lung Disease2016;20(6):786‐92. ">Jensenius 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>23/52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>23/52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No comparative data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012836-bbs2-0014" title="TiberiS , PayenMC , SotgiuG , D'AmbrosioL , GuizadoVA , AlffenaarJW , et al. Effectiveness and safety of meropenem/ clavulanate‐containing regimens in the treatment of MDR‐ and XDR‐TB. European Respiratory Journal2016;47(4):1235‐43. TiberiS , SotgiuG , D'AmbrosioL , CentisR , ArbexMA , ArrascueEA , et al. Comparison of effectiveness and safety of imipenem/clavulanate‐versus meropenem/clavulanate‐containing regimens in the treatment of MDR‐ and XDR‐TB. European Respiratory Journal2016;47(6):1758‐66. ">Tiberi 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>253/267</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>61/267</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>97/267</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>47/267</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>50/267</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No comparative data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012836-bbs2-0003" title="GuglielmettiL , JaspardM , LeDûD , LachâtreM , Marigot‐OuttandyD , BernardC , French MDR‐TB Management Group. Long‐term outcome and safety of prolonged bedaquiline treatment for multidrug‐resistant tuberculosis. European Respiratory Journal2017;49:1601799. [DOI: 10.1183/13993003.01799‐2016] ">Guglielmetti 2017</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>127/43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7/2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8/43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5/43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>31/43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>22/43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9/43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No RR/P‐value reported; small control group; post‐hoc analysis</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012836-bbs2-0001" title="FerlazzoG , MohrE , LaxmeshwarC , HewisonC , HughesJ , JonckheereS , et al. Early safety and efficacy of the combination of bedaquiline and delamanid for the treatment of patients with drug‐resistant tuberculosis in Armenia, India, and South Africa: a retrospective cohort study. Lancet Infectious Diseases2018;18:536‐44. [DOI: 10.1016/S1473‐3099(18)30100‐2] ">Ferlazzo 2018</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12/23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4/5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No RR/P‐value reported; post‐hoc analysis</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012836-bbs2-0010" title="OlayanjuO , LimberisJ , EsmailA , OelofseS , GinaP , PietersenE , et al. Long‐term bedaquiline‐related treatment outcomes in patients with extensively drug‐resistant tuberculosis from South Africa. European Respiratory Journal2018;51:1800544. [DOI: 10.1183/13993003.00544‐2018] ">Olayanju 2018</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>181/55</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>525/217</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18/55</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12/55</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11/55</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No RR/P‐value reported; post‐hoc analysis</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>Abbreviations: NR: not reported; RR: risk ratio; XDR: extensively drug‐resistant.</p> </div> </div> <p>Disaggregated data were available from 12 studies (639 participants), on total number of ‘any' or ‘serious' adverse events or linezolid discontinuation, amongst participants receiving linezolid (<a href="./references#CD012836-bbs2-0009" title="MiglioriGB , EkerB , RichardsonMD , SotgiuG , ZellwegerJP , SkrahinaA , et al. A retrospective TBNET assessment of linezolid safety, tolerability and efficacy in multidrug‐resistant tuberculosis. European Respiratory Journal2009;34(2):387‐93. ">Migliori 2009</a>; <a href="./references#CD012836-bbs2-0006" title="JoKW , LeeSD , KimWS , KimDS , ShimTS . Treatment outcomes and moxifloxacin susceptibility in ofloxacin‐resistant multidrug‐resistant tuberculosis. International Journal of Tuberculosis and Lung Disease2014;18(1):39‐43. ">Jo 2014</a>; <a href="./references#CD012836-bbs2-0012" title="SeddonJA , HesselingAC , Godfrey‐FaussettP , SchaafHS . High treatment success in children treated for multidrug‐resistant tuberculosis: an observational cohort study. Thorax2014;69(5):471‐7. ">Seddon 2014</a>; <a href="./references#CD012836-bbs2-0017" title="ZhangL , PangY , YuX , WangY , GaoM , HuangH , et al. Linezolid in the treatment of extensively drug‐resistant tuberculosis. Infection2014;42(4):705‐11. ">Zhang 2014</a>; <a href="./references#CD012836-bbs2-0007" title="KwakN , KimHR , YooCG , KimYW , HanSK , YimJJ . Changes in treatment outcomes of multidrug‐resistant tuberculosis. International Journal of Tuberculosis and Lung Disease2015;19(5):525‐30. ">Kwak 2015</a>; <a href="./references#CD012836-bbs2-0016" title="VanAltenaR , DeVriesG , HaarCH , DeLangeWC , Magis‐EscurraC , Van denHofS , et al. Highly successful treatment outcome of multidrug‐resistant tuberculosis in the Netherlands, 2000‐2009. International Journal of Tuberculosis and Lung Disease2015;19(4):406‐12. ">Van Altena 2015</a>; <a href="./references#CD012836-bbs2-0002" title="GalliL , LancellaL , TersigniC , VenturiniE , ChiappiniE , BergaminiB , et al. Pediatric tuberculosis in Italian children: epidemiological and clinical data from the Italian register of pediatric tuberculosis. International Journal of Molecular Sciences2016;17(6):960. ">Galli 2016</a>; <a href="./references#CD012836-bbs2-0004" title="JenseniusM , WinjeBA , BlombergB , MengshoelAT , LippeBV , HannulaR , et al. Multidrug‐resistant tuberculosis in Norway: a nationwide study, 1995‐2014. International Journal of Tuberculosis and Lung Disease2016;20(6):786‐92. ">Jensenius 2016</a>; <a href="./references#CD012836-bbs2-0014" title="TiberiS , PayenMC , SotgiuG , D'AmbrosioL , GuizadoVA , AlffenaarJW , et al. Effectiveness and safety of meropenem/ clavulanate‐containing regimens in the treatment of MDR‐ and XDR‐TB. European Respiratory Journal2016;47(4):1235‐43. TiberiS , SotgiuG , D'AmbrosioL , CentisR , ArbexMA , ArrascueEA , et al. Comparison of effectiveness and safety of imipenem/clavulanate‐versus meropenem/clavulanate‐containing regimens in the treatment of MDR‐ and XDR‐TB. European Respiratory Journal2016;47(6):1758‐66. ">Tiberi 2016</a>; <a href="./references#CD012836-bbs2-0003" title="GuglielmettiL , JaspardM , LeDûD , LachâtreM , Marigot‐OuttandyD , BernardC , French MDR‐TB Management Group. Long‐term outcome and safety of prolonged bedaquiline treatment for multidrug‐resistant tuberculosis. European Respiratory Journal2017;49:1601799. [DOI: 10.1183/13993003.01799‐2016] ">Guglielmetti 2017</a>; <a href="./references#CD012836-bbs2-0001" title="FerlazzoG , MohrE , LaxmeshwarC , HewisonC , HughesJ , JonckheereS , et al. Early safety and efficacy of the combination of bedaquiline and delamanid for the treatment of patients with drug‐resistant tuberculosis in Armenia, India, and South Africa: a retrospective cohort study. Lancet Infectious Diseases2018;18:536‐44. [DOI: 10.1016/S1473‐3099(18)30100‐2] ">Ferlazzo 2018</a>; <a href="./references#CD012836-bbs2-0010" title="OlayanjuO , LimberisJ , EsmailA , OelofseS , GinaP , PietersenE , et al. Long‐term bedaquiline‐related treatment outcomes in patients with extensively drug‐resistant tuberculosis from South Africa. European Respiratory Journal2018;51:1800544. [DOI: 10.1183/13993003.00544‐2018] ">Olayanju 2018</a>). Six studies (487 participants), provided data for total number of ‘any' or ‘serious' adverse events amongst participants who did not receive linezolid (<a href="./references#CD012836-bbs2-0012" title="SeddonJA , HesselingAC , Godfrey‐FaussettP , SchaafHS . High treatment success in children treated for multidrug‐resistant tuberculosis: an observational cohort study. Thorax2014;69(5):471‐7. ">Seddon 2014</a>; <a href="./references#CD012836-bbs2-0007" title="KwakN , KimHR , YooCG , KimYW , HanSK , YimJJ . Changes in treatment outcomes of multidrug‐resistant tuberculosis. International Journal of Tuberculosis and Lung Disease2015;19(5):525‐30. ">Kwak 2015</a>; <a href="./references#CD012836-bbs2-0002" title="GalliL , LancellaL , TersigniC , VenturiniE , ChiappiniE , BergaminiB , et al. Pediatric tuberculosis in Italian children: epidemiological and clinical data from the Italian register of pediatric tuberculosis. International Journal of Molecular Sciences2016;17(6):960. ">Galli 2016</a>; <a href="./references#CD012836-bbs2-0003" title="GuglielmettiL , JaspardM , LeDûD , LachâtreM , Marigot‐OuttandyD , BernardC , French MDR‐TB Management Group. Long‐term outcome and safety of prolonged bedaquiline treatment for multidrug‐resistant tuberculosis. European Respiratory Journal2017;49:1601799. [DOI: 10.1183/13993003.01799‐2016] ">Guglielmetti 2017</a>; <a href="./references#CD012836-bbs2-0001" title="FerlazzoG , MohrE , LaxmeshwarC , HewisonC , HughesJ , JonckheereS , et al. Early safety and efficacy of the combination of bedaquiline and delamanid for the treatment of patients with drug‐resistant tuberculosis in Armenia, India, and South Africa: a retrospective cohort study. Lancet Infectious Diseases2018;18:536‐44. [DOI: 10.1016/S1473‐3099(18)30100‐2] ">Ferlazzo 2018</a>; <a href="./references#CD012836-bbs2-0010" title="OlayanjuO , LimberisJ , EsmailA , OelofseS , GinaP , PietersenE , et al. Long‐term bedaquiline‐related treatment outcomes in patients with extensively drug‐resistant tuberculosis from South Africa. European Respiratory Journal2018;51:1800544. [DOI: 10.1183/13993003.00544‐2018] ">Olayanju 2018</a>). </p> <p>A total of 602 adverse events were reported from 426 participants (from 8 studies), receiving linezolid. Among 478 participants (5 studies), who did not receive linezolid, there were 813 adverse events. Fifty‐seven serious adverse events occurred amongst 164 participants (7 studies), who received linezolid, and 47 serious adverse events occurred in 270 participants (5 studies), who did not receive linezolid. </p> <p>Linezolid‐attributed adverse events were reported in a total of 529 participants from 10 studies (<a href="./references#CD012836-bbs2-0009" title="MiglioriGB , EkerB , RichardsonMD , SotgiuG , ZellwegerJP , SkrahinaA , et al. A retrospective TBNET assessment of linezolid safety, tolerability and efficacy in multidrug‐resistant tuberculosis. European Respiratory Journal2009;34(2):387‐93. ">Migliori 2009</a>; <a href="./references#CD012836-bbs2-0015" title="UdwadiaZF , SenT , MoharilG . Assessment of linezolid efficacy and safety in MDR‐ and XDR‐TB: an Indian perspective. European Respiratory Journal2010;35(4):936‐8; author reply 938‐40. ">Udwadia 2010</a>; <a href="./references#CD012836-bbs2-0006" title="JoKW , LeeSD , KimWS , KimDS , ShimTS . Treatment outcomes and moxifloxacin susceptibility in ofloxacin‐resistant multidrug‐resistant tuberculosis. International Journal of Tuberculosis and Lung Disease2014;18(1):39‐43. ">Jo 2014</a>; <a href="./references#CD012836-bbs2-0012" title="SeddonJA , HesselingAC , Godfrey‐FaussettP , SchaafHS . High treatment success in children treated for multidrug‐resistant tuberculosis: an observational cohort study. Thorax2014;69(5):471‐7. ">Seddon 2014</a>; <a href="./references#CD012836-bbs2-0017" title="ZhangL , PangY , YuX , WangY , GaoM , HuangH , et al. Linezolid in the treatment of extensively drug‐resistant tuberculosis. Infection2014;42(4):705‐11. ">Zhang 2014</a>; <a href="./references#CD012836-bbs2-0007" title="KwakN , KimHR , YooCG , KimYW , HanSK , YimJJ . Changes in treatment outcomes of multidrug‐resistant tuberculosis. International Journal of Tuberculosis and Lung Disease2015;19(5):525‐30. ">Kwak 2015</a>; <a href="./references#CD012836-bbs2-0002" title="GalliL , LancellaL , TersigniC , VenturiniE , ChiappiniE , BergaminiB , et al. Pediatric tuberculosis in Italian children: epidemiological and clinical data from the Italian register of pediatric tuberculosis. International Journal of Molecular Sciences2016;17(6):960. ">Galli 2016</a>; <a href="./references#CD012836-bbs2-0014" title="TiberiS , PayenMC , SotgiuG , D'AmbrosioL , GuizadoVA , AlffenaarJW , et al. Effectiveness and safety of meropenem/ clavulanate‐containing regimens in the treatment of MDR‐ and XDR‐TB. European Respiratory Journal2016;47(4):1235‐43. TiberiS , SotgiuG , D'AmbrosioL , CentisR , ArbexMA , ArrascueEA , et al. Comparison of effectiveness and safety of imipenem/clavulanate‐versus meropenem/clavulanate‐containing regimens in the treatment of MDR‐ and XDR‐TB. European Respiratory Journal2016;47(6):1758‐66. ">Tiberi 2016</a>; <a href="./references#CD012836-bbs2-0003" title="GuglielmettiL , JaspardM , LeDûD , LachâtreM , Marigot‐OuttandyD , BernardC , French MDR‐TB Management Group. Long‐term outcome and safety of prolonged bedaquiline treatment for multidrug‐resistant tuberculosis. European Respiratory Journal2017;49:1601799. [DOI: 10.1183/13993003.01799‐2016] ">Guglielmetti 2017</a>; <a href="./references#CD012836-bbs2-0010" title="OlayanjuO , LimberisJ , EsmailA , OelofseS , GinaP , PietersenE , et al. Long‐term bedaquiline‐related treatment outcomes in patients with extensively drug‐resistant tuberculosis from South Africa. European Respiratory Journal2018;51:1800544. [DOI: 10.1183/13993003.00544‐2018] ">Olayanju 2018</a>). These included 108 bone marrow‐related (e.g. anaemia, thrombocytopaenia, leukopenia), and 110 neuropathic (peripheral or optic) events. </p> <p>Clear information on the numbers of participants experiencing adverse events was not available due to incomplete reporting, so we could not ascertain proportions. Follow‐up duration was also not available for all participants, so we could not describe event rates. </p> <p>Linezolid was discontinued in 141 of 624 participants (22.6%; 11 cohorts).</p> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD012836-sec-0095" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD012836-sec-0095">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD012836-sec-0161">Español</a> </li> </nav> </div> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD012836-sec-0095"></div> <section id="CD012836-sec-0096"> <h3 class="title" id="CD012836-sec-0096">Summary of main results</h3> <p><a href="#CD012836-tbl-0003">Table 2</a> and <a href="#CD012836-tbl-0004">Table 3</a> summarize findings from the two RCTs for which we were able to assess intervention effect (104 participants), <a href="./references#CD012836-bbs2-0008" title="LeeM , ChoSN , BarryCE . Linezolid for XDR‐TB ‐ final study outcomes. New England Journal of Medicine2015;373(3):290‐1. LeeM , LeeJ , CarrollMW , ChoiH , MinS , SongT , et al. Linezolid for treatment of chronic extensively drug‐resistant tuberculosis. New England Journal of Medicine2012;367(16):1508‐18. ">Lee 2012</a> and <a href="./references#CD012836-bbs2-0013" title="TangS , YaoL , HaoX , ZhangX , LiuG , LiuX , et al. Efficacy, safety and tolerability of linezolid for the treatment of XDR‐TB: a study in China. European Respiratory Journal2015;45(1):161‐70. ">Tang 2015</a>, respectively. <a href="#CD012836-tbl-0006">Table 5</a> and <a href="#CD012836-tbl-0007">Table 6</a> include a summary of adverse events findings from the 14 non‐randomized studies (1678 participants; 2 prospective, 12 retrospective). We were unable to generate pooled effect estimates using meta‐analysis due to heterogeneity of outcomes studied and reported. <a href="./full#CD012836-tbl-0001">summary of findings Table for the main comparison</a> provides a GRADE assessment of outcomes from <a href="./references#CD012836-bbs2-0013" title="TangS , YaoL , HaoX , ZhangX , LiuG , LiuX , et al. Efficacy, safety and tolerability of linezolid for the treatment of XDR‐TB: a study in China. European Respiratory Journal2015;45(1):161‐70. ">Tang 2015</a>. </p> <p>Settings varied: the RCTs were based in the Republic of Korea (<a href="./references#CD012836-bbs2-0008" title="LeeM , ChoSN , BarryCE . Linezolid for XDR‐TB ‐ final study outcomes. New England Journal of Medicine2015;373(3):290‐1. LeeM , LeeJ , CarrollMW , ChoiH , MinS , SongT , et al. Linezolid for treatment of chronic extensively drug‐resistant tuberculosis. New England Journal of Medicine2012;367(16):1508‐18. ">Lee 2012</a>), and China (<a href="./references#CD012836-bbs2-0013" title="TangS , YaoL , HaoX , ZhangX , LiuG , LiuX , et al. Efficacy, safety and tolerability of linezolid for the treatment of XDR‐TB: a study in China. European Respiratory Journal2015;45(1):161‐70. ">Tang 2015</a>); three cohort studies recruited in the Republic of Korea, five in Europe (one included a centre in a former Soviet Union country), two from South Africa, one each in China and India, and two from multiple heterogeneous centres. <a href="./references#CD012836-bbs2-0013" title="TangS , YaoL , HaoX , ZhangX , LiuG , LiuX , et al. Efficacy, safety and tolerability of linezolid for the treatment of XDR‐TB: a study in China. European Respiratory Journal2015;45(1):161‐70. ">Tang 2015</a>, and seven of the 14 non‐randomized studies, commenced recruitment in 2009 or later. </p> <p>Dosing and duration of linezolid in studies were variable, but also reported incompletely. Five studies did not report dosing at all. In the majority of the remainder it was not clear how many participants received each reported dose. <a href="./references#CD012836-bbs2-0008" title="LeeM , ChoSN , BarryCE . Linezolid for XDR‐TB ‐ final study outcomes. New England Journal of Medicine2015;373(3):290‐1. LeeM , LeeJ , CarrollMW , ChoiH , MinS , SongT , et al. Linezolid for treatment of chronic extensively drug‐resistant tuberculosis. New England Journal of Medicine2012;367(16):1508‐18. ">Lee 2012</a> used 600 mg daily until a second planned randomization to continuing 600 mg or reducing to 300 mg daily. <a href="./references#CD012836-bbs2-0013" title="TangS , YaoL , HaoX , ZhangX , LiuG , LiuX , et al. Efficacy, safety and tolerability of linezolid for the treatment of XDR‐TB: a study in China. European Respiratory Journal2015;45(1):161‐70. ">Tang 2015</a> used 1200 mg daily, then at four to six weeks, all were reduced to 300 mg or 600 mg, until sputum culture conversion. Only eight of the 14 non‐randomized cohorts stated a mean or median duration, all of which were reported to be longer than 90 days. Incompleteness of these data precluded comment on the effect of dose and duration of linezolid on outcomes. Follow‐up duration was variable, when reported; nine of the 14 non‐randomized studies did not report follow‐up duration. </p> <p><a href="./references#CD012836-bbs2-0008" title="LeeM , ChoSN , BarryCE . Linezolid for XDR‐TB ‐ final study outcomes. New England Journal of Medicine2015;373(3):290‐1. LeeM , LeeJ , CarrollMW , ChoiH , MinS , SongT , et al. Linezolid for treatment of chronic extensively drug‐resistant tuberculosis. New England Journal of Medicine2012;367(16):1508‐18. ">Lee 2012</a> did not report data in a manner that permitted reporting of the primary outcomes of this review. However, their reporting of sputum culture conversion did permit comparison between those receiving linezolid immediately versus those starting it two months after randomization. <a href="./references#CD012836-bbs2-0013" title="TangS , YaoL , HaoX , ZhangX , LiuG , LiuX , et al. Efficacy, safety and tolerability of linezolid for the treatment of XDR‐TB: a study in China. European Respiratory Journal2015;45(1):161‐70. ">Tang 2015</a> reported all of the review's primary and secondary outcomes, but reported sputum culture conversion in a way that made it difficult to compare directly with the data for that outcome reported by <a href="./references#CD012836-bbs2-0008" title="LeeM , ChoSN , BarryCE . Linezolid for XDR‐TB ‐ final study outcomes. New England Journal of Medicine2015;373(3):290‐1. LeeM , LeeJ , CarrollMW , ChoiH , MinS , SongT , et al. Linezolid for treatment of chronic extensively drug‐resistant tuberculosis. New England Journal of Medicine2012;367(16):1508‐18. ">Lee 2012</a>. In both studies, the group randomized to receive linezolid from the outset achieved a significantly higher proportion of sputum culture conversion from positive to negative at the time points specified by the study authors than the comparator group, who either started linezolid late or were not given it at all. </p> <p><a href="./references#CD012836-bbs2-0013" title="TangS , YaoL , HaoX , ZhangX , LiuG , LiuX , et al. Efficacy, safety and tolerability of linezolid for the treatment of XDR‐TB: a study in China. European Respiratory Journal2015;45(1):161‐70. ">Tang 2015</a> reported significantly higher cure and lower failure amongst the linezolid‐treated group than controls, with no other significant differences in death, treatment completed and treatment interruption. The differences in cure and failure became insignificant when we performed worst‐case sensitivity analysis, though this method produces extreme effect estimates. Our level of certainty in the evidence was very low for cure and failure, following downgrading for risk of bias, indirectness and imprecision, as presented in <a href="./full#CD012836-tbl-0001">summary of findings Table for the main comparison</a>. </p> <p><a href="./references#CD012836-bbs2-0013" title="TangS , YaoL , HaoX , ZhangX , LiuG , LiuX , et al. Efficacy, safety and tolerability of linezolid for the treatment of XDR‐TB: a study in China. European Respiratory Journal2015;45(1):161‐70. ">Tang 2015</a> reported more anaemia, nausea, and vomiting, and neuropathy events amongst participants in the linezolid group compared with controls. <a href="./references#CD012836-bbs2-0008" title="LeeM , ChoSN , BarryCE . Linezolid for XDR‐TB ‐ final study outcomes. New England Journal of Medicine2015;373(3):290‐1. LeeM , LeeJ , CarrollMW , ChoiH , MinS , SongT , et al. Linezolid for treatment of chronic extensively drug‐resistant tuberculosis. New England Journal of Medicine2012;367(16):1508‐18. ">Lee 2012</a> did not provide comparative adverse event data for those receiving linezolid versus those who did not. Linezolid was discontinued in seven out of 39 (17.9%) participants in <a href="./references#CD012836-bbs2-0008" title="LeeM , ChoSN , BarryCE . Linezolid for XDR‐TB ‐ final study outcomes. New England Journal of Medicine2015;373(3):290‐1. LeeM , LeeJ , CarrollMW , ChoiH , MinS , SongT , et al. Linezolid for treatment of chronic extensively drug‐resistant tuberculosis. New England Journal of Medicine2012;367(16):1508‐18. ">Lee 2012</a> and two out of 33 (6.1%) participants in <a href="./references#CD012836-bbs2-0013" title="TangS , YaoL , HaoX , ZhangX , LiuG , LiuX , et al. Efficacy, safety and tolerability of linezolid for the treatment of XDR‐TB: a study in China. European Respiratory Journal2015;45(1):161‐70. ">Tang 2015</a>. </p> <p>Where reported within the cohort studies, 141 out of 624 (22.6%; 11 cohorts), discontinued linezolid. We could not reliably compare total adverse events, serious adverse events, and overall and specific linezolid‐attributed adverse events, but we have shown these outcomes descriptively in <a href="#CD012836-tbl-0007">Table 6</a>. This is due to a lack of data on follow‐up duration and numbers of participants experiencing events. </p> </section> <section id="CD012836-sec-0097"> <h3 class="title" id="CD012836-sec-0097">Overall completeness and applicability of evidence</h3> <p>Settings of the studies, in terms of tuberculosis incidence and drug‐resistant tuberculosis prevalence, were diverse. India was the only lower‐middle‐income country (<a href="./references#CD012836-bbs2-0015" title="UdwadiaZF , SenT , MoharilG . Assessment of linezolid efficacy and safety in MDR‐ and XDR‐TB: an Indian perspective. European Respiratory Journal2010;35(4):936‐8; author reply 938‐40. ">Udwadia 2010</a>; <a href="./references#CD012836-bbs2-0001" title="FerlazzoG , MohrE , LaxmeshwarC , HewisonC , HughesJ , JonckheereS , et al. Early safety and efficacy of the combination of bedaquiline and delamanid for the treatment of patients with drug‐resistant tuberculosis in Armenia, India, and South Africa: a retrospective cohort study. Lancet Infectious Diseases2018;18:536‐44. [DOI: 10.1016/S1473‐3099(18)30100‐2] ">Ferlazzo 2018</a>), with the remainder being upper‐middle‐ or high‐income countries. Children were included in three studies, two of which exclusively recruited children (<a href="./references#CD012836-bbs2-0012" title="SeddonJA , HesselingAC , Godfrey‐FaussettP , SchaafHS . High treatment success in children treated for multidrug‐resistant tuberculosis: an observational cohort study. Thorax2014;69(5):471‐7. ">Seddon 2014</a>; <a href="./references#CD012836-bbs2-0002" title="GalliL , LancellaL , TersigniC , VenturiniE , ChiappiniE , BergaminiB , et al. Pediatric tuberculosis in Italian children: epidemiological and clinical data from the Italian register of pediatric tuberculosis. International Journal of Molecular Sciences2016;17(6):960. ">Galli 2016</a>). Four non‐randomized studies did not report ages of their participants. </p> <p>Reporting of linezolid dose and duration, and follow‐up was variable, as described in the <a href="#CD012836-sec-0096">Summary of main results</a> and <a href="#CD012836-tbl-0002">Table 1</a>. Seven cohort studies included participants with HIV, of which two reported that most were taking antiretroviral therapy. Four did not report HIV status, and three reported that no participants were known to have HIV. The RCTs excluded people with known HIV (<a href="./references#CD012836-bbs2-0008" title="LeeM , ChoSN , BarryCE . Linezolid for XDR‐TB ‐ final study outcomes. New England Journal of Medicine2015;373(3):290‐1. LeeM , LeeJ , CarrollMW , ChoiH , MinS , SongT , et al. Linezolid for treatment of chronic extensively drug‐resistant tuberculosis. New England Journal of Medicine2012;367(16):1508‐18. ">Lee 2012</a>; <a href="./references#CD012836-bbs2-0013" title="TangS , YaoL , HaoX , ZhangX , LiuG , LiuX , et al. Efficacy, safety and tolerability of linezolid for the treatment of XDR‐TB: a study in China. European Respiratory Journal2015;45(1):161‐70. ">Tang 2015</a>). </p> <p>All participants in the <a href="./references#CD012836-bbs2-0008" title="LeeM , ChoSN , BarryCE . Linezolid for XDR‐TB ‐ final study outcomes. New England Journal of Medicine2015;373(3):290‐1. LeeM , LeeJ , CarrollMW , ChoiH , MinS , SongT , et al. Linezolid for treatment of chronic extensively drug‐resistant tuberculosis. New England Journal of Medicine2012;367(16):1508‐18. ">Lee 2012</a> and <a href="./references#CD012836-bbs2-0013" title="TangS , YaoL , HaoX , ZhangX , LiuG , LiuX , et al. Efficacy, safety and tolerability of linezolid for the treatment of XDR‐TB: a study in China. European Respiratory Journal2015;45(1):161‐70. ">Tang 2015</a> RCTs had XDR‐TB. Amongst the 12 cohorts contributing adverse events outcome data disaggregated for linezolid receipt, 38.7% had XDR‐TB. Background regimens, where reported, were individualized to drug susceptibility results, as per WHO guidance, in all of the non‐randomized studies, but one RCT, <a href="./references#CD012836-bbs2-0013" title="TangS , YaoL , HaoX , ZhangX , LiuG , LiuX , et al. Efficacy, safety and tolerability of linezolid for the treatment of XDR‐TB: a study in China. European Respiratory Journal2015;45(1):161‐70. ">Tang 2015</a>, used a specified universal regimen, whilst <a href="./references#CD012836-bbs2-0008" title="LeeM , ChoSN , BarryCE . Linezolid for XDR‐TB ‐ final study outcomes. New England Journal of Medicine2015;373(3):290‐1. LeeM , LeeJ , CarrollMW , ChoiH , MinS , SongT , et al. Linezolid for treatment of chronic extensively drug‐resistant tuberculosis. New England Journal of Medicine2012;367(16):1508‐18. ">Lee 2012</a> reported a variety of background regimens. Thoracic surgical interventions were undertaken in a minority (&lt; 25%) of participants, and proportions appeared balanced between those who received linezolid and those who did not, where reported. </p> <p>This review highlights the lack of RCT evidence, with only one, with no placebo or blinding, being suitable for analysis for primary and secondary outcomes (<a href="./references#CD012836-bbs2-0013" title="TangS , YaoL , HaoX , ZhangX , LiuG , LiuX , et al. Efficacy, safety and tolerability of linezolid for the treatment of XDR‐TB: a study in China. European Respiratory Journal2015;45(1):161‐70. ">Tang 2015</a>), and the <a href="./references#CD012836-bbs2-0008" title="LeeM , ChoSN , BarryCE . Linezolid for XDR‐TB ‐ final study outcomes. New England Journal of Medicine2015;373(3):290‐1. LeeM , LeeJ , CarrollMW , ChoiH , MinS , SongT , et al. Linezolid for treatment of chronic extensively drug‐resistant tuberculosis. New England Journal of Medicine2012;367(16):1508‐18. ">Lee 2012</a> RCT providing limited comparative data for participants according to receipt of linezolid. Outcome reporting was poor overall in the non‐randomized studies, which were included for adverse events outcomes only. This means the evidence is neither complete, nor widely applicable. </p> <section id="CD012836-sec-0098"> <h4 class="title">Certainty of the evidence</h4> <p>We were unable to find directly comparable RCT data, and had planned, due to anticipated clinical and methodological heterogeneity, not to perform a meta‐analysis on the data from non‐randomized studies. We did not therefore perform a meta‐analysis, but we have provided a GRADE assessment in <a href="./full#CD012836-tbl-0001">summary of findings Table for the main comparison</a>. This found very low certainty in the evidence for all outcomes. </p> <p>As we have described, we found significant problems with risk of bias. We classified 11 of the non‐randomized cohort studies as having serious overall risk of bias, and three as having critical overall risk of bias, using the ROBINS‐I tool (<a href="./references#CD012836-sec-0114" title="">Characteristics of included studies</a>; <a href="./references#CD012836-bbs2-0168" title="SterneJA , HigginsJP , ReevesBC , SavovićJ , TurnerL , ROBINS‐I development group. ROBINS‐I: a tool for assessing Risk Of Bias In Non‐randomized Studies of Interventions. Available from www.riskofbias.info (accessed 14 June 2016). ">Sterne 2016</a>). </p> </section> </section> <section id="CD012836-sec-0099"> <h3 class="title" id="CD012836-sec-0099">Potential biases in the review process</h3> <p>We took measures to limit bias in the review process, by following procedures outlined in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD012836-bbs2-0157" title="HigginsJP , GreenS , editor(s) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011b</a>). The Cochrane Infectious Diseases Group (CIDG) Information Specialist conducted the literature search. It is unlikely that the search missed major studies, but some small unpublished studies may have been missed. We did not make a funnel plot, as included studies did not provide data suitable for meta‐analysis. Two of the review authors examined the search results, determined study selection, and extracted data independently, to minimize bias in study selection and data extraction. </p> </section> <section id="CD012836-sec-0100"> <h3 class="title" id="CD012836-sec-0100">Agreements and disagreements with other studies or reviews</h3> <p>We found five, previously published systematic reviews. These reviews are summarized in <a href="#CD012836-tbl-0008">Table 7</a>. All of these reviews conclude that linezolid is efficacious in the treatment of drug‐resistant tuberculosis, although authors comment on the high likelihood of adverse effects (<a href="./references#CD012836-bbs2-0147" title="CoxH , FordN . Linezolid for the treatment of complicated drug‐resistant tuberculosis: a systematic review and meta‐analysis. International Journal of Tuberculosis and Lung Disease2012;16(4):447‐54. [DOI: 10.5588/ijtld.11.0451] ">Cox 2012</a>; <a href="./references#CD012836-bbs2-0167" title="SotgiuG , CentisR , D'AmbrosioL , AlffenaarJW , AngerHA , CamineroJA , et al. Efficacy, safety and tolerability of linezolid‐containing regimens in treating MDR‐TB and XDR‐TB: systematic review and meta‐analysis. European Respiratory Journal2012;40(6):1430‐42. [DOI: 10.1183/09031936.00022912] ">Sotgiu 2012</a>; <a href="./references#CD012836-bbs2-0146" title="ChangKC , YewWW , TamCM , LeungCC . WHO group 5 drugs and difficult multidrug‐resistant tuberculosis: a systematic review with cohort analysis and meta‐analysis. Antimicrobial Agents and Chemotherapy2013;57(9):4097–104. ">Chang 2013c</a>; <a href="./references#CD012836-bbs2-0180" title="ZhangX , FalagasME , VardakasKZ , WangR , QinR , WangJ , et al. Systematic review and meta‐analysis of the efficacy and safety of therapy with linezolid containing regimens in the treatment of multidrug‐resistant and extensively drug‐resistant tuberculosis. Journal of Thoracic Disease2015;7(4):603‐15. [DOI: 10.3978/j.issn.2072‐1439.2015.03.10] ">Zhang 2015</a>; <a href="./references#CD012836-bbs2-0142" title="AhmadN , AhujaSD , AkkermanOW , AlffenaarJC , AndersonLF , BaghaeiP , et al. Treatment correlates of successful outcomes in pulmonary multi‐drug resistant tuberculosis: an individual patient data meta‐analysis. Lancet2018;362:821‐34. ">Ahmad 2018</a>). Three reviews used studies as the unit of analysis, while two were individual patient data analyses. One review, <a href="./references#CD012836-bbs2-0142" title="AhmadN , AhujaSD , AkkermanOW , AlffenaarJC , AndersonLF , BaghaeiP , et al. Treatment correlates of successful outcomes in pulmonary multi‐drug resistant tuberculosis: an individual patient data meta‐analysis. Lancet2018;362:821‐34. ">Ahmad 2018</a>, reported a risk of bias assessment. Only one of the reviews included a RCT (<a href="./references#CD012836-bbs2-0142" title="AhmadN , AhujaSD , AkkermanOW , AlffenaarJC , AndersonLF , BaghaeiP , et al. Treatment correlates of successful outcomes in pulmonary multi‐drug resistant tuberculosis: an individual patient data meta‐analysis. Lancet2018;362:821‐34. ">Ahmad 2018</a>), and only two included a comparator group of people who did not receive linezolid (<a href="./references#CD012836-bbs2-0146" title="ChangKC , YewWW , TamCM , LeungCC . WHO group 5 drugs and difficult multidrug‐resistant tuberculosis: a systematic review with cohort analysis and meta‐analysis. Antimicrobial Agents and Chemotherapy2013;57(9):4097–104. ">Chang 2013c</a>; <a href="./references#CD012836-bbs2-0142" title="AhmadN , AhujaSD , AkkermanOW , AlffenaarJC , AndersonLF , BaghaeiP , et al. Treatment correlates of successful outcomes in pulmonary multi‐drug resistant tuberculosis: an individual patient data meta‐analysis. Lancet2018;362:821‐34. ">Ahmad 2018</a>). </p> <div class="table" id="CD012836-tbl-0008"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 7.</span> <span class="table-title">Previous systematic reviews of linezolid for drug‐resistant tuberculosis</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Unit of analysis</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Risk of bias assessment</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Type and number of included studies</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of participants who received linezolid</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of participants who did not receive linezolid </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Studies in countries with high tuberculosisburden<sup>a</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Efficacy outcomes assessed</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events outcomes assessed</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Main results</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Authors' conclusions</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012836-bbs2-0147" title="CoxH , FordN . Linezolid for the treatment of complicated drug‐resistant tuberculosis: a systematic review and meta‐analysis. International Journal of Tuberculosis and Lung Disease2012;16(4):447‐54. [DOI: 10.5588/ijtld.11.0451] ">Cox 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not performed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11 case series</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>148</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Treatment success: 68%</p> <p>Adverse events incidence: 61%</p> <p>Linezolid discontinuation: 36%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>“…Linezolid appears…a useful drug…with significant adverse events, and should be considered in the treatment of complicated DR‐TB.” </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012836-bbs2-0167" title="SotgiuG , CentisR , D'AmbrosioL , AlffenaarJW , AngerHA , CamineroJA , et al. Efficacy, safety and tolerability of linezolid‐containing regimens in treating MDR‐TB and XDR‐TB: systematic review and meta‐analysis. European Respiratory Journal2012;40(6):1430‐42. [DOI: 10.1183/09031936.00022912] ">Sotgiu 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not performed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 non‐randomized studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>121</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2/12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Treatment success: 82%.</p> <p>Adverse events incidence: 59%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>“… excellent efficacy but also the necessity of caution in the prescription of linezolid.”</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012836-bbs2-0146" title="ChangKC , YewWW , TamCM , LeungCC . WHO group 5 drugs and difficult multidrug‐resistant tuberculosis: a systematic review with cohort analysis and meta‐analysis. Antimicrobial Agents and Chemotherapy2013;57(9):4097–104. ">Chang 2013c</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Individual participant data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not performed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20 non‐randomized studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>162</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3/12 (countries)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR for favourable outcome with linezolid use vs without: 1.55 (95% CI 1.10 to 2.21)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>“Our findings substantiated the use of linezolid in the treatment of XDR‐TB or fluoroquinolone‐resistant MDR‐TB” </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012836-bbs2-0180" title="ZhangX , FalagasME , VardakasKZ , WangR , QinR , WangJ , et al. Systematic review and meta‐analysis of the efficacy and safety of therapy with linezolid containing regimens in the treatment of multidrug‐resistant and extensively drug‐resistant tuberculosis. Journal of Thoracic Disease2015;7(4):603‐15. [DOI: 10.3978/j.issn.2072‐1439.2015.03.10] ">Zhang 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not performed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>One RCT and 14 non‐randomized studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>367</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3/15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Treatment success: 83% (95% CI 75 to 90)</p> <p>Pooled mortality lower (P &lt; 0.001) and nervous system adverse events higher (P &lt; 0.01) if receiving &lt; 600 mg/day </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>“…Linezolid could be considered as a promising option as treatment of MDR/XDR TB.”</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012836-bbs2-0142" title="AhmadN , AhujaSD , AkkermanOW , AlffenaarJC , AndersonLF , BaghaeiP , et al. Treatment correlates of successful outcomes in pulmonary multi‐drug resistant tuberculosis: an individual patient data meta‐analysis. Lancet2018;362:821‐34. ">Ahmad 2018</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Individual participant data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50 non‐randomized cohort studies and case series</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1011</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11019</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22/50 (recruiting from ≥1 high‐burden country)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>For treatment success with linezolid use vs without: crude OR 1.5 (95% CI 1.2 to 1.9), adjusted OR 3.4 (2.6 to 4.5), adjusted RD 0.15 (0.11 to 0.18). </p> <p>For death with linezolid use vs without: crude OR 0.4 (95% CI 0.3 to 0.5), adjusted OR 0.3 (95% CI 0.2 to 0.3), adjusted RD −0.20 (95% CI −0.23 to −0.16). </p> <p>For people with XDR‐TB, adjusted ORs (success 6.6 (95% CI 4.1 to 10.6), death 0.2 (95% CI 0.1 to 0.3)) and RDs (success 0.31 (95% CI 0.24 to 0.38), death −0.29 (95% CI −0.36 to −0.23)) remained significantly in favour of linezolid use </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>“Although inferences are limited by the observational nature of these data, treatment outcomes were </p> <p>significantly better with use of linezolid…for treatment of multidrug‐resistant tuberculosis.”</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>Abbreviations: CI: confidence interval; DR: drug resistant; MDR: multi‐drug resistant; N/A: not applicable; OR: odds ratio; RD: risk difference; RR: risk ratio; XDR: extensively drug‐resistant.<br/> <sup>a</sup>High‐tuberculosis‐burden countries as defined in <a href="./references#CD012836-bbs2-0176" title="World Health Organization. Use of high burden country lists for TB by WHO in the post‐2015 era. Geneva: World Health Organization, 2015. ">WHO 2015b</a>. </p> </div> </div> <p><a href="./references#CD012836-bbs2-0147" title="CoxH , FordN . Linezolid for the treatment of complicated drug‐resistant tuberculosis: a systematic review and meta‐analysis. International Journal of Tuberculosis and Lung Disease2012;16(4):447‐54. [DOI: 10.5588/ijtld.11.0451] ">Cox 2012</a>, <a href="./references#CD012836-bbs2-0167" title="SotgiuG , CentisR , D'AmbrosioL , AlffenaarJW , AngerHA , CamineroJA , et al. Efficacy, safety and tolerability of linezolid‐containing regimens in treating MDR‐TB and XDR‐TB: systematic review and meta‐analysis. European Respiratory Journal2012;40(6):1430‐42. [DOI: 10.1183/09031936.00022912] ">Sotgiu 2012</a>, and <a href="./references#CD012836-bbs2-0180" title="ZhangX , FalagasME , VardakasKZ , WangR , QinR , WangJ , et al. Systematic review and meta‐analysis of the efficacy and safety of therapy with linezolid containing regimens in the treatment of multidrug‐resistant and extensively drug‐resistant tuberculosis. Journal of Thoracic Disease2015;7(4):603‐15. [DOI: 10.3978/j.issn.2072‐1439.2015.03.10] ">Zhang 2015</a> assessed treatment outcomes and adverse events in 11 (148 participants), 12 (121 participants), and 15 (367 participants) studies, respectively. Most of these studies were case series in which all participants received linezolid. Risk ratios could not be calculated due to the lack of comparative adverse events data on participants who did not receive linezolid. <a href="./references#CD012836-bbs2-0147" title="CoxH , FordN . Linezolid for the treatment of complicated drug‐resistant tuberculosis: a systematic review and meta‐analysis. International Journal of Tuberculosis and Lung Disease2012;16(4):447‐54. [DOI: 10.5588/ijtld.11.0451] ">Cox 2012</a> and <a href="./references#CD012836-bbs2-0167" title="SotgiuG , CentisR , D'AmbrosioL , AlffenaarJW , AngerHA , CamineroJA , et al. Efficacy, safety and tolerability of linezolid‐containing regimens in treating MDR‐TB and XDR‐TB: systematic review and meta‐analysis. European Respiratory Journal2012;40(6):1430‐42. [DOI: 10.1183/09031936.00022912] ">Sotgiu 2012</a> concluded that linezolid was efficacious for drug‐resistant tuberculosis, though both advised caution in its use due to high incidence of adverse events. <a href="./references#CD012836-bbs2-0180" title="ZhangX , FalagasME , VardakasKZ , WangR , QinR , WangJ , et al. Systematic review and meta‐analysis of the efficacy and safety of therapy with linezolid containing regimens in the treatment of multidrug‐resistant and extensively drug‐resistant tuberculosis. Journal of Thoracic Disease2015;7(4):603‐15. [DOI: 10.3978/j.issn.2072‐1439.2015.03.10] ">Zhang 2015</a> suggested that linezolid was a "promising option as treatment of MDR/XDR TB", but advised randomized studies to define dosing. </p> <p><a href="./references#CD012836-bbs2-0146" title="ChangKC , YewWW , TamCM , LeungCC . WHO group 5 drugs and difficult multidrug‐resistant tuberculosis: a systematic review with cohort analysis and meta‐analysis. Antimicrobial Agents and Chemotherapy2013;57(9):4097–104. ">Chang 2013c</a> assembled a cohort from 20 studies reporting on the then‐named "group 5" anti‐tuberculous drugs, including 194 participants, of whom 162 received linezolid. They used a composite "favorable outcome" as the primary outcome, defined as "sputum culture conversion, cure, or treatment completion in the absence of death, treatment interruption, treatment failure, or relapse." Random‐effects meta‐analysis of "favorable outcome" according to linezolid use resulted in a pooled RR of 1.55 (95% CI 1.10 to 2.21), favouring linezolid. The outcomes in our review were not reported separately by <a href="./references#CD012836-bbs2-0146" title="ChangKC , YewWW , TamCM , LeungCC . WHO group 5 drugs and difficult multidrug‐resistant tuberculosis: a systematic review with cohort analysis and meta‐analysis. Antimicrobial Agents and Chemotherapy2013;57(9):4097–104. ">Chang 2013c</a>; in particular, there was no summary or meta‐analysis of adverse events outcomes. </p> <p>Ahmad and colleagues conducted an individual patient data meta‐analysis of 50 studies reporting treatment outcomes in drug‐resistant tuberculosis, including 39 studies reporting use of linezolid (<a href="./references#CD012836-bbs2-0142" title="AhmadN , AhujaSD , AkkermanOW , AlffenaarJC , AndersonLF , BaghaeiP , et al. Treatment correlates of successful outcomes in pulmonary multi‐drug resistant tuberculosis: an individual patient data meta‐analysis. Lancet2018;362:821‐34. ">Ahmad 2018</a>), of which one was a RCT included in our review (<a href="./references#CD012836-bbs2-0008" title="LeeM , ChoSN , BarryCE . Linezolid for XDR‐TB ‐ final study outcomes. New England Journal of Medicine2015;373(3):290‐1. LeeM , LeeJ , CarrollMW , ChoiH , MinS , SongT , et al. Linezolid for treatment of chronic extensively drug‐resistant tuberculosis. New England Journal of Medicine2012;367(16):1508‐18. ">Lee 2012</a>). Their primary outcomes were treatment success and death, with no summary of adverse events outcomes due to heterogeneity in measuring and reporting. The data were in favour of treatment success with linezolid use (722/799) versus without (5066/5864), with a crude odds ratio of 1.5 (95% CI 1.2 to 1.9), adjusted odds ratio 3.4 (95% CI 2.6 to 4.5), and adjusted risk difference 0.15 (0.11 to 0.18). Mortality was lower with linezolid use (84/883) versus without (1456/7320), with a crude odds ratio of 0.4 (95% CI 0.3 to 0.5), adjusted odds ratio 0.3 (95% CI 0.2 to 0.3), and adjusted risk difference −0.20 (95% CI −0.23 to −0.16). However, they found high heterogeneity (&gt; 50%) in the studies overall. When XDR‐TB patients’ outcomes were meta‐analysed separately, the effect estimates remained in favour of linezolid use, with low heterogeneity amongst these studies (&lt; 10%). Similar to our review, the authors highlighted a lack of data from RCTs, prospective studies, and low‐ and middle‐income settings (<a href="./references#CD012836-bbs2-0142" title="AhmadN , AhujaSD , AkkermanOW , AlffenaarJC , AndersonLF , BaghaeiP , et al. Treatment correlates of successful outcomes in pulmonary multi‐drug resistant tuberculosis: an individual patient data meta‐analysis. Lancet2018;362:821‐34. ">Ahmad 2018</a>). </p> <p>Our proportion of linezolid discontinuation (22.6%) was lower than the 36% pooled discontinuation found by <a href="./references#CD012836-bbs2-0147" title="CoxH , FordN . Linezolid for the treatment of complicated drug‐resistant tuberculosis: a systematic review and meta‐analysis. International Journal of Tuberculosis and Lung Disease2012;16(4):447‐54. [DOI: 10.5588/ijtld.11.0451] ">Cox 2012</a>, and 35% reported by <a href="./references#CD012836-bbs2-0180" title="ZhangX , FalagasME , VardakasKZ , WangR , QinR , WangJ , et al. Systematic review and meta‐analysis of the efficacy and safety of therapy with linezolid containing regimens in the treatment of multidrug‐resistant and extensively drug‐resistant tuberculosis. Journal of Thoracic Disease2015;7(4):603‐15. [DOI: 10.3978/j.issn.2072‐1439.2015.03.10] ">Zhang 2015</a>. The other three previous systematic reviews did not report discontinuation specifically. </p> <p>When evidence for the use of linezolid was reviewed for the 2016 WHO guidelines (Annex 4 of <a href="./references#CD012836-bbs2-0177" title="World Health Organization. WHO Treatment Guidelines for Drug‐Resistant Tuberculosis – 2016 update. Geneva: World Health Organization, 2016. ">WHO 2016a</a>), the GRADE assessment for <a href="./references#CD012836-bbs2-0013" title="TangS , YaoL , HaoX , ZhangX , LiuG , LiuX , et al. Efficacy, safety and tolerability of linezolid for the treatment of XDR‐TB: a study in China. European Respiratory Journal2015;45(1):161‐70. ">Tang 2015</a> concluded moderate certainty in the evidence for their comparison of treatment success versus a composite outcome of failure/relapse/death in patients with XDR‐TB. They downgraded for serious risk of bias and imprecision, but upgraded for a strong association. This is methodologically incorrect: upgrading for strong association is only for observational studies where GRADE starts as very low, and is not applicable to RCTs, where GRADE starts as high (<a href="./references#CD012836-bbs2-0154" title="GuyattGH , OxmanAD , SultanS , GlasziouP , AklEA , Alonso‐CoelloP , et al. GRADE guidelines: 9. Rating up the quality of evidence. Journal of Clinical Epidemiology2011;64(12):1311‐6. ">Guyatt 2011</a>). The <a href="./references#CD012836-bbs2-0177" title="World Health Organization. WHO Treatment Guidelines for Drug‐Resistant Tuberculosis – 2016 update. Geneva: World Health Organization, 2016. ">WHO 2016a</a> assessments for treatment success versus failure/relapse/death<i>,</i> and death versus all other outcomes in patients with both MDR‐ and XDR‐TB, when <a href="./references#CD012836-bbs2-0013" title="TangS , YaoL , HaoX , ZhangX , LiuG , LiuX , et al. Efficacy, safety and tolerability of linezolid for the treatment of XDR‐TB: a study in China. European Respiratory Journal2015;45(1):161‐70. ">Tang 2015</a> and six non‐randomized studies were combined, resulted in very low certainty. Our GRADE assessment, with a population of MDR‐ and XDR‐TB in mind, was very low for all outcomes. This was in part due to downgrading by one level for indirectness (the population in <a href="./references#CD012836-bbs2-0013" title="TangS , YaoL , HaoX , ZhangX , LiuG , LiuX , et al. Efficacy, safety and tolerability of linezolid for the treatment of XDR‐TB: a study in China. European Respiratory Journal2015;45(1):161‐70. ">Tang 2015</a> was limited to adults, with XDR‐TB, without HIV co‐infection, in one country), and two levels each for risk of bias (no blinding, no placebo, unclear randomization and allocation methods), and imprecision (small sample size, and for most outcomes, low number of events and wide CIs). We did not upgrade for a large effect size (<a href="./full#CD012836-tbl-0001">summary of findings Table for the main comparison</a>). </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD012836-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012836.pub2/media/CDSR/CD012836/urn:x-wiley:14651858:media:CD012836:CD012836-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012836.pub2/media/CDSR/CD012836/image_t/tCD012836-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram" data-id="CD012836-fig-0001" src="/cdsr/doi/10.1002/14651858.CD012836.pub2/media/CDSR/CD012836/image_n/nCD012836-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012836.pub2/full#CD012836-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012836.pub2/media/CDSR/CD012836/image_n/nCD012836-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012836-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012836.pub2/media/CDSR/CD012836/urn:x-wiley:14651858:media:CD012836:CD012836-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012836.pub2/media/CDSR/CD012836/image_t/tCD012836-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias in included RCTs" data-id="CD012836-fig-0002" src="/cdsr/doi/10.1002/14651858.CD012836.pub2/media/CDSR/CD012836/image_n/nCD012836-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias in included RCTs</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012836.pub2/full#CD012836-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012836.pub2/media/CDSR/CD012836/image_n/nCD012836-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012836-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012836.pub2/media/CDSR/CD012836/urn:x-wiley:14651858:media:CD012836:CD012836-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012836.pub2/media/CDSR/CD012836/image_t/tCD012836-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias in included non‐randomized studies" data-id="CD012836-fig-0003" src="/cdsr/doi/10.1002/14651858.CD012836.pub2/media/CDSR/CD012836/image_n/nCD012836-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias in included non‐randomized studies</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012836.pub2/full#CD012836-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012836.pub2/media/CDSR/CD012836/image_n/nCD012836-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD012836-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Linezolid compared to no linezolid for drug‐resistant pulmonary tuberculosis</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Linezolid compared to no linezolid for drug‐resistant pulmonary tuberculosis</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> drug‐resistant pulmonary tuberculosis<br/> <b>Setting:</b> one study (<a href="./references#CD012836-bbs2-0013" title="TangS , YaoL , HaoX , ZhangX , LiuG , LiuX , et al. Efficacy, safety and tolerability of linezolid for the treatment of XDR‐TB: a study in China. European Respiratory Journal2015;45(1):161‐70. ">Tang 2015</a>): China; all adults; all extensively drug resistant; no participants with HIV (excluded)<br/> <b>Intervention:</b> linezolid<br/> <b>Comparison:</b> no linezolid </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="center" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (trials)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with no linezolid</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with linezolid</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Death</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>9 per 100</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>6 per 100<br/> (1 to 34) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.65<br/> (0.12 to 3.62) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>65<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>a,b,c,d</sup> </p> <p>due to risk of bias, imprecision, and indirectness</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We are uncertain whether or not linezolid reduces death</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Treatment failure</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>47 per 100</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>12 per 100<br/> (5 to 33) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.26<br/> (0.10 to 0.70) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>65<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>a,b,d,e</sup> </p> <p>due to risk of bias, imprecision, and indirectness</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We are uncertain whether or not linezolid reduces treatment failure</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Cure</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>22 per 100</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>52 per 100<br/> (25 to 100) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 2.36<br/> (1.13 to 4.90) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>65<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>a,b,d,f</sup> </p> <p>due to risk of bias, imprecision, and indirectness</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We are uncertain whether or not linezolid increases cure</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Treatment interrupted</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>9 per 100</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>12 per 100<br/> (3 to 50) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.29<br/> (0.31 to 5.33) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>65<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>a,b,c,d</sup> </p> <p>due to risk of bias, imprecision, and indirectness</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We are uncertain whether or not linezolid reduces treatment interruption</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Treatment completed</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>13 per 100</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>18 per 100<br/> (6 to 59) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.45<br/> (0.45 to 4.68) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>65<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>a,b,c,d</sup> </p> <p>due to risk of bias, imprecision, and indirectness</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We are uncertain whether linezolid increases treatment completion as the certainty of the evidence is very low </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Sputum culture conversion</b> <br/> <b>at 24 months</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>38 per 100</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>79 per 100<br/> (49 to 100) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 2.1<br/> (1.3 to 3.4) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>65<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>b,d,f</sup> </p> <p>due to risk of bias, imprecision, and indirectness</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We are uncertain whether or not linezolid increases sputum culture conversion</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Total adverse events</b><sup>g</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>28 (32 participants) in no‐linezolid group; 74 (33 participants) in linezolid group<sup>g</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>65<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>a,d,h,i</sup> </p> <p>due to risk of bias, imprecision, and indirectness</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We are uncertain whether or not linezolid reduces total adverse events</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Serious adverse events</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Antituberculous treatment</b> <br/> <b>discontinuation</b><sup>j</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>3 per 100</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>6 per 100<br/> (1 to 64) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.94<br/> (0.18 to 20.35) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>65<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>a,b,d,k</sup> </p> <p>due to risk of bias, imprecision, and indirectness</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We are uncertain whether or not linezolid reduces anti‐tuberculous treatment discontinuation</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Linezolid discontinuation</b><sup>l</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>2/33 participants receiving linezolid had permanent discontinuation of linezolid</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>65<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Comparison is not possible for this outcome</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>Abbreviations: CI:</b> confidence interval; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/> <b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>No serious inconsistency: only one study was included.<br/> <sup>b</sup>Downgraded by one level for serious indirectness: the population (drug‐resistant tuberculosis), though meeting criteria for inclusion in the review, only included adults, who had extensively drug‐resistant tuberculosis, and tested negative for HIV infection. Recruitment was from only one country (China). Participants were excluded if they could not afford linezolid.<br/> <sup>c</sup>Downgraded by two levels for very serious imprecision: the CI is wide, and the event rate is low.<br/> <sup>d</sup>Downgraded by two levels for risk of bias: random sequence generation and allocation concealment were not described, therefore leading to unclear risk of bias. There was no blinding, nor placebo control, so there was a high risk of performance and detection bias.<br/> <sup>e</sup>Serious imprecision, due to small sample size.<br/> <sup>f</sup>Downgraded by two levels for very serious imprecision: the CI is wide and sample size is small.<br/> <sup>g</sup>Due to lack of reporting of follow‐up duration, we were unable to calculate a risk ratio.<br/> <sup>h</sup>Downgraded by one level for serious indirectness: due to lack of follow‐up duration data, we were unable to perform comparative analysis for this outcome.<br/> <sup>i</sup>Downgraded by two levels for very serious imprecision, due to inability to calculate risk ratio.<br/> <sup>j</sup>Antituberculous treatment (ATT): a further two participants in each group discontinued ATT due to inability to afford the drugs. We included only discontinuations due to clinical reasons in the results, for the purpose of the review.<br/> <sup>k</sup>Downgraded by two levels for very serious imprecision: number of events was small, with a resulting wide CI, ranging from very large increase to an 82% decrease in discontinuation.<br/> <sup>l</sup>Some participants discontinued linezolid temporarily, but the number of those was not reported. Participants discontinuing linezolid due to being unable to afford it (n = 2) are not included in this number. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Linezolid compared to no linezolid for drug‐resistant pulmonary tuberculosis</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012836.pub2/full#CD012836-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD012836-tbl-0002"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Summary of characteristics of included studies</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Study design</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Country</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Recruitment dates</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Age</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Drug resistance</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>HIV status reported</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Linezolid daily dose</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Linezolid duration</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>Number of participants</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Linezolid</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>No linezolid</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Total</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012836-bbs2-0008" title="LeeM , ChoSN , BarryCE . Linezolid for XDR‐TB ‐ final study outcomes. New England Journal of Medicine2015;373(3):290‐1. LeeM , LeeJ , CarrollMW , ChoiH , MinS , SongT , et al. Linezolid for treatment of chronic extensively drug‐resistant tuberculosis. New England Journal of Medicine2012;367(16):1508‐18. ">Lee 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCT, no placebo, partial blinding</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Republic of Korea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2008 to 2011</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adults &gt; 20 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All XDR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes, excluded</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>600 mg, then randomized to 300 mg or 600 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Median 781 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19 immediate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20 delayed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>39</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012836-bbs2-0011" title="PadayatchiN , Mac KenzieWR , Hirsch‐MovermanY , FengPJ , VillarinoE , SaukkonenJ , et al. Lessons from a randomised clinical trial for multidrug‐resistant tuberculosis. International Journal of Tuberculosis and Lung Disease2012, issue 12:1582‐7. ">Padayatchi 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCT, placebo, blinding</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>South Africa</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2009 to 2010</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adults &gt; 18 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All MDR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes, included, mostly on antiretrovirals</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>600 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>112 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012836-bbs2-0013" title="TangS , YaoL , HaoX , ZhangX , LiuG , LiuX , et al. Efficacy, safety and tolerability of linezolid for the treatment of XDR‐TB: a study in China. European Respiratory Journal2015;45(1):161‐70. ">Tang 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCT, no placebo/blinding</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>China</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2009 to 2011</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adults 18 to 64 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All XDR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes, excluded</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1200 mg 4 to 6 weeks, then 300 to 600 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Until sputum culture negative</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>65</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012836-bbs2-0009" title="MiglioriGB , EkerB , RichardsonMD , SotgiuG , ZellwegerJP , SkrahinaA , et al. A retrospective TBNET assessment of linezolid safety, tolerability and efficacy in multidrug‐resistant tuberculosis. European Respiratory Journal2009;34(2):387‐93. ">Migliori 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Retrospective cohort</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Belarus, Germany, Italy, Switzerland</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2001 to 2007</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18/195 XDR, rest MDR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>600 to 1200 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Median 93 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>85</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>110</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>195</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012836-bbs2-0015" title="UdwadiaZF , SenT , MoharilG . Assessment of linezolid efficacy and safety in MDR‐ and XDR‐TB: an Indian perspective. European Respiratory Journal2010;35(4):936‐8; author reply 938‐40. ">Udwadia 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prospective cohort</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>India</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2000 to 2007</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adults &gt; 18 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7/18 XDR, rest MDR (linezolid group)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1200 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean 247 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>78</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012836-bbs2-0006" title="JoKW , LeeSD , KimWS , KimDS , ShimTS . Treatment outcomes and moxifloxacin susceptibility in ofloxacin‐resistant multidrug‐resistant tuberculosis. International Journal of Tuberculosis and Lung Disease2014;18(1):39‐43. ">Jo 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Retrospective cohort</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Republic of Korea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2006 to 2012</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adults &gt;18 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26/70 XDR, rest MDR; all ofloxacin‐resistant</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes, 9/70 tested – all negative</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>300 to 600 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Median 259 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>44</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>70</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012836-bbs2-0012" title="SeddonJA , HesselingAC , Godfrey‐FaussettP , SchaafHS . High treatment success in children treated for multidrug‐resistant tuberculosis: an observational cohort study. Thorax2014;69(5):471‐7. ">Seddon 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Retrospective cohort</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>South Africa</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2009 to 2012</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Children &lt; 15 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6/149 (2/3 receiving linezolid) XDR, 16/149 rifampicin‐monoresistant, rest MDR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes, included, mostly on antiretrovirals</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Median 480 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>146</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>149</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012836-bbs2-0017" title="ZhangL , PangY , YuX , WangY , GaoM , HuangH , et al. Linezolid in the treatment of extensively drug‐resistant tuberculosis. Infection2014;42(4):705‐11. ">Zhang 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Retrospective cohort</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>China</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2012 to 2013</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adults &gt; 18 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All XDR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes, all negative</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>600 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unknown ("at least one month")</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>43</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012836-bbs2-0005" title="JeongBH , JeonK , ParkHY , KwonOJ , LeeKS , KimHK , et al. Outcomes of pulmonary MDR‐TB: impacts of fluoroquinolone resistance and linezolid treatment. Journal of Antimicrobial Chemotherapy2015;70(11):3127‐33. ">Jeong 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Retrospective cohort</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Republic of Korea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2005 to 2011</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adults &gt; 18 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All fluoroquinolone‐resistant MDR, or XDR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes, no HIV‐positive participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>300 to 600 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Median 426 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>58</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>86</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>144</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012836-bbs2-0007" title="KwakN , KimHR , YooCG , KimYW , HanSK , YimJJ . Changes in treatment outcomes of multidrug‐resistant tuberculosis. International Journal of Tuberculosis and Lung Disease2015;19(5):525‐30. ">Kwak 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Retrospective cohort</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Republic of Korea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2006 to 2010</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26/123 XDR, rest MDR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>111</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>123</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012836-bbs2-0016" title="VanAltenaR , DeVriesG , HaarCH , DeLangeWC , Magis‐EscurraC , Van denHofS , et al. Highly successful treatment outcome of multidrug‐resistant tuberculosis in the Netherlands, 2000‐2009. International Journal of Tuberculosis and Lung Disease2015;19(4):406‐12. ">Van Altena 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Retrospective cohort</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Netherlands</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2000 to 2009</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4/112 XDR, rest MDR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes, included</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>600 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean 99 days, median 56 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>53</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>51</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>104</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012836-bbs2-0002" title="GalliL , LancellaL , TersigniC , VenturiniE , ChiappiniE , BergaminiB , et al. Pediatric tuberculosis in Italian children: epidemiological and clinical data from the Italian register of pediatric tuberculosis. International Journal of Molecular Sciences2016;17(6):960. ">Galli 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Retrospective cohort</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Italy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2010 to 2012</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Children &lt; 18 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/11 XDR, rest MDR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012836-bbs2-0004" title="JenseniusM , WinjeBA , BlombergB , MengshoelAT , LippeBV , HannulaR , et al. Multidrug‐resistant tuberculosis in Norway: a nationwide study, 1995‐2014. International Journal of Tuberculosis and Lung Disease2016;20(6):786‐92. ">Jensenius 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Retrospective cohort</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Norway</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1995 to 2014</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All, range 2 to 57 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6/89 XDR, rest MDR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes, included</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"Usually" 1200 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>68</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012836-bbs2-0014" title="TiberiS , PayenMC , SotgiuG , D'AmbrosioL , GuizadoVA , AlffenaarJW , et al. Effectiveness and safety of meropenem/ clavulanate‐containing regimens in the treatment of MDR‐ and XDR‐TB. European Respiratory Journal2016;47(4):1235‐43. TiberiS , SotgiuG , D'AmbrosioL , CentisR , ArbexMA , ArrascueEA , et al. Comparison of effectiveness and safety of imipenem/clavulanate‐versus meropenem/clavulanate‐containing regimens in the treatment of MDR‐ and XDR‐TB. European Respiratory Journal2016;47(6):1758‐66. ">Tiberi 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Retrospective cohort</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Belarus, Belgium, Brazil, Ecuador, Greece, Holland, Italy, Peru, Slovakia, UK</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2003 to 2015</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adults &gt; 15 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>XDR and MDR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes, included, mostly on antiretrovirals</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>300 to 1200 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>267</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>81</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>348</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012836-bbs2-0003" title="GuglielmettiL , JaspardM , LeDûD , LachâtreM , Marigot‐OuttandyD , BernardC , French MDR‐TB Management Group. Long‐term outcome and safety of prolonged bedaquiline treatment for multidrug‐resistant tuberculosis. European Respiratory Journal2017;49:1601799. [DOI: 10.1183/13993003.01799‐2016] ">Guglielmetti 2017</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Retrospective cohort</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>France</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2011 to 2013</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24/45 XDR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes, included</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>600 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>45</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012836-bbs2-0001" title="FerlazzoG , MohrE , LaxmeshwarC , HewisonC , HughesJ , JonckheereS , et al. Early safety and efficacy of the combination of bedaquiline and delamanid for the treatment of patients with drug‐resistant tuberculosis in Armenia, India, and South Africa: a retrospective cohort study. Lancet Infectious Diseases2018;18:536‐44. [DOI: 10.1016/S1473‐3099(18)30100‐2] ">Ferlazzo 2018</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Retrospective cohort</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Armenia, India, South Africa</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2016</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&gt; 18 years and one 14‐year old</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14/28 XDR, rest MDR (10 fluoroquinolone resistant)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes, included</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012836-bbs2-0010" title="OlayanjuO , LimberisJ , EsmailA , OelofseS , GinaP , PietersenE , et al. Long‐term bedaquiline‐related treatment outcomes in patients with extensively drug‐resistant tuberculosis from South Africa. European Respiratory Journal2018;51:1800544. [DOI: 10.1183/13993003.00544‐2018] ">Olayanju 2018</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prospective cohort</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>South Africa</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2008 to 2017</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adults &gt; 18 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All XDR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes, included</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>55</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>217</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>272</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="12"> <div class="table-footnote"> <p>Abbreviations: MDR: multi‐drug resistant; RCT: randomized controlled trial; XDR: extensively drug resistant. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Summary of characteristics of included studies</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012836.pub2/full#CD012836-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD012836-tbl-0003"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Findings from the Lee 2012 randomized trial</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Factor</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Participants who received linezolid immediately</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Participants who received delayed linezolid</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Relative effect RR (95% CI)</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Study characteristics</p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Korea, all XDR, HIV co‐infection excluded, adults</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participants</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Death</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/19</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/20</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unable to calculate</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sputum culture conversion at 4 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15/19 (78.9%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7/20 (35.0%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.26 (1.19 to 4.28)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Total adverse events</p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>56<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serious adverse events</p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>37<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Linezolid discontinuation</p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>7/39 (17.9%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="4"> <div class="table-footnote"> <p><sup>a</sup>Adverse events reported without disaggregation for linezolid receipt being immediate or delayed; total adverse events reported in <a href="./references#CD012836-bbs2-0008" title="LeeM , ChoSN , BarryCE . Linezolid for XDR‐TB ‐ final study outcomes. New England Journal of Medicine2015;373(3):290‐1. LeeM , LeeJ , CarrollMW , ChoiH , MinS , SongT , et al. Linezolid for treatment of chronic extensively drug‐resistant tuberculosis. New England Journal of Medicine2012;367(16):1508‐18. ">Lee 2012</a> but not updated in 2015 article; serious adverse events updated in 2015 article (in 2012 article, 33 were reported) </p> <p>Abbreviations: CI: confidence interval; N/A: not applicable; RR: risk ratio; XDR: extensively drug‐resistant </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Findings from the Lee 2012 randomized trial</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012836.pub2/full#CD012836-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD012836-tbl-0004"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Findings from the Tang 2015 randomized trial</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Factor</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Participants who received linezolid</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Participants who did not receive linezolid</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Relative effect RR (95% CI)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study characteristics</p> </td> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p>China, all XDR, HIV co‐infection excluded, adults</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Death</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2/33 (6.1%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3/32 (9.4%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.65 (0.12 to 3.62)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Failure</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4/33 (12.1%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15/32 (46.9%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.26 (0.10 to 0.70)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cure</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>17/33 (51.5%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7/32 (21.9%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.36 (1.13 to 4.90)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Treatment completed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6/33 (18.2%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4/32 (12.5%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.45 (0.45 to 4.68)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Treatment interruption ("default")</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4/33 (12.1%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3/32 (9.4%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.29 (0.31 to 5.33)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sputum culture conversion at 24 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26/33 (78.8%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12/32 (37.6%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.10 (1.30 to 3.40)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Total adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>74</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unable to calculate</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Serious adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unable to calculate</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Linezolid discontinuation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2/33 (6.1%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/A</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="4"> <div class="table-footnote"> <p>Abbreviations: CI: confidence interval; N/A: not applicable; NR: not reported; RR: risk ratio; XDR: extensively drug‐resistant </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Findings from the Tang 2015 randomized trial</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012836.pub2/full#CD012836-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD012836-tbl-0005"> <div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Sensitivity analysis for Tang 2015</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Sensitivity analysis</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Participants who received linezolid</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Participants who did not receive linezolid</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Relative effect RR (95% CI)</b> </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="4" rowspan="1" valign=""> <p><b>Death</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ITT analysis (as in review protocol)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2/33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3/32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.65 (0.12 to 3.62)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Worst‐case analysis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6/33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3/32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.94 (0.53 to 7.10)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Best‐case analysis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2/33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6/32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.32 (0.07 to 1.48)</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="4" rowspan="1" valign=""> <p><b>Cure</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ITT analysis (as in review protocol)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>17/33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7/32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.36 (1.13 to 4.90)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Worst‐case analysis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>17/33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10/32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.65 (0.89 to 3.04)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Best‐case analysis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>21/33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7/32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.91 (1.44 to 5.88)</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="4" rowspan="1" valign=""> <p><b>Failure</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ITT analysis (as in review protocol)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4/33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15/32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.26 (0.10 to 0.70)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Worst‐case analysis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8/33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15/32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.52 (0.26 to 1.05)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Best‐case analysis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4/33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18/32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.22 (0.08 to 0.57)</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="4"> <div class="table-footnote"> <p>Abbreviations: CI: confidence interval; ITT: intention to treat; RR: risk ratio.</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Sensitivity analysis for Tang 2015</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012836.pub2/full#CD012836-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD012836-tbl-0006"> <div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">Summary of findings in non‐randomized studies</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Baseline characteristics</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Participants who received linezolid</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Participants who did not receive linezolid</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Number of studies reporting outcomes</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p>6</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Participants</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p>639 participants, including 8 children</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p>487 participants, including 160 children</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Proportion with XDR‐TB<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p>440/1137 (38.7%)</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p>343/628 (54.6%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Included participants with HIV</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p>8/12</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p>4/6</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Outcomes</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Number of events</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Number of participants (studies)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Number of events</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Number of participants (studies)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Total adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>602</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>426 (8)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>813</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>478 (5)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Serious adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>57</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>164 (7)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>47</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>270 (5)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Linezolid discontinuation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>141</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>624 (11)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/A</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="5"> <div class="table-footnote"> <p><sup>a</sup>Where reported; not disaggregated for participants receiving linezolid </p> <p>Abbreviation: XDR: extensively drug‐resistant</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">Summary of findings in non‐randomized studies</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012836.pub2/full#CD012836-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD012836-tbl-0007"> <div class="table-heading"><span class="table-label">Table 6.</span> <span class="table-title">Adverse events outcomes data in non‐randomized studies</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Study</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Total adverse events</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Serious adverse events</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Linezolid discontinuation</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>Linezolid‐attributed adverse events</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Our observations</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Linezolid</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>No linezolid</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Linezolid</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>No linezolid</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Total</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Neuropathy</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Bone marrow</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012836-bbs2-0009" title="MiglioriGB , EkerB , RichardsonMD , SotgiuG , ZellwegerJP , SkrahinaA , et al. A retrospective TBNET assessment of linezolid safety, tolerability and efficacy in multidrug‐resistant tuberculosis. European Respiratory Journal2009;34(2):387‐93. ">Migliori 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19/85</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>52/85</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3/85</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30/85</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No comparative data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012836-bbs2-0015" title="UdwadiaZF , SenT , MoharilG . Assessment of linezolid efficacy and safety in MDR‐ and XDR‐TB: an Indian perspective. European Respiratory Journal2010;35(4):936‐8; author reply 938‐40. ">Udwadia 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9/18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8/18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No comparative data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012836-bbs2-0006" title="JoKW , LeeSD , KimWS , KimDS , ShimTS . Treatment outcomes and moxifloxacin susceptibility in ofloxacin‐resistant multidrug‐resistant tuberculosis. International Journal of Tuberculosis and Lung Disease2014;18(1):39‐43. ">Jo 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20/26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6/26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8/26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>22/26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16/26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2/26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No comparative data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012836-bbs2-0012" title="SeddonJA , HesselingAC , Godfrey‐FaussettP , SchaafHS . High treatment success in children treated for multidrug‐resistant tuberculosis: an observational cohort study. Thorax2014;69(5):471‐7. ">Seddon 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>245/142</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11/146</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No RR/P‐value reported; small group received linezolid</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012836-bbs2-0017" title="ZhangL , PangY , YuX , WangY , GaoM , HuangH , et al. Linezolid in the treatment of extensively drug‐resistant tuberculosis. Infection2014;42(4):705‐11. ">Zhang 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11/15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11/15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4/15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No comparative data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012836-bbs2-0007" title="KwakN , KimHR , YooCG , KimYW , HanSK , YimJJ . Changes in treatment outcomes of multidrug‐resistant tuberculosis. International Journal of Tuberculosis and Lung Disease2015;19(5):525‐30. ">Kwak 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8/12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>36/111</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8/12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>32/111</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2/12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3/12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2/12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No RR/P‐value reported; linezolid added if failing therapy, or XDR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012836-bbs2-0005" title="JeongBH , JeonK , ParkHY , KwonOJ , LeeKS , KimHK , et al. Outcomes of pulmonary MDR‐TB: impacts of fluoroquinolone resistance and linezolid treatment. Journal of Antimicrobial Chemotherapy2015;70(11):3127‐33. ">Jeong 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012836-bbs2-0005" title="JeongBH , JeonK , ParkHY , KwonOJ , LeeKS , KimHK , et al. Outcomes of pulmonary MDR‐TB: impacts of fluoroquinolone resistance and linezolid treatment. Journal of Antimicrobial Chemotherapy2015;70(11):3127‐33. ">Jeong 2015</a> reported no adverse event data other than linezolid dose reduction </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012836-bbs2-0016" title="VanAltenaR , DeVriesG , HaarCH , DeLangeWC , Magis‐EscurraC , Van denHofS , et al. Highly successful treatment outcome of multidrug‐resistant tuberculosis in the Netherlands, 2000‐2009. International Journal of Tuberculosis and Lung Disease2015;19(4):406‐12. ">Van Altena 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5/53</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No comparative data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012836-bbs2-0002" title="GalliL , LancellaL , TersigniC , VenturiniE , ChiappiniE , BergaminiB , et al. Pediatric tuberculosis in Italian children: epidemiological and clinical data from the Italian register of pediatric tuberculosis. International Journal of Molecular Sciences2016;17(6):960. ">Galli 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2/5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2/5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No RR/P‐value reported; small sample size</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012836-bbs2-0004" title="JenseniusM , WinjeBA , BlombergB , MengshoelAT , LippeBV , HannulaR , et al. Multidrug‐resistant tuberculosis in Norway: a nationwide study, 1995‐2014. International Journal of Tuberculosis and Lung Disease2016;20(6):786‐92. ">Jensenius 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>23/52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>23/52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No comparative data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012836-bbs2-0014" title="TiberiS , PayenMC , SotgiuG , D'AmbrosioL , GuizadoVA , AlffenaarJW , et al. Effectiveness and safety of meropenem/ clavulanate‐containing regimens in the treatment of MDR‐ and XDR‐TB. European Respiratory Journal2016;47(4):1235‐43. TiberiS , SotgiuG , D'AmbrosioL , CentisR , ArbexMA , ArrascueEA , et al. Comparison of effectiveness and safety of imipenem/clavulanate‐versus meropenem/clavulanate‐containing regimens in the treatment of MDR‐ and XDR‐TB. European Respiratory Journal2016;47(6):1758‐66. ">Tiberi 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>253/267</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>61/267</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>97/267</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>47/267</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>50/267</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No comparative data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012836-bbs2-0003" title="GuglielmettiL , JaspardM , LeDûD , LachâtreM , Marigot‐OuttandyD , BernardC , French MDR‐TB Management Group. Long‐term outcome and safety of prolonged bedaquiline treatment for multidrug‐resistant tuberculosis. European Respiratory Journal2017;49:1601799. [DOI: 10.1183/13993003.01799‐2016] ">Guglielmetti 2017</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>127/43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7/2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8/43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5/43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>31/43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>22/43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9/43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No RR/P‐value reported; small control group; post‐hoc analysis</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012836-bbs2-0001" title="FerlazzoG , MohrE , LaxmeshwarC , HewisonC , HughesJ , JonckheereS , et al. Early safety and efficacy of the combination of bedaquiline and delamanid for the treatment of patients with drug‐resistant tuberculosis in Armenia, India, and South Africa: a retrospective cohort study. Lancet Infectious Diseases2018;18:536‐44. [DOI: 10.1016/S1473‐3099(18)30100‐2] ">Ferlazzo 2018</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12/23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4/5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No RR/P‐value reported; post‐hoc analysis</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012836-bbs2-0010" title="OlayanjuO , LimberisJ , EsmailA , OelofseS , GinaP , PietersenE , et al. Long‐term bedaquiline‐related treatment outcomes in patients with extensively drug‐resistant tuberculosis from South Africa. European Respiratory Journal2018;51:1800544. [DOI: 10.1183/13993003.00544‐2018] ">Olayanju 2018</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>181/55</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>525/217</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18/55</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12/55</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11/55</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No RR/P‐value reported; post‐hoc analysis</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="10"> <div class="table-footnote"> <p>Abbreviations: NR: not reported; RR: risk ratio; XDR: extensively drug‐resistant.</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 6.</span> <span class="table-title">Adverse events outcomes data in non‐randomized studies</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012836.pub2/full#CD012836-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD012836-tbl-0008"> <div class="table-heading"><span class="table-label">Table 7.</span> <span class="table-title">Previous systematic reviews of linezolid for drug‐resistant tuberculosis</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Unit of analysis</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Risk of bias assessment</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Type and number of included studies</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of participants who received linezolid</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of participants who did not receive linezolid </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Studies in countries with high tuberculosisburden<sup>a</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Efficacy outcomes assessed</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events outcomes assessed</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Main results</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Authors' conclusions</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012836-bbs2-0147" title="CoxH , FordN . Linezolid for the treatment of complicated drug‐resistant tuberculosis: a systematic review and meta‐analysis. International Journal of Tuberculosis and Lung Disease2012;16(4):447‐54. [DOI: 10.5588/ijtld.11.0451] ">Cox 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not performed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11 case series</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>148</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Treatment success: 68%</p> <p>Adverse events incidence: 61%</p> <p>Linezolid discontinuation: 36%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>“…Linezolid appears…a useful drug…with significant adverse events, and should be considered in the treatment of complicated DR‐TB.” </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012836-bbs2-0167" title="SotgiuG , CentisR , D'AmbrosioL , AlffenaarJW , AngerHA , CamineroJA , et al. Efficacy, safety and tolerability of linezolid‐containing regimens in treating MDR‐TB and XDR‐TB: systematic review and meta‐analysis. European Respiratory Journal2012;40(6):1430‐42. [DOI: 10.1183/09031936.00022912] ">Sotgiu 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not performed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 non‐randomized studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>121</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2/12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Treatment success: 82%.</p> <p>Adverse events incidence: 59%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>“… excellent efficacy but also the necessity of caution in the prescription of linezolid.”</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012836-bbs2-0146" title="ChangKC , YewWW , TamCM , LeungCC . WHO group 5 drugs and difficult multidrug‐resistant tuberculosis: a systematic review with cohort analysis and meta‐analysis. Antimicrobial Agents and Chemotherapy2013;57(9):4097–104. ">Chang 2013c</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Individual participant data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not performed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20 non‐randomized studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>162</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3/12 (countries)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR for favourable outcome with linezolid use vs without: 1.55 (95% CI 1.10 to 2.21)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>“Our findings substantiated the use of linezolid in the treatment of XDR‐TB or fluoroquinolone‐resistant MDR‐TB” </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012836-bbs2-0180" title="ZhangX , FalagasME , VardakasKZ , WangR , QinR , WangJ , et al. Systematic review and meta‐analysis of the efficacy and safety of therapy with linezolid containing regimens in the treatment of multidrug‐resistant and extensively drug‐resistant tuberculosis. Journal of Thoracic Disease2015;7(4):603‐15. [DOI: 10.3978/j.issn.2072‐1439.2015.03.10] ">Zhang 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not performed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>One RCT and 14 non‐randomized studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>367</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3/15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Treatment success: 83% (95% CI 75 to 90)</p> <p>Pooled mortality lower (P &lt; 0.001) and nervous system adverse events higher (P &lt; 0.01) if receiving &lt; 600 mg/day </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>“…Linezolid could be considered as a promising option as treatment of MDR/XDR TB.”</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012836-bbs2-0142" title="AhmadN , AhujaSD , AkkermanOW , AlffenaarJC , AndersonLF , BaghaeiP , et al. Treatment correlates of successful outcomes in pulmonary multi‐drug resistant tuberculosis: an individual patient data meta‐analysis. Lancet2018;362:821‐34. ">Ahmad 2018</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Individual participant data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50 non‐randomized cohort studies and case series</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1011</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11019</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22/50 (recruiting from ≥1 high‐burden country)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>For treatment success with linezolid use vs without: crude OR 1.5 (95% CI 1.2 to 1.9), adjusted OR 3.4 (2.6 to 4.5), adjusted RD 0.15 (0.11 to 0.18). </p> <p>For death with linezolid use vs without: crude OR 0.4 (95% CI 0.3 to 0.5), adjusted OR 0.3 (95% CI 0.2 to 0.3), adjusted RD −0.20 (95% CI −0.23 to −0.16). </p> <p>For people with XDR‐TB, adjusted ORs (success 6.6 (95% CI 4.1 to 10.6), death 0.2 (95% CI 0.1 to 0.3)) and RDs (success 0.31 (95% CI 0.24 to 0.38), death −0.29 (95% CI −0.36 to −0.23)) remained significantly in favour of linezolid use </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>“Although inferences are limited by the observational nature of these data, treatment outcomes were </p> <p>significantly better with use of linezolid…for treatment of multidrug‐resistant tuberculosis.”</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="11"> <div class="table-footnote"> <p>Abbreviations: CI: confidence interval; DR: drug resistant; MDR: multi‐drug resistant; N/A: not applicable; OR: odds ratio; RD: risk difference; RR: risk ratio; XDR: extensively drug‐resistant.<br/> <sup>a</sup>High‐tuberculosis‐burden countries as defined in <a href="./references#CD012836-bbs2-0176" title="World Health Organization. Use of high burden country lists for TB by WHO in the post‐2015 era. Geneva: World Health Organization, 2015. ">WHO 2015b</a>. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 7.</span> <span class="table-title">Previous systematic reviews of linezolid for drug‐resistant tuberculosis</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012836.pub2/full#CD012836-tbl-0008">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD012836.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD012836-note-0005">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD012836-note-0018">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD012836-note-0004">Français</a> </li> <li class="section-language"> <a class="" href="ms#CD012836-note-0003">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="ru#CD012836-note-0002">Русский</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD012836-note-0001">简体中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734739000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734739000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773542000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773471000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012836\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012836\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012836\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012836\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012836\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012836\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012836\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012836\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012836\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012836\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012836\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012836\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012836\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012836\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012836\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012836\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012836\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012836\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=WcPhDegp&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012836.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD012836.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD012836.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD012836.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012836.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"/> <span class="taglib-text hide-accessible">Sign In</span> </span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740726409488"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD012836.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"/> <span class="taglib-text hide-accessible">Sign In</span> </span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740726409492"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD012836.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918e92ef7a3b9368',t:'MTc0MDcyNjQxMC4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 